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ABSTRACT 
 
This thesis investigates relationships between clinical, neuroimaging and 
neuropathological features in autosomal dominant familial Alzheimer’s disease (FAD), 
with the aim of studying phenotypic heterogeneity and preclinical change. 
 
Chapters 1 and 2 introduce the background to the problem to be addressed in this thesis 
with an emphasis on current understanding of clinical and imaging changes in AD, and 
specifically in FAD. The FAD phenotype can be highly variable and, although it shares 
many clinical features with sporadic AD, it also possesses important differences. The 
clinical spectrum of FAD is first investigated, through analysis of all symptomatic cases 
studied at our research centre over the past twenty-five years (Chapter 3). Associations 
between phenotypic and pathological heterogeneity are then explored, with a study 
investigating genetic determinants of white matter hyperintensities and cerebral amyloid 
angiopathy (CAA) in FAD (Chapter 4). CAA is a common but variable feature of AD 
that appears to be an important factor in amyloid-modifying therapy and the term 
‘ARIA’ has been coined to describe amyloid-related imaging abnormalities, thought to 
relate to vascular amyloid, that have been observed in a variety of amyloid-modifying 
therapy trials. Spontaneous changes of ARIA in FAD and the genetic risk factors that 
may provoke them are then described (Chapter 5). The recent launch of preclinical 
treatment trials for FAD necessitates better understanding of the trajectory of biomarker 
changes early in the disease. Observations from amyloid imaging studies, of 
presymptomatic amyloid deposition in the thalamus and striatum, motivated the final 
study, which examines changes in volume and diffusivity of these subcortical structures 
and their connecting white matter tracts in symptomatic and presymptomatic FAD 
mutation carriers (Chapter 6).  
 
Together, these studies demonstrate that exploring phenotypic heterogeneity and 
preclinical imaging changes can illuminate aspects of the underlying disease process, 
informing our understanding of FAD and potential effects of treatment.  
 
 
 
 4 
TABLE OF CONTENTS 
1	 Introduction ............................................................................................................... 9	
1.1	 History	and	conceptualisation	of	Alzheimer’s	disease	...........................................	9	
1.2	 Alzheimer’s	disease	pathogenesis	and	the	role	of	genetic	mutations	............	19	
1.3	 Clinical	manifestations	of	Alzheimer’s	disease	......................................................	22	
1.4	 Future	perspectives	.........................................................................................................	38	
2	 Imaging biomarkers in Alzheimer’s disease ......................................................... 41	
2.1	 Introduction	.......................................................................................................................	41	
2.2	 Imaging	in	Clinical	Practice	...........................................................................................	42	
2.3	 Imaging	in	Research	........................................................................................................	46	
2.4	 Imaging	presymptomatic	Alzheimer’s	disease	.......................................................	51	
3	 Clinical phenotype and genetic associations in autosomal dominant familial 
Alzheimer’s disease: a case series ................................................................................ 60	
3.1	 Introduction	.......................................................................................................................	60	
3.2	 Materials	and	methods	...................................................................................................	61	
3.3	 Results	..................................................................................................................................	64	
3.4	 Discussion	...........................................................................................................................	81	
4	 Genetic determinants of white matter hyperintensities and amyloid angiopathy 
in familial Alzheimer’s disease ..................................................................................... 86	
4.1	 Introduction	.......................................................................................................................	86	
4.2	 Materials	and	methods	...................................................................................................	88	
4.3	 Results	..................................................................................................................................	91	
4.4	 Discussion	.........................................................................................................................	105	
5	 Amyloid-related imaging abnormalities (ARIA) in familial Alzheimer’s  
disease ........................................................................................................................... 112 
5.1	 Cerebral	microbleeds	(ARIA-H)	in	familial	Alzheimer’s	disease	...................	113	
5.2	 Spontaneous	ARIA-E	and	cerebral	amyloid	angiopathy	related	inflammation	
in	PSEN1-associated	familial	Alzheimer’s	disease	.........................................................	117	
6	 MRI evidence for presymptomatic change in thalamus and caudate in familial 
Alzheimer’s disease ..................................................................................................... 125	
6.1	 Introduction	.....................................................................................................................	125	
6.2	 Materials	and	methods	.................................................................................................	128	
6.3	 Results	................................................................................................................................	133	
 5 
6.4	 Discussion	.........................................................................................................................	144	
7	 Thesis summary and conclusions ......................................................................... 151	
7.1	 Summary	...........................................................................................................................	151	
7.2	 Imaging	manifestations	of	familial	Alzheimer’s	disease	pathology	..............	153	
7.3	 White	matter	involvement	in	familial	Alzheimer’s	disease	.............................	157	
7.4	 Heterogeneity	in	the	familial	Alzheimer’s	disease	phenotype	.......................	159	
7.5	 Limitations	........................................................................................................................	160	
7.6	 Clinical	implications	......................................................................................................	161	
7.7	 Directions	for	future	research	...................................................................................	163	
7.8	 Implications	for	clinical	trials	....................................................................................	165	
7.9	 Applying	findings	from	familial	Alzheimer’s	disease	to	sporadic	Alzheimer’s	
disease	...........................................................................................................................................	166	
8	 Publications ............................................................................................................ 168	
9	 Division of labour .................................................................................................. 175	
10	 Acknowledgements ............................................................................................... 178	
11	 Appendix ................................................................................................................ 179	
11.1	 Neurological	presentations	of	familial	Alzheimer’s	disease	.........................	179	
11.2	 Genetics	methods	.........................................................................................................	180	
11.3	 Immunohistochemical	methods	in	the	pathology	cohort	..............................	182	
11.4	 Grading	system	used	to	assess	severity	of	cerebral	amyloid	angiopathy	.	182	
11.5	 Semi-quantitative	assessment	of	myelin	loss,	gliosis	and	microglial	
expression.	...................................................................................................................................	182	
12	 Bibliography .......................................................................................................... 184	
13	 Glossary ................................................................................................................. 229	
 
 
 
 
 
 
 
 
 6 
TABLES 
 
Table 1.1 Clinical and pathological features of autosomal dominant APP mutations 
lying within the Aβ coding domain ......................................................................... 35	
Table 3.1 Mutations carried by the individuals in the cohort ......................................... 65	
Table 3.2 Mutations associated with atypical phenotypes and additional neurological 
features in our cohort .............................................................................................. 72	
Table 4.1 Subjects’ characteristics and total age-related white matter change (ARWMC) 
scores ....................................................................................................................... 93	
Table 4.2 Mean total white matter hyperintensity score for each PSEN1 mutation in the 
cohort ....................................................................................................................... 94	
Table 4.3. Autopsy cohort subject demographics and results of CAA grading and blood 
vessel analysis ......................................................................................................... 98	
Table 4.4 Semi-quantitative assessment of white matter pallor, gliosis and microglial 
expression in parietal and occipital deep white matter ......................................... 102	
Table 6.1 Subject demographics, neuropsychological and clinical data. ...................... 135	
Table 6.2  Mean ± sd volumes and diffusivity indices in the grey matter regions of 
interest. .................................................................................................................. 140	
Table 6.3.  Mean ± sd diffusivity indices in the white matter tracts of interest. ........... 142	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7 
FIGURES 
 
Figure 1.1 Neurofibrillary tangles drawn by Alzheimer above the caption ‘Peculiar 
fibrillary changes of the nerve cells. Progressed stage of disease’ ......................... 12	
Figure 1.2 Recombinant events in DRC Family 23 localised the AD locus to a region 
that included APP .................................................................................................... 16	
Figure 1.3 APP gene with mutations indicated ............................................................... 21	
Figure 2.1 Medial temporal lobe atrophy on MRI; a sensitive marker of 
neurodegeneration in AD. ....................................................................................... 45	
Figure 2.2. Amyloid imaging with PIB-PET can be positive early in AD and may 
predict conversion from MCI to AD ....................................................................... 48	
Figure 2.3 PIB-PET imaging showing prominent striatal amyloid deposition in a 
presymptomatic PSEN1 mutation carrier approximately three years prior to 
anticipated age at onset. .......................................................................................... 53	
Figure 2.4 Hypothetical model of dynamic biomarkers of AD expanded to explicate the 
preclinical phase, ..................................................................................................... 55	
Figure 3.1 Familial Alzheimer’s disease study participants ........................................... 62	
Figure 3.2 Age at onset for individuals with mutations involving each exon of the 
PSEN1 gene. ............................................................................................................ 69	
Figure 3.3 Location of the mutations present in our cohort of PSEN1 mutation carriers, 
shown according to age-at-onset quartiles .............................................................. 70	
Figure 3.4 Cognitive presentations in APP and PSEN1 mutation carriers in our cohort, 
with presenting symptoms in the PSEN1 group shown by exon ............................ 71	
Figure 3.5 Proportion of cases with each neurological feature for mutations involving 
each of the exons of PSEN1 .................................................................................... 75	
Figure 3.6 Neuropathological findings in a 70 year old man with the novel PSEN1 
p.Ser132Ala mutation presenting with a Dementia with Lewy bodies phenotype . 78	
Figure 3.7 Neuropathological findings in a 42 year old man with a PSEN1 double 
substitution, p.Thr291Ala and p.Ala434Thr, presenting with cognitive impairment, 
pyramidal and extrapyramidal signs ....................................................................... 80	
Figure 4.1: Example MR images from subjects with (A) p.Glu120Lys (B) Intron 4 
(g.23024delG) (C) p.Met139Val (D) p.Ile202Phe (E) p.Leu235Val (F) 
p.Glu280Gly (G) and (H) p.Arg278Ile and (I) p.Pro264Leu mutations, whose 
location within the PSEN1 gene is indicated. ......................................................... 95	
 8 
Figure 4.2 Mean density of immunohistochemical staining in parietal and occipital 
white matter. ............................................................................................................ 99	
Figure 4.3 Pathological analysis of familial Alzheimer’s disease with PSEN1 mutations.
 ............................................................................................................................... 103	
Figure 5.1 3T T2-weighted FLAIR coronal MRI shows white matter lesions, but no 
significant medial temporal lobe atrophy in a patient with the p.Arg269His PSEN1 
mutation. ................................................................................................................ 115	
Figure 5.2 3T T2* MRI shows multiple lobar hypointensities consistent with 
microbleeds in a patient with the p.Arg269His PSEN1 mutation. ........................ 116	
Figure 5.3 Serial MRI scans demonstrating the appearance and then subsequent partial 
resolution of ARIA ................................................................................................ 119	
Figure 5.4 Neuropathological analysis .......................................................................... 120	
Figure 6.1 Regions of interest ....................................................................................... 130	
Figure 6.2 Mean and standard error z scores for presymptomatic and symptomatic 
mutation carriers on standard neuropsychological tests. ....................................... 134	
Figure 6.3 VBM results showing (top left) areas of grey matter reduction in PMCs 
compared with controls after correction for multiple comparisons at FWE < 0.1 
and the effect-map for the PMC versus control group comparison. ..................... 137	
Figure 6.4. VBM results showing (top) grey matter reduction and (bottom) white matter 
reduction in SMCs compared with controls. ......................................................... 138	
Figure 6.5 TBSS results demonstrating areas of significantly decreased FA and 
significantly increased axial, radial and mean diffusivity in SMCs compared to 
controls. ................................................................................................................. 139	
 
 
 
 
 
 
 
 
 
 
 9 
1 Introduction 
1.1 History and conceptualisation of Alzheimer’s disease 
 
It is just over one hundred years since the death of Aloysius "Alois" Alzheimer (1864-
1915). In that time the disease that bears his name has gone from being considered a 
rare condition only affecting younger people to a major public health priority as 
Governments face ever-increasing numbers of people with dementia (Fox and Petersen, 
2013). Worldwide some 40 million people have dementia and AD is the most important 
cause (Prince et al., 2013). A recent UK poll identified AD as the greatest concern about 
later life for British people over 60 years old, more feared even than cancer or the death 
of family and friends [1]. Whilst AD may now be at the forefront of the public 
imagination, it was not always thus. Over the past century, concepts of what AD is, who 
it affects and how common it may be have undergone a number of dramatic shifts. As 
the historian of medicine and psychiatry Erwin Ackerknecht has argued, if any science 
is to chart new and reliable paths, it must continually re-examine its essential premises, 
which can best be understood by studying its origins. In this first section of the 
Introduction, I therefore examine the diverse factors that have contributed to the 
evolution of the concept of AD that exists today. The study of families affected by 
genetic forms of AD and developments in neuroimaging emerge as two of the major 
driving forces behind the modern conceptualisation of AD and form key themes of this 
thesis. These topics: familial AD (FAD) and neuroimaging, are then each discussed in 
detail, providing the background to the data chapters that follow. 
 
The metaphor of ‘framing’ has been used to describe the dynamic process by which 
schemes for explaining and classifying disease are created and evolve (Rosenberg and 
Golden, 1992). Defining a disease involves first putting a name to the symptoms of an 
underlying biological event and creating a disease concept; a process that is dependent 
on the nature of the biological event and the forms of knowledge and technology 
available at the time to explain it. However, the definition is framed in a way that makes 
sense to, and serves wider objectives of, the groups it concerns. Disease frames 
therefore reflect and incorporate values of the society and culture that created them and 
provide a means for projecting, legitimizing and enforcing these ideas. They are 
constructed and refined through negotiations between all groups interested in the 
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disease and as the number of groups interested in a disease grows, these negotiations 
become more complex and multi-layered. Doctors and scientists, governments, research 
institutions and pharmacological companies and patients and their families may all play 
a role in shaping how a disease is framed. Each of these parties has contributed to the 
changing conceptualisation of AD over the past century.  
 
1.1.1 Alzheimer, Auguste D., and the defining of a disease 
On 25th November 1901, a 51 year old woman was admitted to the Municipal Asylum 
for Lunatics and Epileptics in Frankfurt. The patient was Auguste D. and the admitting 
psychiatrist Alois Alzheimer. Mislaid for years, the original file describing her case with 
her admission clerking handwritten by Alzheimer was found in 1995.  It contains a 
detailed description of her clinical presentation: she had been well until March 1901 
when she developed unprovoked paranoia that her husband was having an affair with a 
neighbour. Soon after, she was noticed to have difficulty remembering things and was 
making mistakes preparing meals and dealing with money. She became progressively 
disoriented to time and place and paranoid that people were talking about her. 
Alzheimer gives examples of the deficits he observes on cognitive assessment, 
including severely impaired recall memory of objects she has just seen and correctly 
named. On reading, she omits sentences, and she is unable to progress with writing, 
repeating “I have lost myself”. Her spontaneous speech is “full of paraphrasic 
derailments and perseverations”. Later in her admission, he notes “she behaves as if 
blind, touching other patients on their faces while they fight her.” Auguste D. remained 
in the institution until her death in 1904. By this time, Alzheimer had moved to Munich 
to continue his medical and scientific work at the Royal Psychiatric Clinic, under the 
directorship of Emil Kraepelin. Alzheimer headed the neuroanatomic laboratory and 
requested that Auguste D.’s file and brain be sent to him so that he could study the 
neuropathological features of her disease. As a physician-researcher, he believed that 
clinical practice and laboratory research complemented each other in the quest to 
understand the diseases that afflicted his patients, once writing “Why should not the 
physician improve his competence by enlarging scientific knowledge of psychiatry 
besides doing his daily clinical practice?” (Whitehouse et al., 2000) 
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Alzheimer presented the clinical and pathological findings from Auguste D.’s case at 
the meeting of Southwest German Psychiatrists held in Tübingen, in 1906 and his 
lecture was published under the title ‘A Characteristic Disease of the Cerebral Cortex’ 
the following year. He described and beautifully recorded (Figure 1.1) characteristic 
changes in the neurofibrils revealed by the Bielschowsky silver stain at autopsy. Thick 
fibrils accumulated in apparently normal-appearing cells until “eventually, the nucleus 
and cytoplasm disappeared, and only a tangled bundle of fibrils indicated the site where 
once the neuron had been located.” Severe neuronal loss was observed and “…over the 
entire cortex, and in large numbers especially in the upper layers, miliary foci could be 
found which represented the sites of deposition of a peculiar substance.” Many years 
later, hyperphosphorylated tau was found to be the key component of the tangles and 
amyloid-beta (Aβ) the ‘peculiar substance’ that formed the core of the plaques. 
Psychoanalytic studies presented at the meeting received more attention than 
Alzheimer’s paper and were the ones to get reported in the local press. However, in 
1910 Kraepelin coined the term ‘Alzheimer’s disease’ in the eighth edition of his 
Handbook of Psychiatry, declaring it to be a specific clinical-pathological disease entity. 
 
Examining the historical context in which these events occurred reveals a number of 
disparate factors that enabled the observations to be made by Alzheimer and may have 
influenced Kraepelin in defining them soon after as an eponymous disease. As often is 
the case, technological advances laid the ground for novel insights: the growth of 
German industry in the second half of the nineteenth century was revolutionizing 
histology. Improved microscopes had been developed and the creation of the aniline dye 
industry brought a plethora of new dyes and advances in staining methods, some of 
which found applications in histopathology. Alzheimer had worked closely with the 
neurologist and histopathologist Franz Nissl and could not have made his observations 
without the silver staining techniques developed by Bielschowsky in 1902, which 
allowed alterations to the neuronal cytoskeleton to be seen in such remarkable detail. 
Another important factor was the evolution of concepts around psychiatric disease. For 
Kraepelin, the explanation for mental disorders lay in organic changes in the brain and 
clinical delineation of distinct disease entities was the route to understanding the 
relationship between mind and brain. The clinical-pathological syndrome described by 
Alzheimer provided Kraepelin with a strong example of his approach; naming it a 
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“disease” after a colleague who shared his belief in an organic basis for psychiatric 
illness can perhaps be seen as putting down a marker for his theory over rival 
psychoanalytic ideologies. 
 
Figure 1.1 Neurofibrillary tangles drawn by Alzheimer above the caption ‘Peculiar 
fibrillary changes of the nerve cells. Progressed stage of disease’           
in Alzheimer, Alois "Über eigenartige Krankheitsfälle des späteren Alters." Zeitschrift 
für die gesamte Neurologie und Psychiatrie: Originalen vol. 4 (1910-1911): 356–385. 
Reprinted from (Ryan et al., 2015), with permission. 
 
 
 
There was, however, a fundamental issue with Kraepelin’s concept of AD, which was 
evident when he defined it and has remained a source of ambiguity and contention ever 
since. This was the relationship with senile dementia and normal ageing. Plaques and 
tangles had both been described previously, but in the brains of elderly patients with 
dementia. Extraneuronal plaques had been observed by Beljahow (1887), Redlich 
(1898) and Fischer (1907) and were renamed ‘senile plaques’ in 1910 by Simchowitz 
when he found they could also be present in non-demented elderly people, but in lower 
numbers. In 1906, ‘destruction of the neurofibrillae’ and ‘neurofibrillary bundles’ were 
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noted in senile dementia patients by Bianchi and Fuller respectively (Huppert et al., 
1994). However, the prevailing notion at the time was that senile dementia was an 
inevitable consequence of aging. “Senile dementia is that mental impairment which is a 
direct result of cerebral deterioration from old age,” wrote the psychiatrist William 
Pickett in 1904. Over thirty years later, there had been little change to this view of 
aging. British neurologist MacDonald Critchley commented in 1939 that “frontiers 
between healthy and abnormal old age – between senescence and senility – [are] so ill-
defined as to be scarcely recognizable.”  
 
A key feature that allowed Kraepelin to define AD as a discrete disease entity was the 
young age of the patients. In his 1910 Handbook of Psychiatry, he drew on Alzheimer’s 
original description of Auguste D, a subsequent case report by Bonfiglio (1908) of a 60 
year old Italian patient with similar clinical and histopathological findings and a case 
series (at the time unpublished) by his colleague Perusini (1910), which added two 
further young onset patients. Kraepelin felt that there were clinical features in addition 
to age that also distinguished these patients from those with senile dementia, including 
rapid progression, language disturbance, seizures and focal signs. Kraepelin however 
acknowledged that “The clinical interpretation of this Alzheimer’s disease is still 
confused. Whilst the anatomical findings suggest that we are dealing with a particularly 
serious form of senile dementia, the fact that this disease sometimes starts already 
around the age of 40 does not allow this supposition.” Age was therefore such a central 
parameter in Kraepelin’s classification system and the idea that senile dementia was 
related to aging so entrenched in the thinking of the time that young patients were, by 
definition, precluded from being categorized together with senile dementia. Being so 
closely tied to normal aging, it was unclear whether senile dementia was a disease at all. 
AD as defined by Kraepelin, on the other hand, clearly fell within the realm of 
psychiatry and the dominant view in the decades that followed was that it represented a 
rare “pre-senile” condition.  
 
1.1.2 Alzheimer’s disease redefined as a ‘major killer’ 
It was not until the second half of the twentieth century that AD become redefined as 
affecting late as well as early onset patients. This shift in thinking accompanied a 
transformation in the conceptualization of senile dementia and normal aging. The 
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British psychiatrist Martin Roth made a seminal contribution with his 1955 study, in 
which he argued that mental disorders in the elderly could be split into distinct 
categories, which carried very different prognoses (Roth, 1955). With senile dementia 
increasingly viewed as a pathological condition and distinguished from other psychiatric 
disorders of the elderly it could be studied in its own right, and it soon became apparent 
that the historical distinction from AD no longer seemed valid. In the late 1960s, Roth 
and his colleagues Blessed and Tomlinson demonstrated that the majority of cases of 
senile dementia had neurofibrillary tangles and amyloid plaques and the latter correlated 
with severity of cognitive impairment (Blessed et al., 1968). Roth concluded in 1970 
that “Traditionally the distinction between Alzheimer’s disease and Senile dementia was 
a clear one. It rested on the occurrence in Alzheimer’s disease of focal phenomena: the 
Parietal lobe group of features, the characteristic mixture of apraxia, agnosia, spatial 
disorientation and so on. In Senile dementia, on the other hand, a simple amnestic 
dementia was held to be the principal ingredient of the clinical picture…  …German 
workers have recently called this distinction into question. Lauter and Meyer claim to 
have demonstrated focal phenomena in the senile cases. In the light of these is the 
distinction (between Alzheimer’s disease and Senile dementia) valid clinically or 
pathologically, or are we left with age criteria alone?” (Whitehouse et al., 2000). 
 
With AD and senile dementia unified in a single disease concept, a line was now drawn 
between dementia and normal aging and it was increasingly appreciated that major 
cognitive impairment was not an inevitable outcome of aging. Although Glennerstedt 
had reported plaques in 84% of non-demented elderly people in 1933, observations that 
pathological features of AD may occur without dementia could be incorporated into the 
new framework. The work by Blessed and colleagues had demonstrated that the severity 
of pathology was worse in patients with dementia and, according to the psychodynamic 
model that was prominent among some psychiatrists working on senile dementia at the 
time, an individual’s ability to withstand organic damage depended on a variety of 
personality factors, stress and life crises, as well as the underlying pathology. Once the 
separation between AD and senile dementia was eliminated, it was realized that AD was 
in fact responsible for the majority of dementia and was very common. In an editorial 
published in Archives of Neurology in 1976 entitled ‘The prevalence and malignancy of 
Alzheimer’s disease: A major killer,’ Robert Katzman argued for a unifying concept of 
AD and senile dementia and estimated that the disease may rank as the fourth or fifth 
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most common cause of death in the United States (Katzman, 1976). It took some time 
for the distinction to be completely abandoned, with the terms ‘Alzheimer’s disease’ 
and ‘senile dementia of the Alzheimer type’ recommended initially. However, the new 
conceptualisation of AD had a profound impact on public attitudes. It represented the 
start of AD becoming redefined as a major social and public health issue and concern 
for public policy.  
 
1.1.3 Insights into the biology and genetics underlying Alzheimer’s disease  
Alongside the changing public perception of AD, scientific understanding of the 
biological basis of the disease began to grow. In the late 1970s, the cholinergic deficit in 
AD was identified and linked to selective degeneration of cells in the nucleus basalis of 
Meynert, paving the way for the subsequent development of cholinesterase inhibitors as 
symptomatic treatments. In 1984, George Glenner identified the Aβ protein in 
angiopathic blood vessels from patients with Down syndrome, and made the 
observation that it was homologous with that found in AD, highlighting an important 
possible clue to the genetic aetiology of AD. It had been recognized as early as the 
1930s that there were some rare families in which multiple individuals developed AD 
with a pattern suggesting autosomal dominant inheritance (Lowenberg and Waggoner, 
1934). The finding that individuals with AD and with full trisomy 21, who invariably 
develop plaques and tangles at autopsy if they live to middle age, have the same Aβ 
pathology put chromosome 21 in the spotlight. Aβ was subsequently identified in 
plaques and in 1987 the amyloid precursor protein (APP) gene was cloned and found to 
localize, as predicted, to chromosome 21. Direct sequencing of APP in a large family 
from Nottinghamshire with early onset AD (Dementia Research Centre (DRC) Family 
23 – F23) who had volunteered to participate in research identified a mutation at codon 
717, which co-segregated with disease (Goate et al., 1991). Chromosome 21 linkage 
was not, however, identified in many of the other kindreds that were studied and it soon 
became clear that AD was genetically heterogeneous. Four years later, Presenilin 1 
(PSEN1) on chromosome 14 was identified as the major locus for autosomal dominant 
familial AD (FAD) (Sherrington et al., 1995) and Presenilin 2 (PSEN2) on chromosome 
1 as the locus for a minority of cases (Levy-Lahad et al., 1995). It had also recently 
been found that the Apolipoprotein E4 allele was a major risk factor for sporadic early 
and late onset forms of AD (Corder et al., 1993).  
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Figure 1.2 Recombinant events in DRC Family 23 localised the AD locus to a 
region that included APP 
Diagram courtesy of John Hardy, Institute of Neurology, University College London 
(Goate et al., 1991) 
  
 
 
After the identification of APOE4 as a major risk factor for AD, almost fifteen years 
passed before another gene was found to be conclusively associated with the disease. 
However, the last decade has seen some major developments in our understanding of 
genetic risk factors for sporadic AD. Genome-wide association studies have identified 
multiple genetic loci with low risk effects for AD, including CLU, PICALM, CR1, 
BIN1, MS4A6A, ABCA7, SORL1, PTK2B, EPHA1, and HLA-DRB5-HLA-DRB1 
(Guerreiro and Hardy, 2014). The biological processes that these loci are involved in: 
immune and inflammatory responses; cholesterol and lipid metabolism; and endosomal 
vesicle recycling; have as a result been highlighted as potentially important pathways in 
AD pathogenesis. The role of the innate immune system was brought further to the 
forefront by the discovery in 2013 that rare variants in TREM2, a microglial surface 
receptor, are associated with a significantly increased risk (3x) of AD. Much as the 
mainstay of current symptomatic treatments for AD, the acetylcholinesterase inhibitors 
donepezil, rivastigmine and galantamine, can be seen to have been derived from 
pathological neurochemical findings of a cholinergic deficit, the current search for 
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disease-modifying treatments is strongly influenced by genetic findings. The biological 
pathways illuminated by the autosomal dominant genes and by more recent genetic 
studies open up further potential therapeutic avenues for drug discovery efforts in AD. 
 
Although autosomal dominant mutations account for a very small proportion of cases of 
AD, the discoveries from these young onset families had, and continue to have, 
profound implications. The amyloid cascade hypothesis was proposed, which posits that 
accumulation of Aβ is the initiating event in AD pathogenesis (Hardy and Higgins, 
1992). This hypothesis has had a major influence on research and motivated the 
development of therapies that aim to reduce production of Aβ or increase its clearance 
from the brain. Identification of FAD mutations also provided the information necessary 
to make transgenic animals in which these therapies could be tested, some with dramatic 
effect, before going in to a series of trials in humans. Ironically, these initial clinical 
trials tended to exclude the familial patients that had contributed to the ideas and models 
on the basis of their young age. 
 
1.1.4 Young onset and familial Alzheimer’s disease return to the spotlight 
More recently, there has been a refocus on young onset AD and in particular FAD, with 
clinical trials belatedly turning their attention towards individuals with autosomal 
dominantly inherited mutations. This was largely because of changes in the view of 
when the disease first develops in the brain, when it is first detectable in vivo, and when 
it may be most effective to intervene. This paradigm shift has been driven by a 
realisation that AD has a long presymptomatic period, partly informed by the 
prospective study of asymptomatic individuals including those at risk of FAD.  The 
potential for early identification and intervention has been enhanced by the development 
of new cerebrospinal fluid (CSF) markers and brain positron emission tomography 
(PET) imaging measures of amyloid and tau. More recent research diagnostic criteria 
for AD incorporate biomarkers and preclinical states of disease into the framework 
(Dubois et al., 2014). Just as technological developments at the turn of the twentieth 
century, in the form of new histological staining methods and microscopes, facilitated 
the original definition of AD, advances in biomarker and imaging technology over the 
past decade have supported this latest conceptualization of the disease. Molecular 
imaging with PET tracers that bind amyloid and tau now allow us to see what 
 18 
Alzheimer couldn’t see: the "plaques and tangles” during life. The increasing 
recognition of the long preclinical period to AD coincided with a series of failures of 
treatment trials that included patients with mild to moderately severe dementia. The 
concern that emerged is that if the disease has a 10-15 year presymptomatic period (or 
longer) when plaques and tangles become established and widely distributed in the 
brain, it may be too late or at least more difficult to a slow a process that has already 
gathered momentum by the time a patient has established dementia. If it is possible to 
detect and track the extent of amyloid and tau pathology in vivo as well as more 
downstream effects such as atrophy and cognitive impairment then presymptomatic 
treatment trials become more feasible; offering the prospect of interventions when there 
has been the minimum of irreversible neuronal damage and when there is most to save 
in terms of function.  
 
Hence we enter the era of presymptomatic secondary prevention trials, with studies 
underway to test treatments in asymptomatic individuals at risk for Alzheimer’s disease 
by virtue of genetics, FAD or APOE4, or because of imaging or biochemical evidence 
of prodromal cerebral amyloid accumulation.  The effects of therapy will be tracked 
with MRI, PET and CSF as well as sensitive cognitive measures, aiming to delay the 
onset of the symptoms that led to Auguste D’s institutionalisation and that are so 
devastating to millions globally. Alzheimer and Auguste’s contributions and the debates 
that surrounded them remain as relevant as ever. Observations that around a third of 
cognitively normal older people have positive amyloid scans have resurrected some of 
the century-old discussions about the relationship between dementia and normal aging, 
and the question of how generalizable early onset (and particularly familial) AD is to 
late onset disease has never been so timely. In this context, with the report in 2013 that 
Auguste D. had had a PSEN1 mutation it seemed that perhaps a full circle had been 
reached, with treatments being tested in families that may have been her distant 
relatives. However, in a follow-up report the following year the mutation in Auguste D. 
was not validated, nor were mutations in APP or PSEN2 identified (Rupp et al., 2014). 
The rediscovery of Auguste D.’s brain sections in 1997 had allowed the pathological 
diagnosis of AD to be confirmed by modern immunohistochemical methods but any 
genetic basis for her disease (she was APOE3 homozygous) remains, as with so many 
other early onset AD patients, a mystery.  
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The past century has seen a number of transformations in the conceptualization of AD. 
The 2013 G8 dementia summit recognized AD as a growing global health and economic 
problem, requiring serious action in terms of investment in research and development of 
disease-modifying therapies but also that alongside the search for prevention and 
treatment strategies we must invest in enabling people to live well with dementia - 
ensuring that patients and their families have access to early diagnosis and support that 
is all too often lacking. A hundred years on, Alzheimer’s legacy is more relevant than 
ever – in fact the question of how tractable is this disease and how we care for those 
with it is perhaps one of the key challenges for the coming century. The concept of AD 
will no doubt undergo further refinements and reinventions over future decades. 
Reflection on the diverse factors that have shaped the concept of AD over the past 
century may, therefore, inform our understanding of developments in the way we 
perceive and respond to the disease in the years to come. 
 
1.2  Alzheimer’s disease pathogenesis and the role of genetic mutations 
 
Since the discoveries in the early 1990s that FAD could be caused by autosomal 
dominantly inherited mutations in APP, PSEN1 and PSEN2 over two hundred variants 
have been described in these genes. Many are clearly established as pathogenic for AD, 
some are thought to represent non-pathogenic polymorphisms and in other cases, the 
pathogenic nature of the change is as yet unclear. In addition to trisomy 21, duplications 
of the APP gene have also been identified as a cause of FAD (Rovelet-Lecrux et al., 
2006). Mutations in PSEN1 account for the majority of cases of FAD and it is in PSEN1 
that the greatest numbers of mutations have been found, with 219 recorded to date 
(January 2017) compared to 51 and 16 in APP and PSEN2 respectively [2]. Collectively, 
these mutations are thought to account for less than 1% of Alzheimer’s disease cases. 
The degree to which FAD may be a paradigm for the much commoner, late onset, 
sporadic form of the disease is uncertain but the insights gleaned from the study of FAD 
have catalysed much of our current knowledge of the pathobiological basis of the 
disease. The development of cellular models and transgenic mice harbouring mutations 
in APP and the Presenilins has allowed the disease mechanism to be explored in detail 
and probed with potential therapeutic agents. As these therapies come closer to clinical 
application, the debate regarding how generalisable the changes of FAD are to those of 
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sporadic AD grows in significance. Unravelling the pathway through which specific 
genetic mutations translate into the manifestations of clinical AD, and how the resulting 
phenotypes may vary, are clearly important areas of investigation. However although 
much has been published describing novel FAD gene mutations and exploring their 
functional effects at a molecular level, there have been fewer detailed reports of the 
resulting clinical phenotypes (Larner and Doran, 2006, Larner and Doran, 2009, 
Jayadev et al., 2010, Tang et al., 2016). In this section of the Introduction, I review how 
closely the phenotype of FAD resembles and differs from that of sporadic AD. The 
importance of appreciating the degree of phenotypic heterogeneity that exists in both 
familial and sporadic AD becomes apparent and will form a major theme of this thesis. 
Finally, I discuss several mechanisms by which the clinical picture, and underlying 
pathology, may be influenced by genotype.  
 
The pathological hallmarks of AD in both familial and sporadic cases are extracellular 
plaques of Aβ and intraneuronal inclusions of hyperphosphorylated tau. Although the 
initiating driver of pathology in sporadic AD remains unclear, it is now well recognised 
that mutations in all three genes known to cause FAD ultimately result in enhanced 
production and/or deposition of Aβ (Selkoe, 1997). The mechanisms through which 
they achieve this are complex and variable. APP is a transmembrane protein whose 
function is not yet fully determined, although it appears to play a role in neural plasticity 
and the regulation of synapse formation. APP may be proteolytically cleaved by α, β 
and γ secretases and, during its normal metabolism, it can undergo cleavage via 
alternative pathways. Cleavage by α-secretase is considered to be part of the non-
amyloidogenic pathway in APP processing. It precludes Aβ formation as it cleaves 
within the segment of APP that would otherwise give rise to Aβ (see Figure 1.3) (Esch 
et al., 1990). Upon cleavage by α-secretase, APP releases its extracellular domain, a 
fragment called APPsα, which is known to have neurotrophic effects. Alternatively, 
APP may undergo sequential cleavage by β and γ secretase. Extracellular cleavage by β-
secretase (also known as BACE1: β-site of APP cleaving enzyme) generates a soluble 
extracellular fragment and is followed by cleavage of APP within its transmembrane 
domain by γ secretase. The unusual property of γ-secretase is that it may cleave APP at 
a variety of different sites, generating a peptide from 39-43 amino acids in length; the 
amyloid- β (Aβ) protein. PSEN1 forms part of the γ secretase complex (De Strooper et 
al., 1998) and the majority of pathogenic PSEN1 mutations are located in areas thought 
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to lie in the vicinity of its transmembrane domains. Under normal conditions, the 
majority of Aβ is in the form of a 40 amino acid long peptide “Aβ-40”. There is some 
additional production of the longer moiety; Aβ-42, which accounts for 5-15% of the 
total pool of Aβ in health. Smaller quantities of other Aβs, both longer and shorter, may 
also be observed. Aβ peptides, particularly Aβ-42, can cause toxic effects on neuronal 
and synaptic function as intracellular oligomers and can also seed to form extracellular 
precipitates in the form of amyloid plaques. Aβ-42 is the most amyloidogenic form of 
the peptide; its hydrophobic nature makes it more susceptible to conformational change 
leading to amyloid fibrillogenesis (Jarrett et al., 1993, McGowan et al., 2005).  
 
Figure 1.3 APP gene with mutations indicated     
Diagram courtesy of Richard Crook, Mayo Clinic Jacksonville, and John Hardy, 
Institute of Neurology, University College London. Reprinted from (Ryan and Rossor, 
2010), with permission. 
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Most FAD-causing mutations were thought to either increase Aβ-40 and Aβ-42 or alter 
the ratio between them. However, the discovery of the ‘Arctic’ APP mutation 
(p.Glu693Gly) in a Swedish family, which is located away from the secretase sites, led 
to the suggestion of an alternative pathogenic mechanism. Aβ-40 and Aβ-42 are actually 
found in decreased levels with this mutation, however they have an increased propensity 
to form protofibrils, which may accelerate their deposition in intracellular or 
extracellular locations, or both (Nilsberth et al., 2001). More recent kinetic studies have 
investigated how γ-secretase carries out a number of sequential cleavages of its 
substrates. There is an initial endopeptidase cleavage releasing a soluble intracellular 
domain, which may translocate to the nucleus to regulate gene expression. Successive 
carboxypeptidase-like cleavages then process the remaining transmembrane fragment. 
PSEN1 mutations all appear to decrease the efficiency of this carboxypeptidase-like 
activity, resulting in the release of longer Aβ peptides, which are more prone to 
aggregation (Chavez-Gutierrez et al., 2012, Szaruga et al., 2015).  
 
1.3  Clinical manifestations of Alzheimer’s disease 
 
The most obvious and striking difference between familial and sporadic AD in general 
is that individuals harbouring FAD mutations typically have a much younger age at 
onset. That the disease should manifest at an earlier age is not surprising, given the 
increased Aβ deposition that these mutations cause. The youngest ages at onset are seen 
in families with PSEN1 mutations, which typically fall within the range 35-55 years –
although cognitive symptoms may manifest as early as the third decade of life 
(Moehlmann et al., 2002). APP mutations tend to give rise to symptom onset between 
40-65 years and PSEN2 mutations between 40-70 years. It has been suggested that, as 
well as being associated with a younger age at onset of disease, PSEN1 mutations give 
rise to shorter disease durations (4.8-6.8 years) than PSEN2 and APP mutations (range 
4.4 – 10.8 years and 9.0 – 16 years respectively) (Holmes, 2002). However, the survival 
data of different series demonstrate considerable variation. Although the disease course 
of FAD is often considered to be more aggressive, some reports find comparable disease 
durations for the familial and sporadic forms of AD (Godbolt et al., 2004). A large 
meta-analysis, which pooled information from a number of different FAD datasets, 
found the average disease duration in FAD (9.7 years) to be just modestly shorter than 
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the average disease duration in sporadic AD (11.3 years) (Ryman et al., 2014). Drawing 
direct comparisons between disease duration in familial and sporadic AD is problematic 
as survival is likely to be affected by age at onset itself. Younger, healthier patients may 
survive longer at more severe stages of disease than older patients with sporadic AD, 
who are more likely to be frail and often have multiple co-morbidities. Another major 
difficulty in interpreting survival data is that estimates for age at symptom onset are 
highly subjective and unreliable. Symptoms tend to develop insidiously so, in some 
cases, may pass unrecognised for quite some time. On the other hand, as awareness of 
the heritable nature of the disease heightens with subsequent generations, symptoms are 
likely to be noticed at an earlier stage. This probably contributes to the range in age at 
onset that is witnessed both between and within families with the same mutation. 
However, other genetic and epigenetic factors are also likely to be important in 
modulating age at onset.  
 
Possession of an APOE4 allele has been reported to be associated with younger 
symptom onset in a family with the APP p.Val717Ile mutation (Sorbi et al., 1995), as is 
the case in sporadic AD, although  APOE genotype was not found to influence age at 
onset in kindreds with APP mutations at codon 692 or 693 (Haan et al., 1994). In 
PSEN1 mutations, a modifying effect on age at onset by the E4 allele was not 
previously thought to occur (Van Broeckhoven et al., 1994). However, when a single 
large Colombian kindred with the p.Glu280Ala PSEN1 mutation was examined, the 
APOE4 allele did appear to be associated with an earlier age at onset (Pastor et al., 
2003). Younger ages at onset in APOE4 carriers have also been reported in kindreds of 
Volga German descent carrying the same p.Asn141Ile PSEN2 mutation (Wijsman et al., 
2005). In the recent meta-analysis of pooled FAD datasets, as expected, an individual’s 
age at symptom onset correlated strongly with their parental age at onset, the mean age 
at onset for their family and the mean age at onset for their mutation type (Ryman et al., 
2014). However, although mutation type accounted for a majority of the variance in age 
at symptom onset, substantial variation remained within many families and mutation 
types, suggesting the existence of other genetic, environmental and stochastic modifying 
factors (Fox et al., 1997). Although there were trends towards younger ages at onset in 
APOE4 carriers and later ages at onset in APOE2 carriers, these did not reach 
significance in the pooled datasets. Pathological studies have shown that the proportion 
of brain tissue occupied by Aβ-42-containing plaques is significantly higher in PSEN1-
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associated AD than sporadic AD. Although there does not appear to be a difference in 
the amount of tissue containing Aβ-40 between these two disease groups, both PSEN1-
AD and sporadic AD show the same relationship between Aβ deposition and APOE 
genotype: Individuals who carry an E4 allele demonstrate a greater proportion of Aβ-40 
deposition in both familial and sporadic disease. It has been suggested that, in the 
presence of the apolipoprotein E4 isoform, the threshold for Aβ-40 fibrillisation is 
decreased, fostering the deposition of Aβ-40 onto Aβ-42-containing plaques (Mann et 
al., 2001).  
 
1.3.1 Cognitive phenotypes 
1.3.1.1 Amnestic presentations 
The majority of individuals with FAD have similar clinical presentations to those with 
sporadic AD, comprising early impairment of episodic memory, which gradually 
progresses to involve multiple cognitive domains. Longitudinal group studies of 
individuals at risk of FAD demonstrate that the earliest neuropsychological 
manifestations are a subtle fall in verbal memory and performance IQ scores, occurring 
at least 2-3yrs presymptomatically (Fox et al., 1998). The neuropsychological profile of 
FAD at a group level has also been found to show relatively well preserved naming, 
spelling and visuoperceptual skills compared with sporadic AD in the early stages 
(Warrington et al., 2001, Godbolt et al., 2004). There can therefore be a particularly 
long prodromal phase in FAD, where subtle memory problems are the only clinical 
feature for several years (Godbolt et al., 2004). Presymptomatic cognitive deficits are 
accompanied by a range of neuroimaging changes (discussed in chapter 2) with 
gradually accelerating rates of whole brain and hippocampal atrophy in the five years 
prior to symptom onset (Scahill et al., 2002) (Chan et al., 2003). 
 
The early stages of sporadic AD have been harder to study. Historically, individuals 
with memory concerns have tended to seek medical attention only when their symptoms 
are well established. However, we are currently witnessing a change in the tide of public 
opinion towards an appreciation of the importance of early diagnosis. There is increased 
recognition that most patients with sporadic AD are likely to have experienced a period 
of relatively isolated, usually amnestic, deficits termed mild cognitive impairment 
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(MCI) prior their diagnosis of AD (Petersen et al., 1999). The term MCI is usually used 
to refer to individuals with cognitive decline which is more than anticipated from 
normal aging but insufficient to fulfil criteria for dementia. The term will thus be 
applied to a heterogeneous group, not all of whom will develop AD, and there is a great 
research effort aiming to improve the characterization of these individuals and refine the 
definition of the MCI label (Albert et al., 2011, Dubois et al., 2014). Nevertheless, there 
are now many lines of evidence supporting the notion that sporadic AD is preceded by a 
long prodromal stage. The canonical FAD phenotype, manifesting with early 
progressive impairment of episodic memory, can perhaps then be viewed as equivalent 
to the typical amnestic AD phenotype, preceded by MCI, that is seen commonly in 
sporadic disease. 
 
Many atypical presentations of FAD have, however, been reported and there can be 
significant heterogeneity both between and within families regarding clinical phenotype. 
Heterogeneity, however, also exists within sporadic AD and as recognition of these 
more unusual variants increases, they may be found to occur more frequently than was 
previously appreciated. 
 
1.3.1.2 Language presentations 
Several PSEN1 mutations have been reported to present with language impairment 
including p.Gly209Val, p.His163Tyr, p.Pro264Leu and p.Arg278Ile. The p.Pro264Leu 
and p.Arg278Ile mutations were detected in patients who were given initial clinical 
diagnoses of progressive non-fluent aphasia (Godbolt et al., 2004, Mahoney et al., 
2013). Language deficits have been described in association with many other mutations 
later in the disease course, as is also often the case in sporadic AD. There is a growing 
body of research aiming to better characterise individuals with neurodegenerative 
disease who have predominant impairments of language function at presentation. 
Primary progressive aphasia (PPA) was traditionally thought to signify a disease in the 
spectrum of frontotemporal lobar degenerations. However, a ‘logopenic’ variant (LPA) 
of PPA is now also recognised, in which AD appears to be the commonest underlying 
pathology (Gorno-Tempini et al., 2008). 
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1.3.1.3 Behavioural and psychiatric presentations 
In sporadic AD, symptoms of agitation, depression, delusions and hallucinations occur 
commonly, particularly in the later stages of disease. Many PSEN1 mutations are 
associated with behavioural and psychiatric symptoms during the course of the disease 
and these can, rarely, be the presenting features. Prominent early behavioural symptoms 
have also been reported in association with several PSEN2 mutations, including 
pMet239Val, p.Thr122Arg and p.Tyr231Cys. (Marcon et al., 2009).  An underlying 
pathological diagnosis of AD has been obtained for some PSEN1 mutations where a 
behavioural presentation has been described, including p.Val89Leu (Queralt et al., 
2002), p.Leu226Phe (Zekanowski et al., 2006) and p.Met139Val (Rippon et al., 2003). 
It has been suggested that a distribution of pathology involving structures in frontal-
subcortical circuits, such as the thalamus and striatum, may contribute to the 
behavioural phenotype in some of these patients (Queralt et al., 2002). Pathological 
confirmation for other PSEN1 mutations such as p.Leu113Pro remains to be established. 
(Raux et al., 2000) In some cases, the presence of behavioural and language features has 
been prominent enough to prompt a clinical diagnosis of frontotemporal dementia 
(FTD), as was the case for the PSEN1 insArg352 genotype (Amtul et al., 2002, Tang-
Wai et al., 2002). It was initially hypothesised that this PSEN1 genotype may be 
capable of inducing a distinct neurodegenerative illness, more akin to FTD than AD. 
Intriguingly, not only did the members of the kindred have an FTD phenotype but when 
an affected individual eventually came to autopsy, ubiquitin pathology typical of FTD 
was found. The subsequent discovery of the progranulin gene as a cause of familial 
FTD led to a re-evaluation of this case, which was indeed found to harbour a 
progranulin mutation (Pickering-Brown et al., 2006). With the benefit of hindsight, the 
change in PSEN1 was then reconsidered to be a non-pathogenic polymorphism. This 
case highlights the importance of exercising caution when ascribing pathogenicity to 
rare PSEN1 variants, especially when the phenotype is unusual. 
 
1.3.1.4 Visual presentations 
Visuospatial and visuoperceptual deficits commonly occur in the later stages of both 
sporadic and familial AD. In sporadic AD, a posterior cortical atrophy (PCA) variant 
may occur, where marked visual processing deficits are the presenting features and 
memory is relatively well preserved until later in the disease (Mendez et al., 2002, 
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Tang-Wai et al., 2004, Crutch et al., 2012). PCA is an umbrella term for a 
neurodegenerative syndrome that preferentially affects parietal, occipital and occipito-
temporal brain regions, characterised by progressive deterioration of higher visual 
processing skills and other posterior cortical functions including literacy, numeracy and 
praxis. Although AD is by far the most common underlying cause (Renner et al., 2004), 
a number of different pathologies can also give to the PCA syndrome, including 
corticobasal degeneration (CBD), dementia with Lewy bodies (DLB), prion disease and 
subcortical gliosis (Victoroff et al., 1994, Renner et al., 2004, Tang-Wai et al., 2004). 
Some studies comparing the distribution of pathology in AD cases with PCA and 
typical amnestic presentations have demonstrated higher amyloid plaque and 
neurofibrillary tangle burden in primary visual and visual association areas in PCA (Hof 
et al., 1997). Others found increased neurofibrillary tangle but similar amyloid plaque 
density in visual areas, with fewer tangles or plaques in the hippocampus in PCA 
compared to typical AD (Tang-Wai et al., 2004). Estimates of the overall prevalence of 
PCA are difficult, partly because it tends to be under-diagnosed and because different 
ways of describing the syndrome are used inconsistently. However, in a study of all AD 
patients presenting to one specialist centre, 5% were found to have had a visual and 3% 
an apraxic presentation (Snowden et al., 2007).  
 
Symptom onset in PCA tends to occur at a much earlier age than in AD in general: 
typically mid-50s to early 60s (Mendez et al., 2002), although a wider age spread (40-
86 years) has been reported (Tang-Wai et al., 2004). Despite the young age at onset, the 
available cases series indicate that PCA patients do not tend to have any stronger family 
history of dementia than patients with typical AD. In earlier studies, PCA appeared to 
be associated with the same or lower APOE4 allele frequency as typical AD (Mendez et 
al., 2002, Tang-Wai et al., 2004, Schott et al., 2006, van der Flier et al., 2006, Snowden 
et al., 2007, Balasa et al., 2011). More recently, in a large study of patients with a 
clinical diagnosis of PCA and a separate group of patients lacking clinical information 
who had posterior AD neuropathologically, APOE4 did appear to be a risk factor for 
PCA and CLU, BIN1 and ABCA7 were identified as additional potential risk loci 
(Carrasquillo et al., 2014). An international consortium to assess genetic risk factors for 
PCA has since been established, which confirmed that APOE is a risk factor for PCA 
(although a weaker risk factor than for typical AD), and identified CR1, ABCA7, BIN1 
and three novel loci (SEMA3C, CNTNAP5 and FAM46A) as potential genes of interest 
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in PCA (Schott et al., 2016). There have been only single case reports of patients with 
familial disease presenting with PCA – including PCA due to a PSEN1 mutation (Sitek 
et al., 2013) and familial prion disease due to a 5-octapeptide repeat insertion (Depaz et 
al., 2012) in the prion protein gene. 
 
1.3.2 Neurological symptoms and signs 
 
Neurological symptoms and signs tend to be more prominent in FAD than sporadic AD, 
and have been recognised as a feature of the disease ever since it was first reported. 
Myoclonus and seizures are common. Spastic paraparesis, extrapyramidal signs and 
cerebellar ataxia have also been described, though less frequently. Rarely, neurological 
manifestations may be presenting symptoms of FAD (Appendix 11.1). All of these 
features seem to be particularly prominent in kindreds with very early onset of 
symptoms, below the age of 40 (Snider et al., 2005). However, it is important to note 
that significant phenotypic heterogeneity is observed, both between families sharing a 
common mutation and within the affected individuals of a single family. Whilst all of 
these unusual features do appear to occur more frequently in familial than sporadic AD, 
the fact that younger patients often survive to more severe stages of disease may 
contribute in part to the trend. The preference for reporting atypical cases of FAD over 
those with sporadic AD may also play a role. Furthermore, atypical AD phenotypes 
often cause diagnostic uncertainty in sporadic disease and are less likely to be reported 
unless post-mortem (or other) confirmation of AD is obtained. In some reports of 
individuals with FAD, particularly those including longitudinal assessments, it is clear 
that neurological symptoms and signs developed at an early stage of the disease and 
there are cases where these features predate cognitive impairment. However, other 
reports of ‘early’ atypical features should be read with caution as sometimes the disease 
may be well established by the time a patient first presents to a clinician.  
 
1.3.2.1 Myoclonus and seizures 
Myoclonus, especially perhaps fine finger myoclonus, can be a particularly prominent 
and early sign in FAD, in contrast to sporadic AD where it tends to become apparent 
later in the course of the disease. The same pattern appears to occur with seizures, 
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which seem to be reported more frequently and at an earlier stage in the disease in FAD 
than in sporadic AD (Kennedy et al., 1993, Zarea et al., 2016). Myoclonus and seizures 
are often reported in very young onset cases of FAD. In fact, tonic-clonic seizures pre-
dating the onset of cognitive impairment by several years have been reported in 
association with the PSEN1 p.Leu166Pro and p.Leu235Pro mutations, both of which 
may cause cognitive symptoms in the third decade of life (Campion et al., 1996, 
Moehlmann et al., 2002). Fine finger myoclonus has also been noted to occur prior the 
onset of objective memory impairment, although it may not necessarily be apparent to 
the patient or their family at this mild early stage (Godbolt et al., 2004). Interestingly, 
there is a cluster of mutations associated with early myoclonus and seizures in the 
region encoding transmembrane domain III of the PSEN1 gene (p.Leu166Pro, 
p.Ser169Leu, p.Ser169Pro, p.Ser170Phe). Early myoclonus and seizures are also 
observed in individuals with APP mutations and particularly with APP duplications (see 
below). 
 
1.3.2.2 Spastic paraparesis 
Spastic paraparesis has been reported in association with over twenty different PSEN1 
mutations (Karlstrom et al., 2008). Symptoms of spastic paraparesis may occur 
simultaneously with cognitive deficits or may predate them by several years. 
Progressive spastic paraparesis occurring for over a decade prior to the onset of 
cognitive impairment has been reported in association with the PSEN1 p.Arg278Lys 
mutation (Assini et al., 2003). In some families, individuals with spastic paraparesis 
have appeared to have a delayed onset of dementia compared to their relatives lacking 
these features (Smith et al., 2001, Assini et al., 2003). There is a particular association 
of spastic paraparesis with PSEN1 exon 9 deletions, although not all individuals with 
these deletions demonstrate the phenotype (Hiltunen et al., 2000). In those who do, 
there are frequently characteristic histological findings of large, rounded plaques in the 
frontal cortex known as ‘cotton wool plaques’ (Verkkoniemi et al., 2000). Composed of 
Aβ40 and 42, cotton wool plaques usually lack a compact amyloid core and show very 
little neuritic change or glial cell component. The spastic paraparesis phenotype of FAD 
is often not associated with any specific imaging findings. However, significant white 
matter abnormalities on cranial MRI, presumed secondary to amyloid angiopathy, have 
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been observed in a family exhibiting spastic paraparesis and cotton wool plaques 
secondary to the p.Glu280Gly PSEN1 mutation (O'Riordan et al., 2002). 
 
Several hypotheses have been proposed to explain why certain PSEN1 mutations may 
give rise to the spastic paraparesis phenotype. The observation that most of the 
mutations associated with spastic paraparesis cause exceptionally high levels of Aβ42 
suggests that a dosage effect may be operating (Houlden et al., 2000). Intraneuronal Aβ 
may also play a role; this is a more frequent finding in AD patients with cotton wool 
plaques. As intraneuronal Aβ is known to induce only a weak immune response, it has 
been postulated that cotton wool plaques may result from a combination of increased 
Aβ production and decreased clearance (Tabira et al., 2002). However, the presence of 
cotton wool plaques per se is not enough to explain the phenotype as these have also 
been found in patients lacking signs of spastic paraparesis (Yokota et al., 2003). 
Furthermore, the presence of spastic paraparesis is highly variable, even between the 
affected individuals of a single family sharing identical mutations and similar 
environmental exposures. There may, therefore, be additional as yet unidentified factors 
operating in these patients that drive the pathology towards structures, like the 
corticospinal tracts and motor cortex, which are usually spared in both familial and 
sporadic AD.   
 
1.3.2.3 Extrapyramidal signs 
Extrapyramidal signs have been reported in association with several different PSEN1 
mutations, particularly those causing very early onset disease and other neurological 
signs such as spastic paraparesis (Dintchov et al., 2009). A novel PSEN2 mutation 
(p.Ala85Val) has also been reported where Parkinsonism was a feature (Piscopo et al., 
2008). In the majority of cases, the Parkinsonism does not become apparent until 
several years into the clinical course. However, an extrapyramidal syndrome 
characterised by rigidity, bradykinesia and an abnormal posture and gait was present 
from the onset of cognitive symptoms in the first reported kindred harbouring the 
PSEN1 p.Gly217Asp mutation (Takao et al., 2002). The autopsy findings in this family 
included, in addition to neurofibrillary tangles, amyloid angiopathy and neuritic 
plaques, neuronal rarefaction in the substantia nigra and numerous cotton wool plaques. 
These were distributed throughout the cerebral cortex but were also concentrated in 
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subcortical structures, particularly the striatum. As the authors suggest, the topography 
of pathology in these patients could account for their clinical presentations. Furthermore 
these cases illustrate how the separate, yet often overlapping, phenotypes of spastic 
paraparesis and Parkinsonism in FAD may share a common pathological substrate of 
cotton wool plaques located in specific anatomical areas.  
 
Another histological feature that can underlie a Parkinsonian presentation of FAD is 
Lewy body pathology (LBP). Both LBP and cotton wool plaques were detected in a 
patient exhibiting a dopa-responsive Parkinsonian syndrome who developed cognitive 
symptoms seven years after the onset of his movement disorder. He was found to 
possess a novel three base pair deletion (p.Thr440del) in PSEN1 (Ishikawa et al., 2005). 
Widespread neocortical LBP has been demonstrated in a kindred with very early onset 
FAD secondary to a p.Ser170Phe PSEN1 mutation, in which the age at symptom onset 
was as young as 26 (Snider et al., 2005). In this family, myoclonus, seizures and 
extrapyramidal signs were features of the disease. Parkinsonism, seizures, a very early 
onset of disease and LBP were also reported in association with the p.Met233Val 
mutation in PSEN1 (Houlden et al., 2001). However, not all FAD patients with 
extrapyramidal signs are found to have LBP and equally, many patients with LBP do 
not manifest Parkinsonism clinically. In fact, concomitant LBP is a frequent finding in 
neuropathological examinations of patients with both familial and sporadic AD, 
occurring in up to 60% patients with each disease according to some series (Lippa et al., 
1998, Hamilton, 2000). Studies including analysis of the frequency of LBP in different 
FAD gene mutations have suggested that PSEN1 mutations are significantly more likely 
to have associated LBP than PSEN2 mutations (Leverenz et al., 2006). Furthermore, 
there appear to be mutation-specific effects on the development of LBP in FAD. Certain 
PSEN1 mutations such as p.Ala260Val are associated with diffuse LBP whereas in 
others, like p.Gly209Val, the LBP seems to occur in the amygdala only. In other PSEN1 
mutations, such as p.Ala246Glu, there tends to be very little LBP at all (Lippa et al., 
1998). LBP has also been observed in association with APP mutations and, with both 
the Presenilins and APP, no correlations between mutation position and the 
development of this pathological picture have been identified (Houlden et al., 2001). It 
has been suggested that the presence of diffuse LBP in FAD is associated with longer 
durations of disease than when the LBP is restricted to limbic areas (Leverenz et al., 
2006). However, a detailed understanding of the significance of LBP in FAD and how 
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LBP relates to duration and manifestation of disease remains to be elucidated, 
particularly as many studies were conducted before synuclein antibodies became 
available.  
 
1.3.2.4 Cerebellar signs 
Variable cerebellar Aβ deposition has been observed in both familial and sporadic AD 
(Cole et al., 1989, Larner, 1997). In several PSEN1 mutations, particularly p.Glu280Ala 
(Lemere et al., 1996), p.Ile143Thr (Martin et al., 1991), p.Met139Val (Haltia et al., 
1994) and p.Gly209Val (Lampe et al., 1994) severe involvement of the cerebellum by 
Aβ plaque deposition has been noted. This has also been found in FAD secondary to the 
APP717 mutations (Mann et al., 1996) and in the brains of elderly patients with Down 
syndrome (Mann et al., 1990, Mann and Iwatsubo, 1996). Even in cases of FAD with 
similar amounts of Aβ deposition to sporadic AD in the cerebellum, cerebellar Purkinje 
cell loss and reactive astrocytosis are significantly more severe in FAD than sporadic 
AD (Fukutani et al., 1997). Pathological involvement of the cerebellum may occur 
without cerebellar signs featuring in the clinical presentation (Larner and Doran, 2006). 
However, progressive cerebellar ataxia has been reported as preceding cognitive 
impairment in the p.Ser170Phe (Piccini et al., 2007) and p.Pro117Ala (Anheim et al., 
2007) mutations in PSEN1. Furthermore, cerebellar signs have been observed during the 
disease course in a range of other mutations in PSEN1, including p.Glu280Ala 
(Sepulveda-Falla et al., 2014) and p.Leu282Val (Dermaut et al., 2001). This latter 
mutation is notable for its association with an unusually high amount of amyloid 
angiopathy, which was found to involve the cerebellum in the individual manifesting 
cerebellar signs.  
 
1.3.3 Influence of mutation location on pathology and phenotype 
1.3.3.1 Presenilin 1 mutations  
Two distinct histopathological profiles have been identified in FAD caused by PSEN1 
mutations and the type of pathology appears to be driven by the position of the mutation 
within the gene (Mann et al., 2001). Mutations occurring before codon 200 are more 
frequently associated with a type 1 pattern of pathology whilst mutations beyond codon 
200 tend to have type 2 pathology, which includes more severe cerebral amyloid 
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angiopathy (CAA). Type 1 pathology more closely resembles the pathology seen in 
sporadic AD, with many diffuse and cored plaques and few white matter plaques. CAA 
is only mild to moderate, and is usually confined to leptomeningeal vessels. In type 2 
pathology, the number and distribution of diffuse and cored plaques is similar but these 
tend to be much larger and concentrated around amyloidotic arteries. CAA is nearly 
always severe, involving both leptomeningeal and intraparenchymal arteries. Aβ40 
deposition tends to be increased in those with type 2 pathology, and this effect is 
independent of APOE genotype. As might be expected, the distinction between the two 
types of pathology is not absolute; some mutations occurring before codon 200 have 
been associated with widespread CAA, such as p.Glu184Asp (Yasuda et al., 1997) and 
p.Ile83_Met84del (Steiner et al., 2001). Equally, the p.Asn405Ser mutation, occurring 
after codon 200, appears to produce limited CAA (Yasuda et al., 2000). However, 
overall there do appear to be clinical implications of the different histopathological 
signatures. Individuals with type 1 pathology have been reported to have a younger age 
at onset (by on average 5 years) and shorter disease duration (by around 2.5 years) than 
those with type 2 pathology (Mann et al., 2001). The influence of PSEN1 mutation 
position on the clinical phenotype of FAD is explored in more detail in chapter 3 of this 
thesis. 
 
In order to explain the dichotomous manner by which the mutation site influences the 
development of amyloid angiopathy, it has been suggested that PSEN1 mutations may 
actually act through two separate pathways (Mann et al., 2001). First, they increase the 
production and deposition of Aβ42 and secondly, by affecting Notch signalling, they 
induce breakdown of the vascular epithelium. The subsequent leakage of Aβ into brain 
tissue may seed onto existing deposits of Aβ, producing the large plaques seen around 
vessels in type 2 pathology, and promoting the development of CAA. Interestingly, the 
residues of PSEN1 that are thought to be functionally most important, namely aspartyl 
residues at the active site and PSEN1 cleavage site, are located in the region of the gene 
where mutations are associated with severe amyloid angiopathy. Also important is the 
observation that these type 2 cases have less aggressive phenotypes, with later ages at 
onset and longer disease durations.  
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1.3.3.2 APP mutations  
The majority of APP mutations reported to date lie in the vicinity of the β and γ 
secretase cleavage sites. APP residue 717, located just distal to the C-terminus of the Aβ 
domain by the γ secretase site, was recognised early on to represent a mutation hotspot. 
The ‘London’ APP V717I mutation was the first described (in DRC family 23), 
comprising valine substituted by isoleucine, but valine substituted by glycine, 
phenylananine or leucine at the 717 codon also results in a similar phenotype.  Families 
with mutations at this site were found to share common features of early impairment of 
episodic memory, dyscalculia, lack of insight and prominent myoclonus and seizures 
(Rossor et al., 1993). A double point mutation at APP 670/671 (G to T, A to C), 
resulting in a lysine methionine to asparagine leucine double substitution, was later 
identified in two Swedish families (Mullan et al., 1992). This double mutation frames 
the other end of the Aβ domain, lying at the N-terminus by the β secretase site. 
 
Some mutations have also been found within the Aβ coding sequence, and these appear 
to have specific pathological and clinical features, particularly in relation to CAA 
(Table 1.1). The ‘Dutch mutation’ in APP; a missense mutation resulting in a glutamate 
to glutamine substitution at position 693 (APP p.Glu693Gln) gives rise to a highly 
distinct phenotype (Van Broeckhoven et al., 1990). These individuals have severe CAA 
leading to recurrent cerebral haemorrhage. The main clinical features are focal 
neurological symptoms and signs relating to these cerebrovascular events, although 
most patients do also develop dementia. Pathologically, diffuse parenchymal deposits of 
Aβ are observed, but the hallmark neuritic plaques and neurofibrillary tangles of AD are 
absent. A neighbouring mutation at residue 692 (an alanine to glycine substitution) has 
been reported in a separate family and labelled the Flemish mutation (Hendriks et al., 
1992). The affected individuals suffered either haemorrhages or a progressive dementia 
or both. A biopsy of a family member with haemorrhages revealed CAA with sparse 
neuritic plaques but no neurofibrillary tangles. Postmortem examination of mutation 
carriers presenting with dementia did, however, demonstrate neurofibrillary tangles, in 
addition to neuritic plaques and CAA (Roks et al., 2000). Presymptomatic carriers of 
the Flemish mutation have also been investigated and found to have significantly 
increased periventricular and subcortical white matter lesions on cranial MRI (Roks et 
al., 2000).  
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Table 1.1 Clinical and pathological features of autosomal dominant APP mutations 
lying within the Aβ coding domain 
 
APP Mutation 
 
CAA 
 
Amyloid 
plaques 
 
Neurofibrillary 
tangles 
 
Clinical Phenotype 
 
Flemish 
p.Ala692Gly 
 
Present 
 
Present 
 
Usually present 
  
 
Recurrent cerebral 
haemorrhage or 
dementia or both 
 
 
Dutch 
p.Glu693Gln 
 
Present 
 
Absent 
 
Absent 
 
 
 
 
Predominantly 
recurrent cerebral 
haemorrhage. Usually 
also followed by 
dementia 
 
 
Arctic 
p.Glu693Gly 
 
 
Present 
 
Present, with 
characteristic 
ring-like 
structure 
 
Present 
 
Dementia only 
 
Iowa 
p.Asp694Asn 
 
 
 
Present 
 
Present, with 
extensive 
Aβ40 
deposition 
 
Present 
 
Dementia only 
 
 
Another APP mutation within the Aβ sequence, known as the Iowa mutation (APP 
p.Asp694Asn) has also been found to be associated with severe CAA on pathological 
investigation. Widespread neurofibrillary tangles and amyloid plaques with particularly 
abundant Aβ40 deposition are seen with this mutation. Clinically, however, these 
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affected individuals lacked symptoms of recurrent cerebrovascular events and presented 
with progressive cognitive impairment (Grabowski et al., 2001). A similar picture was 
found with the ‘Arctic’ mutation APP p.Glu693Gly, which has a purely cognitive 
phenotype, typical of AD, despite the presence of marked CAA (Basun et al., 2008). 
The pathological findings in the Arctic mutation also include neurofibrillary tangles and 
abundant amyloid plaques with characteristic ring-like structures. Why the presence of 
CAA should have clinical manifestations with some of these mutations but not with 
others is intriguing. This is particularly true for the Arctic and Dutch mutations, which 
occur at exactly the same position (amino acid 693) but give rise to totally different 
phenotypes. It has been proposed that the explanation may lie in the polarity of the 
substituted amino acid. The Dutch mutation involves replacement of a glutamic acid 
with glutamine, which is polar and hydrophilic. Dutch Aβ may therefore have a greater 
affinity for, and propensity to disrupt, the vessel wall than Arctic Aβ, which is non-polar 
and hydrophobic (Basun et al., 2008). 
 
Mutations at codon 673 of APP, which alter the residue at position two in the Aβ 
peptide, also cause strikingly different effects depending on the nature of the substituted 
amino acid. The p.Ala673Val variant was identified in an Italian pedigree with an 
autosomal recessive pattern of inheritance of early onset AD (Di Fede et al., 2009, 
Giaccone et al., 2010) and only causes disease in the homozygous state. The 
substitution causes a shift in APP processing towards the amyloidogenic pathway 
through increased processing at the β-secretase site, together with enhancement of the 
aggregation and fibrillogenic properties of Aβ, whilst interaction between mutant and 
wild-type Aβ hinders amyloidogenesis in the heterozygous state. However, an alanine to 
threonine substitution at position 673 (p. Ala673Thr) actually protects against AD and 
the development of cognitive decline in elderly people without AD. The APP 
p.Ala673Thr variant was identified in whole-genome sequence data from the Icelandic 
population, where it was observed to be significantly more common in the healthy 
elderly control group than in those with AD (Jonsson et al., 2012). This variant impairs 
APP processing at the β-secretase site, resulting in an almost 40% reduction in 
amyloidogenic peptide formation in vitro. The protective effect of the p.Ala673Thr 
variant provides proof of principle for the idea that reducing BACE1 cleavage of APP 
may protect against AD, supporting the notion that BACE1 inhibition may be a 
promising therapeutic target. 
 37 
1.3.3.3 APP duplications 
The well established link between Down syndrome and AD provided early evidence 
that copy number variation may play a role in AD pathogenesis and it is now well 
recognised that duplications of the APP gene can give rise to FAD (Rovelet-Lecrux et 
al., 2006). The phenotype associated with APP duplication can be diverse, even within a 
single family (Guyant-Marechal et al., 2008). However, characteristic features include a 
high frequency of seizures, up to 57% in one series, and prominent amyloid angiopathy 
(Rovelet-Lecrux et al., 2006). An autosomal dominant family history of partial seizures 
present from adolescence has been reported in one APP duplication family 
(McNaughton et al., 2010). The size of the duplication does not appear to influence the 
clinical presentation. The cognitive phenotype resembles that of typical AD, with early 
progressive impairment of episodic memory. In some families, the clinical presentation 
is solely cognitive, with no distinguishing neurological features (Kasuga et al., 2009). 
Knowledge of the prevalence of APP duplications and spectrum of associated clinical 
features is likely to expand as increasing numbers of centres search for copy number 
variation in their cohorts of patients.  
 
Interestingly, a post-mortem study of an individual with an APP duplication revealed 
diffuse neocortical LBP with additional CAA and AD pathology (Guyant-Marechal et 
al., 2008). The clinical phenotype of this patient, comprising cognitive decline 
associated with visual hallucinations and extrapyramidal signs, was also compatible 
with a diagnosis of DLB. As the authors suggest, this case adds weight to the hypothesis 
that accumulation of Aβ can induce LBP. However, further work must be done in larger 
cohorts of patients to elucidate more about the clinical manifestations of coexistent 
Lewy body pathology in FAD, and to investigate the relationship between β-amyloid 
and alpha-synuclein in neurodegenerative disease in general. 
 
1.3.4 Genetic modifiers of phenotype in sporadic AD 
In FAD, genetic factors clearly modify the clinical phenotype in striking ways. The 
manifestations of sporadic AD are also likely to be influenced by genetic factors, though 
generally in a far subtler manner. The involvement of the APOE gene in sporadic AD 
has long been known, with possession of the E4 allele conferring both an increased risk 
of developing the disease and possibly driving the pathology towards limbic areas 
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(Schott et al., 2006). More recently identified ‘risk genes’ for sporadic AD include 
CLU, PICALM, CR1, BIN1, MS4A, CD2AP, CD33, EPHA1, ABCA7 (Harold et al., 
2009, Lambert et al., 2009, Naj et al., 2011) and TREM2 (Guerreiro et al., 2013, 
Jonsson et al., 2013). An important direction for future work will be to investigate 
whether these variants have phenotypic associations, particularly in sporadic AD but 
also in familial disease.   
 
Genes known to cause FAD may also play a role in sporadic disease. There are certain 
PSEN1 polymorphisms, for example p.Glu318Gly, whose pathogenic nature remains 
uncertain. It has been suggested that some PSEN1 polymorphisms may modify the 
phenotype of sporadic AD by altering the rate of cognitive decline (Belbin et al., 2009). 
There is some evidence to suggest that FAD-causing gene mutations may sometimes be 
even more directly implicated in cases of apparently sporadic AD; through somatic and 
germline mosaicism (Beck et al., 2004). An individual who underwent negative genetic 
testing on a peripheral blood sample was subsequently found to have the PSEN1 
p.Pro436Gln mutation in DNA extracted from cerebral cortex. Although this proband 
had no family history of dementia herself, one of her daughters subsequently developed 
symptoms and was found to have inherited the mutant haplotype from her mother. 
Interestingly, the two affected individuals had a difference in age at onset of around 15 
years and strikingly different clinical phenotypes, although both featured prominent 
neurological signs. As the authors suggest, these findings have several important 
implications. Differing levels of mosaicism may account for some of the phenotypic 
variation seen in FAD. Furthermore, there may be many patients with AD who have 
pathogenic somatic mutations expressed in brain tissue that are not found on 
conventional sequencing of DNA extracted from blood lymphocytes. Indeed, 
developments in deep DNA sequencing technology have recently allowed mosaic 
mutations with low allelic frequency in AD-relevant genes to be detected in brain-
derived DNA from a number of sporadic AD patients (Sala Frigerio et al., 2015).  
 
1.4  Future perspectives  
 
In the decades since the identification of the first FAD mutation, significant advances 
have been made in our understanding of FAD at a molecular, genetic, pathological and 
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clinical level. The number of known mutations has risen exponentially and, with them, 
an expanding spectrum of clinical phenotypes has been identified. Observations of how 
certain symptoms and signs tend to cluster with particular mutations has led to an 
appreciation of how the location of a mutation within a gene can dictate the type of 
pathology that develops, particularly in relation to CAA. Familial and sporadic AD have 
been shown to share many similarities. They commonly present with identical 
symptoms of impaired episodic memory but can both, more rarely, have initial deficits 
in other cognitive domains. The factors dictating the topography of pathology in both 
familial and sporadic disease remain to be elucidated. However, possible mechanisms 
have been proposed. As has often been the case, the insights gained from studying FAD 
continue to inform our understanding of AD in general. With disease-modifying therapy 
trials now focussing interest on the earliest stages of disease, longitudinal study of the 
presymptomatic phase in individuals destined to develop FAD has become a major 
priority for AD research.  
 
Increased recognition of how knowledge gleaned from the study of FAD has the 
potential to increase our understanding of AD as a whole led to the launch of the first 
international collaborative study of individuals carrying FAD mutations; the dominantly 
inherited Alzheimer network (DIAN) (Bateman et al., 2011). This multicentre study 
collects longitudinal data to explore the clinical, imaging, neuropsychological, blood 
and cerebrospinal fluid changes that occur in the long period leading up to symptom 
onset in FAD. By establishing the largest cohort of FAD patients studied to date, it will 
allow some of the unresolved questions surrounding the relationship between genotype 
and phenotype in FAD to be addressed. Aided by initiatives like DIAN, research into 
FAD is likely to progress at an accelerating pace over the coming decade. The advent of 
disease-modifying therapy provides great momentum for driving forward this progress, 
as it creates an unprecedented need to understand the pathogenesis of AD in more 
detail. Issues such as the relationship between AD pathology and CAA, for example, 
have been brought to the forefront by amyloid immunotherapy trials. It has been found 
that, in patients treated with Aβ42 immunotherapy, removal of amyloid plaques may be 
accompanied by accumulation of Aβ42 in perivascular drainage pathways, with an 
associated transient increase in CAA (Weller et al., 2009). It appears that this plaque-
derived Aβ42 can be cleared, given sufficient time (Boche et al., 2008). However, 
factors including APOE genotype are likely to influence how effectively this is 
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achieved. Understanding more about the mechanisms underlying the variable 
occurrence and clinical manifestation of CAA in FAD may thus have far-reaching 
implications. It is clear that in both familial and sporadic AD, a range of atypical 
clinical phenotypes can occur and by understanding more about how genetic factors 
modify the pathological, biomarker and clinical picture, we may find that the phenotype 
contains clues suggesting the most appropriate treatment for an individual. 
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2 Imaging biomarkers in Alzheimer’s disease 
2.1 Introduction 
 
Imaging plays an increasingly important role in both clinical practice and research in 
AD. Clinically, there is growing appreciation that imaging provides not just exclusion 
of alternative pathologies, but also positive predictive, diagnostic and prognostic 
information in dementia. Imaging can improve specificity of diagnosis in trial 
populations, facilitate research on the earlier stages of disease and provide crucial 
information regarding drug safety and toxicity. With the advent of disease-modifying 
therapies, these properties acquire increasing importance. Furthermore, imaging 
biomarkers have the potential to serve as outcome measures of disease progression. A 
whole arsenal of imaging modalities has now been developed, each allowing a different 
aspect of the disease process to be explored. However, the limitations of each technique 
must also be appreciated. A multimodal approach, where imaging markers are 
combined, may be required to maximise the potential of imaging to enhance our 
understanding of AD and to help find effective therapies. In this introductory chapter, I 
outline the current role of neuroimaging in AD within the realms of both clinical 
practice and research. I discuss the potential for expansion of this role in the future and 
consider some of the challenges that this will entail. Finally, I review how imaging has 
been used to gain insights into preclinical change in AD, which forms one of the major 
themes of this thesis. 
 
The idea that inspecting the structure of the brain can open a window into understanding 
aspects of its function has a long history. Early 19th century theories of phrenology, 
despite their scientific and moral flaws, were important in stimulating interest in how 
human cognition can be explored by examining the structure of different brain regions 
(Zola-Morgan, 1995). In the decades that followed, neuropathological studies of 
patients with lesions advanced understanding of localised cognitive function further. 
This drive to explore the workings of the brain through investigation of its structure was 
revolutionised by the development of neuroimaging. The introduction of computed 
tomography (CT) in the 1970s and magnetic resonance imaging (MRI) in the 1980s 
allowed the brain to be viewed directly, during life, for the first time. More recently, 
functional and molecular imaging have added to our ability to “see” the brain in life. 
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The capacity to examine non-invasively the processes occurring within the brain, and to 
investigate the variable ways in which it responds to disease and intervention, have had 
a huge impact on clinical practice and research within neurology. Over the past forty 
years an array of increasingly sophisticated neuroimaging techniques has evolved, 
allowing specific aspects of disease to be probed in detail. There are now techniques 
that assess brain activity, microstructure, perfusion, connectivity, metabolism, and even 
histopathological hallmarks of disease – all in vivo.  In the field of AD, this is proving to 
be particularly important. Although tremendous efforts and progress have been made in 
our understanding of the biological basis of AD, we remain fairly ignorant about the 
sequence of pathological events and how they relate to the clinical manifestations of 
disease. As discussed in the preceding chapter, AD is heterogeneous with patients 
presenting in a variety of ways. It is also a diffuse disease, with amyloid plaques, 
neurofibrillary tangles and synapse loss affecting ineloquent as well as eloquent areas of 
the brain. This may be very relevant to the pathological cascade. Furthermore, we are 
still unclear about aspects of the underlying mechanisms by which our treatments for 
AD affect the pathological process. Motivated by the current trials of disease-modifying 
therapy for AD, this thesis includes several studies that use imaging techniques to 
investigate the pathological underpinnings of phenotypic heterogeneity and preclinical 
change in AD. 
 
2.2  Imaging in Clinical Practice 
 
Diagnosis in dementia is not always straightforward. Post-mortem studies have shown 
that, even in specialist centres, 10-15% patients thought to have AD are incorrectly 
diagnosed (Knopman et al., 2001). Differentiating AD from other possible diagnoses 
such as DLB or FTD is often difficult clinically, particularly early on in the illness. 
However, the early stage of the disease may be precisely the time when certain 
therapeutic interventions are most likely to be effective and it is also the period where 
there is the most to save in terms of cognitive function. There is increasing evidence that 
the clinical manifestations of AD are preceded by a long period during which 
pathological changes accrue (Price and Morris, 1999). Interventions to the pathological 
cascade may need to be made early on in this process to be effective. Gaining an early 
diagnosis is also extremely important from the perspective of an individual patient and 
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their family. It allows them to make decisions about the future at a stage where they still 
have the cognitive abilities to do so, and to gain access to the services and support they 
need before a crisis point is reached. The concept of early diagnosis should not be 
confused with screening for which there is not evidence of benefit in dementia; what is 
clear is that once patients and their families are aware of a problem and seek medical 
help there are often long days in the assessment and diagnostic process which all too 
often remains inexact as well as slow. The fact that an early (or perhaps more precisely 
a timely) diagnosis is a priority for patients and carers is reflected in the importance 
given to improving early diagnosis by carer organisations like the Alzheimer’s 
Association and Alzheimer’s Society, and by government initiatives such as the UK’s 
National Dementia Strategy [3].  
 
The role of neuroimaging in the diagnosis of AD has, until recently, focussed on 
excluding alternative pathologies as the cause of an individual’s cognitive impairment. 
Current diagnostic guidelines advise that all patients complaining of cognitive 
symptoms should have structural imaging (unenhanced CT or MRI) at least once to 
exclude structural causes such as tumours and haematomas (Knopman et al., 2001, 
Waldemar et al., 2007, Hort et al., 2010). These surgical causes are rare and we are 
currently witnessing a change in thinking towards an appreciation of the positive 
diagnostic information that can be revealed by MRI. Patterns of atrophy offer important 
clues to the underlying diagnosis and in some cases, can even act as the signature for a 
specific molecular pathology. For example semantic dementia, one of the main clinical 
variants of FTD, is characterised by the distinctive imaging appearance of asymmetrical 
anterior dominant (usually left) temporal lobe atrophy, best seen on coronal T1-
weighted MRI, and the predictable neuropathological findings of ubiquitin-positive, tau-
negative neuronal inclusions (Hodges and Patterson, 2007). Investigation of the 
differential diagnosis in a patient with cognitive symptoms can be enhanced further by 
selectively employing a range of different MRI techniques. Diffusion weighted imaging 
(DWI), for example, often reveals characteristic areas of hyperintense signal 
abnormality in the cortex and putamen in patients with sporadic Creutzfold-Jakob 
disease (CJD) and in the pulvinar nucleus of the thalamus in variant CJD (Schroter et 
al., 2000). These DWI changes have been shown to correlate with the histopathological 
spongiform and gliotic changes seen at autopsy in these individuals (Manners et al., 
2009). T2-weighted imaging (especially FLAIR – fluid attenuated inversion recovery – 
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imaging) is particularly useful for assessing vascular load and white matter disease. 
Although this is still a rather uncertain area, the appearances of extensive, irregular 
white matter signal change, multiple infarcts and/or high signal foci in the basal ganglia, 
thalamus and infratentorial regions can be highly suggestive of vascular dementia 
(Schmidt, 1992). Conversely the absence of these changes on imaging makes a vascular 
cause much less likely. Furthermore, the presence of an unusual pattern or significant 
white matter signal change in an individual who lacks vascular risk factors can provide 
an important warning sign to a clinician to investigate the patient for alternative and 
potentially reversible causes of cognitive decline such as vasculitis, metabolic or 
inflammatory disease or demyelination; additional investigation may include additional 
blood tests, CSF analysis or rarely brain biopsy (Waldemar et al., 2007). As we will 
discuss in Chapters 4 and 5, the presence of white matter hyperintensities in posterior 
cortical areas (Thanprasertsuk et al., 2014) and cortico-subcortical microbleeds on 
gradient echo (T2*-GRE) sequences (Cordonnier and van der Flier, 2011), may predict 
underlying CAA.  
 
There is now a wealth of evidence that, in addition to its ability to identify surgically 
treatable lesions and more unusual causes of dementia, MRI can demonstrate 
characteristic features that positively support a diagnosis of AD (Waldemar et al., 2007, 
Hort et al., 2010). In the UK this recognition is included in guidance from the National 
Institute of Health and Clinical Excellence (NICE) [4]. Most established is the presence 
of disproportionate medial temporal lobe atrophy on MRI. By the time patients with AD 
present with symptoms, hippocampal volumes are already significantly reduced and the 
severity of AD pathology and neuronal loss correlates with the degree of hippocampal 
atrophy on antemortem MRI (Jack et al., 2002) (Figure 2.1). Furthermore, the presence 
of medial temporal lobe atrophy has been shown to predict conversion from MCI to AD 
(DeCarli et al., 2007). This atrophy can be detected by both volumetric measurements 
and by visual assessments of scans (Scheltens et al., 1992, De Leon et al., 1997). 
Visually rating just a single coronal slice of an MRI has been shown to have 80-85% 
sensitivity and sensitivity for distinguishing patients with AD from those with no 
cognitive impairment, and similar sensitivity and specificity levels for diagnosing 
amnestic MCI (Duara et al., 2008). The overall pattern of cortical atrophy also provides 
valuable diagnostic information; studies which have included pathological confirmation 
of the diagnosis have shown that the combination of posterior atrophy together with 
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medial temporal lobe atrophy on MRI carries positive predictive value for diagnosing 
AD (Likeman et al., 2005).  
 
Figure 2.1 Medial temporal lobe atrophy on MRI; a sensitive marker of 
neurodegeneration in AD.  
Reprinted from (Ryan and Fox, 2009), with permission. 
 
	
 
In recognition of the diagnostic value of MRI, it has been proposed that the presence of 
medial temporal lobe atrophy on MRI should be incorporated into new diagnostic 
criteria for AD (Dubois et al., 2007, Albert et al., 2011, Dubois et al., 2014). 
Furthermore, it is appreciated that in cases where uncertainty about the diagnosis 
persists after clinical assessment and structural imaging, there can be a role for 
functional imaging. Single photon emission computed tomography (SPECT) studies of 
regional blood flow and measurements of glucose metabolism with positron emission 
tomography (FDG-PET) are the most frequently applied functional imaging studies in 
clinical practice. The most commonly described criterion for AD is a symmetrical 
reduction in blood flow or glucose metabolism in parieto-temporal areas. Patterns on 
functional imaging with FDG-PET have been reported to have levels of sensitivity and 
specificity of around 90% and 70% for separating AD patients from controls (Silverman 
et al., 2001, Jagust et al., 2007). Although this specificity level is only moderate, the 
relatively high sensitivity level means that a negative scan favours a normal outcome at 
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follow up. In cases where it is unclear whether a degenerative disease is present at all, 
this extra reassurance can be clinically helpful. 
 
2.3  Imaging in Research 
 
The power of imaging to enable earlier detection of disease is particularly important in 
the realm of clinical research; it opens a window of opportunity for conducting research 
on the early phase of disease and for allowing earlier intervention. Imaging measures 
are also attractive putative markers of disease progression for clinical trials, although 
they are still far from acting as surrogate outcomes in AD and are likely to require 
multiple results from disease-modifying trials in order for this to occur (Fox and 
Kennedy, 2009). However, the need for reliable biomarkers for clinical trials in AD is 
clearly pressing and increasingly, changes in imaging markers are included as secondary 
outcome measures (Cash et al., 2014). Withdrawal and survival studies are difficult in a 
disease like AD where survival may be for as long as 15 years. The clinical scores used 
to assess new treatments are problematic as they are non-linear and are influenced by a 
multitude of factors affecting the performance of both the patient and examiner on a 
particular day. Furthermore, they have a limited ability to address the fundamental 
question of whether a treatment causes a true long-lasting disease modifying effect or 
simply a short-term improvement in symptoms. This distinction is crucially important; 
the expected duration of benefit is a factor in the decision for an individual patient of 
whether to embark on a new experimental treatment, especially when the side-effect 
profile is significant. Imaging allows repeated assessments but without the practice 
effects involved in repeated neuropsychology. It provides a closer reflection of the 
changes occurring at a pathological level than can be achieved by neuropsychological 
and clinical scoring alone. Furthermore, it is non-invasive, making it more likely to be 
acceptable to some patients than other putative biomarkers such as CSF, obtained by 
lumbar puncture.  
 
Importantly, different modalities of neuroimaging can allow different aspects of brain 
function and disease process to be probed. Cerebral perfusion, metabolism and 
activation can be assessed by SPECT scanning, perfusion MRI, FDG-PET and 
functional MRI (fMRI). Tissue microstructural changes are indicated by changes in 
 47 
diffusion imaging and magnetisation transfer. Changes in the integrity of white matter 
tracts connecting different brain areas can be investigated with diffusion tensor imaging 
(DTI). The metabolic environment of the brain can be investigated with MR 
spectroscopy. Certain pathological effects can be visualised by specific scanning 
sequences, such as microbleeds on susceptibility-weighted MRI. Finally, molecular 
imaging can be employed to show aspects of the pathological cascade directly. For 
example, deposition of fibrillar amyloid, detected using the carbon-11 (11C) based PET 
ligand Pittsburgh compound B (PIB) and more recently fluorine-18 (18F) based amyloid 
tracers; deposition of tau with even newer tracers such as 11C-PBB3 or a number of 18F-
tau ligands; or loss of dopamine transport using the SPECT tracer [123I]FP-CIT. In the 
future it may well be that a multimodal imaging approach is employed to investigate 
responses to treatment from several different perspectives simultaneously. 
 
Whilst the use of imaging biomarkers as surrogate end-points may take some time to be 
adopted (and regulatory acceptance will require much supporting evidence), baseline 
imaging measurements do already have an established role in clinical trials. In 
recruiting individuals to trials, imaging is used to improve the specificity of diagnosis in 
order to create a more homogenous trial population. Trials of agents targeting specific 
aspects of the AD disease process are more likely to show a true effect if the individuals 
in the trial do actually have AD rather than non-AD pathologies such as FTD or 
vascular dementias. The most straightforward way of identifying individuals with a 
vascular cause of their cognitive impairment is by the use of MRI; similarly focal 
fronto-temporal atrophy suggests FTD rather than AD. As we move towards more 
complex, dangerous and targeted therapies this becomes increasingly important as we 
want to be sure that the patients we are trialling these treatments on do in fact possess 
the molecular targets. MRI can also open an earlier therapeutic window in clinical trials. 
In MCI studies, recruitment of subjects is enriched if the presence of medial temporal 
lobe atrophy on MRI is part of the inclusion criteria, as this atrophy is predictive of 
conversion from MCI to AD (Devanand et al., 2007).  
 
Amyloid imaging also shows changes very early on in AD, with high PIB-retention 
observed in patients with MCI who later will convert to AD (Forsberg et al., 2008) 
(Figure 2.2). However, we are yet to determine the significance of the 20-30% of 
healthy controls who also demonstrate amyloid deposition (Rowe et al., 2007). Whether 
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these individuals are those who will subsequently develop AD (and when) will only be 
determined with long term follow up studies.  
 
Figure 2.2. Amyloid imaging with PIB-PET can be positive early in AD and may 
predict conversion from MCI to AD  
Images courtesy of David Brooks, Imperial College, London. Reprinted from (Ryan and 
Fox, 2009), with permission. The “hot colours” in red and yellow indicate areas of 
tracer retention and therefore fibrillary amyloid; the scans illustrated are from two 
individuals with MCI; the image on the left shows only non-specific white-matter 
binding and the individual has not progressed clinically after several years; the image on 
the right shows extensive cortical amyloid deposition and the individual progressed to a 
diagnosis of AD over the following 18 months.  
 
 
 
Imaging, because it provides topographical information (unlike a blood or CSF marker), 
also has value for investigating the site of action and nature and extent of the therapeutic 
effect, together with potential toxicity. It can act as a sensitive maker of effects that may 
be clinically silent initially. In the first active immunotherapy for AD study, the side-
effect of meningoencephalitis was detected on imaging (Gilman et al., 2005). A 
subsequent passive immunotherapy trial of Bapineuzumab picked up asymptomatic 
changes on T2-weighted/FLAIR sequences that were initially referred to as “vasogenic 
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oedema” in some individuals on their safety MRI, allowing these participants to have 
tailored treatment with their immunotherapy being withheld until the imaging changes 
had resolved (Sperling et al., 2012). Identification of additional cases with similar 
imaging abnormalities in subsequent trials led to the realisation that amyloid-modifying 
therapies could be associated with a spectrum of imaging changes (Coric et al., 2012, 
Ostrowitzki et al., 2012). The umbrella term ‘ARIA’ was coined to describe these 
amyloid-related imaging abnormalities, which include FLAIR signal abnormalities 
believed to represent cerebral oedema and sulcal effusions (ARIA-E) and abnormalities 
on T2*-GRE sequences thought to represent microbleeds and haemosiderosis (ARIA-H) 
(Sperling et al., 2011). Monitoring for ARIA with safety MRI has now become an 
essential part of AD clinical trials and a rating scale has been developed with the aim of 
standardising the measures (Barkhof et al., 2013). Typical protocols for MRI safety 
scans include a FLAIR sequence, sensitive to oedema, effusion, inflammation and 
infarction and T2*-GRE or susceptibility-weighted imaging (SWI) sequences to detect 
microbleeds and haemosiderosis.  
 
The hope for drug discovery efforts is that biomarkers will allow disease modifying 
effects to be identified, and that this will be achieved with smaller sample sizes if the 
selection of appropriate individuals is refined by biomarkers. The size of a trial is 
determined by the variance of the outcome measure. The power analysis from the 
Alzheimer’s disease neuroimaging initiative (ADNI) demonstrated that, for a 25% slope 
reduction in AD disease progression, many more individuals would be needed to 
demonstrate a difference using the ADAS-cog than if MRI-derived measures of atrophy 
were used (Schuff et al., 2009). It may well be that personalised biomarkers prove to be 
the most effective approach towards monitoring AD progression. Characterising an 
individual’s own rate of atrophy and measuring the effect of a therapy on this rate may 
be more valuable than comparing rates between individuals. An individual’s serial MRI 
scans can be registered together and used to calculate an atrophy rate, either for the 
whole brain or for specific regions such as the hippocampus. The rate of whole brain 
atrophy in AD is 4-5 times the rate in normal ageing (Fox et al., 2005). Much of our 
knowledge of the brain atrophy that occurs in the very early stage of AD comes from 
the study of individuals with the rare, familial form of the disease. FAD, through 
prospective study of individuals who are cognitively normal but genetically destined to 
develop the disease, provides an insight into the earliest manifestations of the 
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pathological process. This has helped to illuminate the long preclinical phase during 
which AD pathology accumulates prior to symptom onset. It has also revealed how rates 
of whole brain atrophy accelerate in the five years prior to symptom onset in FAD gene 
mutation carriers (Chan et al., 2003). If disease-modifying therapies do prove to be 
effective, one can envisage a time in the future where these individuals who are 
undoubtedly going to develop AD undergo monitoring of their atrophy rate, with 
acceleration of this rate prompting initiation of treatment. 
 
Although imaging clearly has the potential to provide valuable biomarkers for AD 
research, there is still much work to be done to refine the techniques themselves and to 
understand more about how they reflect the underlying pathology. Firstly, the 
assumption in clinical trials will be that slowing of atrophy indicates slowing of 
neurodegeneration, however this is yet to be proven. Furthermore, it is important to 
consider the possibility that the timings of change in a biomarker and in the clinical 
outcome it is intended to represent may not be simultaneous. For example, the AN1792 
Aβ immunisation study revealed the unexpected result that patients who mounted high 
antibody responses showed greater atrophy rates than those who responded less, the 
converse of what might have been expected (Fox et al., 2005). At the time several 
possible explanations were proposed including accelerated neuronal loss, increased 
clearance of amyloid from the brain with associated fluid shifts or reduced plaque-
associated inflammation in antibody-responders. More recent work examining post-
mortem brain tissue from AD subjects who participated in that trial has shown that there 
is indeed evidence that Aβ immunisation may have accelerated loss of damaged 
degenerating neurons (Paquet et al., 2015) and resulted in reductions in associated 
inflammation. Whatever the underlying cause of the volume changes, this study showed 
that MRI could provide evidence that a treatment was reaching the target (brain) and 
was having an effect on brain structure, but that one cannot simply assume that a 
biomarker will behave in the same way in a treatment trial as it does in untreated 
subjects (Vellas et al., 2009). Essentially, it will be important to investigate how 
imaging markers respond to our treatments, as well as how they respond to the disease 
itself, including studying imaging effects in animal models (Frisoni and Delacourte, 
2009). There will also be a need to exercise caution in drawing conclusions from 
functional imaging. Most importantly, disease-modifying changes will need to be 
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distinguished from symptomatic effects. With amyloid imaging, there is the additional 
concern that it may prove insensitive to change once at a clinical stage for the disease, 
when there appears to be a ceiling effect of amyloid binding with little progression over 
time (Engler et al., 2006). Equally a specific molecular marker may not lie on the causal 
pathway from pathogenesis to symptoms; amyloid imaging may demonstrate fibrillary 
amyloid plaques but not the oligomers, which are increasingly thought to have a 
fundamental role in AD pathogenesis (Selkoe, 2008).  
 
Each imaging modality carries its own set of limitations. However, as long as these are 
appreciated and taken into account, imaging is likely to play a prominent part in the 
scientific journey to understand AD in the future, particularly if the strength of 
combining imaging biomarkers is realised. The role of imaging in the clinical 
investigation of patients with dementia is also evolving. There are always large issues to 
overcome in translating research into clinical practice. Methods need to be accessible, 
practical and have value for detection, differential diagnosis and prognosis. Imaging has 
the potential to fulfil all of these requirements. In the few decades that have passed since 
neuroimaging was first developed, considerable progress has been made in advancing 
the techniques and applying them to clinical problems. Although there is still much 
work to be done, the pressing need for reliable biomarkers in AD provides great 
momentum for driving this progress forwards. 
 
2.4  Imaging presymptomatic Alzheimer’s disease 
 
It is now well established that the pathophysiological process of AD begins many years, 
even decades, before symptoms develop and there is currently great interest in defining 
and characterising the preclinical stages of the disease (Sperling et al., 2011). This 
interest has been driven in part by the disappointing results of trials of amyloid-
modifying therapies in patients with so-called “mild to moderate” AD, with at least one 
trial (of Solanezumab) showing in a post-hoc analysis that milder subjects appeared to 
do better than more affected individuals (Doody et al., 2014, Karran and Hardy, 2014). 
The suggestion being that treatment in the majority of trials may have been “too little, 
too late” with the implication that treating earlier in the disease would have had greater 
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chances of slowing progression. The observation from some previous trials, of apparent 
treatment-related reductions in Aβ burden at autopsy or on amyloid imaging, have 
encouraged the view that disease-modification may be possible, but perhaps with only 
limited benefit if downstream neurodegeneration is already well established. 20-40% of 
cognitively normal older individuals show evidence of Aβ accumulation in both PET 
imaging and CSF studies and a similar proportion of healthy elderly people have been 
found to have AD pathology at post-mortem (Sperling et al., 2011) – the percentage 
who are “amyloid-positive” is very age-related and is also higher in those who carry an 
ApoE4 allele. The proportion of these individuals who will or would have gone on to 
develop AD dementia is currently unknown, so research recommendations have 
proposed the term ‘asymptomatic at risk state for AD’ to refer to this particular 
preclinical stage (Dubois et al., 2010). The other proposed preclinical stage of AD is 
‘presymptomatic AD, a term reserved for individuals with autosomal dominantly 
inherited mutations in the PSEN1, PSEN2 and APP genes who will inevitably develop 
symptoms of FAD. In this final introductory section, I describe the insights into 
presymptomatic AD that have been gained through previous imaging studies of FAD 
mutation carriers and discuss some of the uncertainties and future challenges that 
remain as we enter an era of prevention trials for AD. 
 
Understanding the timing and temporal order by which different imaging biomarkers 
become abnormal in presymptomatic AD is a fundamental issue for the field. The 
longitudinal study of healthy FAD mutation carriers with multi-modal imaging provides 
a unique opportunity to address this question. In recent years a number of large 
initiatives have been gathering such data: the DIAN study, with sites across the USA, 
Australia and in the UK; and the Alzheimer’s Prevention Initiative (API), which studies 
a large Colombian kindred affected by the PSEN1 p.Glu280Ala mutation. So far, the 
results reported from these studies have largely been cross-sectional but as symptoms 
tend to arise at a similar age within a family, the ages at which an individual’s relatives 
became clinically affected have been used to predict how far from symptom onset a 
presymptomatic participant may be. On this basis, amyloid imaging with PIB-PET in 
DIAN and Florbetapir-PET in API have demonstrated accumulation of Aβ in mutation 
carriers who are as far as 15 years below their expected age at symptom onset (Bateman 
et al., 2012, Fleisher et al., 2012, Benzinger et al., 2013). This confirms findings from 
earlier smaller studies, that Aβ deposition on PET is an early event in presymptomatic 
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FAD. A striking observation from the initial FAD PIB-PET studies was that Aβ 
deposition was most intense in the striatum (Figure 2.3); a pattern reported for a variety 
of PSEN1 mutations and for APP mutation and duplication cases (Klunk et al., 2007, 
Remes et al., 2008, Villemagne et al., 2009). This striatal predominance does not appear 
to be seen with the Colombian kindred PSEN1 mutation, and other PSEN1 mutations 
have subsequently been found to be associated with more prominent thalamic PIB 
uptake (Knight et al., 2011). The topography of early amyloid deposition in FAD 
caused by different mutations therefore appears to be more heterogeneous than was 
once thought.  
 
Figure 2.3 PIB-PET imaging showing prominent striatal amyloid deposition in a 
presymptomatic PSEN1 mutation carrier approximately three years prior to 
anticipated age at onset.  
Reprinted from ‘Neuroimaging in Dementia’, published by Springer, with permission.  
 
 
 
Whilst amyloid-PET imaging measures the accumulation of abnormal protein, the other 
imaging modalities that have been applied to presymptomatic FAD are thought to 
capture aspects of neurodegeneration further downstream. The most widely used of 
these have been FDG-PET to measure glucose metabolism and structural MRI to 
investigate atrophy. MR spectroscopy has also been used and found to demonstrate 
posterior cingulate metabolic changes in presymptomatic mutation carriers who were on 
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average 10 years younger than the mean age at onset for their family (Godbolt et al., 
2006). Using FDG-PET, widespread hypometabolism has been observed in 
presymptomatic FAD in a pattern similar to that seen in sporadic AD (Mosconi et al., 
2006). In the DIAN study, parietal hypometabolism was evident from around 10 years 
prior to the parental age at symptom onset. Most regions appeared to show the sequence 
of events predicted by theoretical biomarker models of AD, with amyloid accumulation 
occurring first, followed by hypometabolism followed by atrophy (Jack et al., 2010) 
(Figure 2.4). However, the DIAN data also indicated that there may be more complexity 
to the trajectory of presymptomatic biomarker changes than such models at first 
suggest. Firstly, different brain regions appear to vary in their vulnerability to the 
presence of amyloid pathology. Whilst all subcortical regions showed elevated PIB 
uptake, hypometabolism was only evident in the hippocampus (Benzinger et al., 2013). 
Secondly, the direction of biomarker change was not always as predicted.  In very 
young mutation carriers who were ~25 years from expected age at onset, there was 
some suggestion that there might be a hypermetabolic phase in some regions including 
precuneus and posterior cingulate. The numbers in this subgroup were small, however, 
so replication of the results in a larger cohort will be required. Furthermore longitudinal 
studies will be critical to understanding these changes. 
 
Structural MRI is the imaging modality that has been most thoroughly investigated in 
FAD and, importantly, it has been used to study mutation carriers longitudinally from a 
presymptomatic stage up to the actual age at onset of clinical symptoms. Accelerating 
hippocampal and whole brain atrophy rates have been observed at 5.5 and 3.5 years 
respectively before symptom onset in mutation carriers (Ridha et al., 2006). Cortical 
thinning of precuneus and posterior cingulate cortex has been reported approximately 
four and three years before onset (Knight et al., 2011) In these small cohort studies, 
longitudinal measures were able to detect presymptomatic change earlier than when a 
cross-sectional approach was taken. A more recent longitudinal study of a larger group 
of mutation carriers detected thinning of precuneus up to eight years before expected 
symptom onset and identified a signature pattern of cortical thinning in FAD (Weston et 
al., 2016). Baseline thickness of this cortical signature (which comprises entorhinal 
cortex, supramarginal gyrus, superior frontal cortex, superior and inferior parietal cortex 
and precuneus) was found to predict rate of subsequent thinning and correlate with 
presymptomatic cognitive change. Visual rating of hippocampal atrophy in 
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presymptomatic FAD appears to be relatively insensitive (Ringman et al., 2010); visual 
assessment may be less sensitive in FAD and early onset disease than in late onset AD 
(Ryan and Fox, 2009).  
 
Figure 2.4 Hypothetical model of dynamic biomarkers of AD expanded to explicate 
the preclinical phase, 
 Reprinted from (Sperling et al., 2011), with permission. Aβ as identified by 
cerebrospinal fluid Aβ42 assay or PET amyloid imaging. Synaptic dysfunction 
evidenced by FDG-PET or functional magnetic resonance imaging (fMRI), with a 
dashed line to indicate that synaptic dysfunction may be detectable in APOE4 carriers 
before detectable Aβ deposition. Neuronal injury is evidenced by CSF tau or phospho-
tau, brain structure is evidenced by structural MRI. Biomarkers change from normal to 
maximally abnormal (y-axis) as a function of disease stage (x-axis). The temporal 
trajectory of two key indicators used to stage the disease clinically, cognitive and 
behavioral measures, and clinical function are also illustrated. Figure adapted with 
permission from (Jack et al., 2010). 
 
 
 
 
 56 
In view of the early striatal and thalamic amyloid deposition witnessed in FAD, more 
recent studies have also examined whether these subcortical structures undergo 
presymptomatic atrophy. In Chapter 6, I describe decreased volumes of thalamus and 
caudate in mutation carriers who were on average 5.6 years from parental age at onset, 
at a stage where hippocampal atrophy was not yet evident (Ryan et al., 2013). 
Presymptomatic atrophy of thalamus, caudate and putamen has also been reported in a 
separate cohort of mutation carriers who were ~15 years younger than the median age of 
dementia diagnosis in their family (Lee et al., 2013). A voxel-based morphometry 
(VBM) analysis of DIAN data demonstrated decreasing thalamic grey matter in 
presymptomatic DIAN mutation carriers closer to age at onset (Cash et al., 2013). 
Subsequent analysis of a larger cohort from DIAN using an automated segmentation 
technique to assess cortical thickness and subcortical regional volumes demonstrated 
atrophy of the hippocampus, putamen, thalamus, amygdala and accumbens ~10 years 
and cortical thinning, particularly of precuneus, ~5 years before the parental age at 
symptom onset (Benzinger et al., 2013). The lack of caudate atrophy in the DIAN data 
is somewhat surprising, particularly given the high amyloid burden observed in this 
structure. However, the caudate has been associated with a number of unexpected 
results in studies of presymptomatic FAD. Lee et al. found that, although caudate 
volumes were reduced in young presymptomatic mutation carriers, there was a trend 
towards increasing caudate size in symptomatic mutation carriers during the pre-
dementia phase (Lee et al., 2013). Another group reported increased caudate volumes 
and cortical thickness in precuneus and parietotemporal areas in a small number of 
mutation carriers who were approximately a decade younger than their family’s median 
age at symptom onset – with the intriguing possibility that early amyloid deposition 
may cause volume increases perhaps due to plaque-associated inflammatory responses. 
(Fortea et al., 2010). Like the report of hypermetabolism in very young mutation 
carriers, these observations of possible increases in regional volumes require replication 
in larger studies to ensure that they are not artefactual but they do raise the possibility 
that biomarkers may change in unexpected ways during the presymptomatic stages of 
the disease. 
 
 DTI is another modality that has been found to show some unexpected abnormalities in 
presymptomatic FAD. This advanced MRI technique provides insights into tissue 
microstructure by examining the magnitude and directionality of water diffusion within 
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white matter tracts and fibre-rich grey matter regions. Diffusion in white matter is 
described as anisotropic as it occurs preferentially along the major axis of a fibre. The 
three-dimensional nature of this diffusion is characterised by a diffusion tensor, from 
which various metrics can be extracted. Fractional anisotropy (FA) describes the overall 
shape of the tensor, with axial (AxD) and radial diffusivity (RD) representing diffusion 
in the principal direction of the tract and in the plane perpendicular to this. Mean 
diffusivity (MD) describes the overall magnitude of diffusion. Early DTI studies 
focussed on white matter FA alone and decreased FA in the fornix, interpreted as loss of 
structural integrity, was reported in presymptomatic mutation carriers who were on 
average 13 years younger than the age at dementia diagnosis in their family (Ringman et 
al., 2007). In Chapter 6, I report a different observation; symptomatic mutation carriers 
were found to have the expected widespread reductions in white matter FA with 
increased MD, RD and AxD, however presymptomatic mutation carriers demonstrated a 
contrasting decrease in MD and AxD in the right cingulum (Ryan et al., 2013). 
Reductions in AxD occur in axonal injury, which we hypothesise may be an early event 
in presymptomatic FAD. I also examined diffusion characteristics in grey matter regions 
of interest and found a corresponding reduction in MD in the right hippocampus. 
Reduced caudate MD has been reported in another cohort of presymptomatic PSEN1 
mutation carriers and it has been suggested that reductions in MD may reflect early 
pathological responses to amyloid accumulation such as microglial activation and/or 
swelling of neurons and glia (Fortea et al., 2010). Finally, I observed increased FA in 
the thalamus and caudate of presymptomatic mutation carriers, which may be due to the 
degeneration of long-coursing white matter tracts with preservation of short 
interneurons within these highly connected structures. Refinement of DTI analysis 
methods and their application to larger cohorts, particularly those with longitudinal data, 
will hopefully allow these initial findings to be explored in greater depth. 
 
Another advanced MRI technique that is starting to be applied to the study of 
presymptomatic FAD is fMRI. Detailed discussion of this imaging modality is outside 
the scope of this thesis but briefly, it has been found to detect very early differences 
between mutation carriers and their mutation-negative siblings. In the Colombian 
kindred, altered hippocampal activation during memory encoding on fMRI and 
decreased right parietal volume has been reported approximately two decades before the 
median age at onset of mild cognitive impairment for the family (Reiman et al., 2012). 
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Another study has found decreased left hippocampal fMRI activity during memory 
retrieval in mutation carriers (Braskie et al., 2013). In the DIAN study, resting state 
fMRI data has been analysed to look at functional connectivity in the default mode 
network; the set of brain regions whose coordinated activity during wakeful rest appears 
to be critical for successful memory function. Reduced connectivity in 
precuneus/posterior cingulate and right parietal cortex was observed in mutation carriers 
on average 12 years from parental age at onset, with decreasing functional connectivity 
observed in those closer to their expected age at onset (Chhatwal et al., 2013). 
 
One of the challenges in comparing different imaging studies of presymptomatic AD is 
that different groups have used different measures to estimate how far from clinical 
onset the mutation carriers may be. These include years from the parental age at 
symptom onset, the mean or median age at symptom onset for the family or the 
mean/median age at diagnosis of mild cognitive impairment or dementia. The latter two 
of these will of course occur later than the age at symptom onset and may vary 
according to a range of sociocultural factors surrounding presentation to health 
professionals. Recollections of when a relative’s symptoms began are themselves 
subjective and can change over time. Furthermore, although symptoms appear to 
manifest at broadly similar ages within families, there is variability. Our understanding 
is currently quite limited regarding both the degree of such variability and the potential 
genetic or environmental modifiers that may underpin it. All of these caveats should be 
considered when cross-sectional studies are used to predict the temporal evolution of 
imaging changes in presymptomatic FAD. Comparability between studies may also be 
limited by differences in image analysis techniques as variability in methods, for 
example the approach used to segment a structure of interest like the caudate, may have 
an influence on the results generated. Finally, it remains uncertain how heterogeneously 
different FAD mutations affect imaging biomarkers in the presymptomatic phase. 
 
Overall, the literature to date indicates that a variety of imaging biomarker 
abnormalities is evident in presymptomatic FAD. The use of a range of modalities has 
started to provide insights into the selective vulnerability of different regions to Aβ 
pathology, which longitudinal data should help to clarify. Longitudinal imaging will 
also be important for exploring the suggestion that the direction of change in some 
biomarkers may be dynamic at different points during the presymptomatic stage of 
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disease. Appreciating the possibility that imaging biomarkers may change in 
unpredictable ways during preclinical disease is important, particularly in light of 
upcoming treatment trials. Previous clinical trials have shown that treatments can also 
have unexpected effects on biomarkers, with the greatest volume losses in the AN1792 
Aβ active immunisation trial seen in antibody-responders (Fox et al., 2005). As the API 
and DIAN study have now both launched presymptomatic prevention trials of amyloid-
modifying therapies, information about the sequence of biomarker changes during the 
natural history of the disease and in the context of treatment will be acquired in tandem. 
Study of the asymptomatic at-risk state of sporadic AD may progress in a similar 
fashion, with an anti-amyloid treatment trial (the A4 trial) in healthy older people with 
evidence of Aβ deposition on amyloid PET scans also underway (Sperling et al., 2014). 
In this context, where imaging will be used to both define and study an at-risk state, a 
multi-modal approach will be important and insights from the study of presymptomatic 
FAD may be particularly valuable. 
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3 Clinical phenotype and genetic associations in autosomal dominant 
familial Alzheimer’s disease: a case series 
 
3.1 Introduction  
 
Other than the younger age at symptom onset, FAD is considered to be clinically similar 
to sporadic AD, with progressive impairment of episodic memory characterising both 
forms of the disease. While atypical phenotypes are seen in both familial and sporadic 
AD (Ryan and Rossor, 2010, Crutch et al., 2012, Shea et al., 2015), relatively little is 
known about the proportion of individuals with FAD who present with atypical 
cognitive symptoms, the prevalence of additional neurological features, or the 
relationships between genotype and phenotype and the pathophysiological mechanisms 
that may underlie them.  
 
Prevention trials for autosomal dominant FAD are underway and have stimulated 
important work investigating biomarker changes in preclinical disease. However, they 
also necessitate better understanding of the natural history of the disease in the 
symptomatic phase and of factors that influence age at onset. A recent meta-analysis 
found that mutation type accounted for a large proportion of the variance in age at onset, 
but substantial variation was still observed between, and even within, families with the 
same mutation (Ryman et al., 2014). Younger ages at onset in APOE4 carriers have 
been reported in some studies analysing families with APP, PSEN1 or PSEN2 mutations 
(Sorbi et al., 1995, Pastor et al., 2003, Wijsman et al., 2005) although this association 
was not evident in the recent meta-analysis (Ryman et al., 2014). Relatively little is 
known about the factors underlying variability in age at onset between different 
mutations within a single gene although, as will be discussed in Chapter 4, PSEN1 
mutations beyond codon 200 have been found to be associated with a later age at onset, 
more severe CAA and a greater burden of white matter hyperintensities on MRI than 
mutations located before codon 200 (Mann et al., 2001, Ryan et al., 2015, Shea et al., 
2015).  
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The aim of this study was to analyse the clinical phenotype data gathered on a large 
cohort of symptomatic individuals from FAD families studied in the UK over the past 
twenty-five years. We aimed to ascertain the initial cognitive symptoms and frequency 
of additional neurological features in the cohort, to investigate potential associations 
with age at symptom onset, mutation position and APOE genotype and to report the 
clinical and neuropathological features of the cases with novel mutations.  
 
3.2 Materials and methods 
3.2.1 Participants 
Between July 1, 1987 and October 31, 2015, families with histories suggestive of 
dominantly inherited AD were referred to the Dementia Research Centre (DRC) at 
University College London’s Institute of Neurology from clinical and research centres 
across the UK and Ireland. Following identification of the first APP mutation in one of 
these families (Goate et al., 1991), APP mutations have been found in 11 of the families 
in our longitudinal FAD research study and PSEN1 mutations in 55 other families. Five 
families with APP duplications have also been identified, which are not included in this 
study as they have been reported in detail elsewhere (McNaughton et al., 2010). To 
date, no pathogenic PSEN2 mutations have been identified in our cohort. Individuals 
with reported APP or PSEN1 sequence variants of questionable pathogenicity were not 
included in this study.   
 
Information regarding age at symptom onset, defined as the age at which clearly 
progressive symptoms of cognitive, behavioural or motor change were first noticed by 
someone who knew the subject well, was available for 213 individuals; 168 with 
PSEN1 and 45 with APP mutations. Detailed contemporaneous records documenting 
the medical history and neurological examination findings were available for 121; 85 
with PSEN1 and 36 with APP mutations. Assessments were evaluated to determine the 
initial cognitive/behavioural symptoms and the presence of the following neurological 
features: myoclonus, seizures, pyramidal, extrapyramidal and cerebellar signs. 
Neurological features were classified as ‘early’ or ‘late’ depending on whether they 
were first observed before or after five years from symptom onset. APOE status could 
be established for 126 individuals; 95 with a PSEN1 and 31 with an APP mutation. 
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Ethical approval for the study was obtained from the local institutional ethics committee 
and carried out in accordance with the Declaration of Helsinki; written informed 
consent was obtained from all participants or from their guardian if cognitive 
impairment prohibited written informed consent. A flow diagram detailing the number 
of participants involved in each component of this study and in the imaging studies 
reported in subsequent chapters of the thesis is shown in Figure 3.1. 
 
 
Figure 3.1 Familial Alzheimer’s disease study participants 
 
 
 
3.2.2 Procedures 
Mutation analysis was carried out as described previously (Janssen et al., 2003), for 
details see Appendix 11.2. The likely pathogenicity of novel variants was predicted 
using a previously published algorithm, which classifies variants as possibly, probably 
or definitely pathogenic (Guerreiro et al., 2010). The software tools Polyphen (version 
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1.1.3) and Provean (version 2) were also used to predict whether the resulting amino 
acid substitutions were likely to impact on the biological function of the protein. 
Polyphen allocates a score between 0 and 1, with 1 representing the most damaging 
change. Provean generates a score, which predicts that the protein variant will have a 
“deleterious” effect if it is equal or below -2.5 and a “neutral” effect if it is above this 
threshold. Cases that were found to have novel variants in PSEN1 or APP were then 
assessed for the presence of additional mutations in other dementia related genes using 
the Ion Torrent Dementia Chip, as described in Appendix 11.2. 
 
Two novel variant cases underwent post-mortem brain donation to the Queen Square 
Brain Bank for Neurological Disorders, UCL Institute of Neurology. Aβ-positive plaque 
and neurofibrillary tangle pathology were assessed using Consortium to Establish a 
Registry for AD (CERAD) recommendations and Braak and Braak staging respectively 
(Mirra et al., 1991, Braak et al., 2006). 
 
3.2.3 Statistical analysis 
Differences in age at symptom onset between the APP and PSEN1 mutation groups, 
between APOE4 carriers and noncarriers within each genetic group and between 
individuals with PSEN1 mutations located before or after codon 200 were investigated 
using two sample t tests. Associations between age at onset and PSEN1 mutation were 
analysed using a linear mixed effects model with random effects for mutation and 
family. The intraclass correlation coefficient was used to quantify the proportion of 
variance in age at onset explained by mutation, and by mutation and family. Groups of 
individuals with APP and PSEN1 mutations were analysed separately to calculate the 
proportion of individuals presenting with amnestic symptoms; or with atypical 
symptoms of behavioural change, language impairment, dyscalculia or executive 
impairment; and the proportions with myoclonus, seizures, and pyramidal, 
extrapyramidal or cerebellar signs. Two sample t tests were used to investigate whether 
age at onset differed between those with typical and atypical presentations, or those with 
and without additional neurological features. Fisher’s exact tests were used to 
investigate associations between atypical cognitive presentations or additional 
neurological features and APOE4 status, PSEN1 exon and PSEN1 mutation location 
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compared to codon 200. All results are reported as statistically significant if p<0.05; 
analyses were performed using Stata (version 12). 
 
3.3 Results 
3.3.1 Genetics 
The numbers of individuals and families with each mutation are summarised in Table 
3.1. One individual had a novel APP variant (p.Thr719Asn, NM_000484.3:c.2156C>A) 
and four individuals had novel PSEN1 variants. The PSEN1 p.Ser132Ala 
(NM_000021.3:c.394T>G), p.Gln222Pro (NM_000021.3:c.665A>C) and p.Phe283Leu 
(NM_000021.3:c.849T>G) variants were identified in three different individuals. The 
fourth individual had two PSEN1 substitutions: p.Thr291Ala 
(NM_000021.3:c.871A>G) and p.Ala434Thr (NM_000021.3:c.1301G>A). The 
remainder of the cases had recognised mutations. The case with the novel PSEN1 
p.Ser132Ala variant, who had pathological confirmation of Alzheimer’s disease, also 
had an intronic variant (NM_005910.5: rs11872014) in the MAPT gene. There is no 
consensus on the impact of the variant on MAPT splicing; it may alter an acceptor 
splice site and altered splicing can play a role in neurodegenerative disease 
(Karambataki et al., 2010). However, we would not expect a MAPT mutation to cause 
Aβ  pathology. In addition, this MAPT variant has not only been found in an elderly 
healthy control (unpublished data, MRC Prion Unit), but described 321 times on the 
Exome Aggregate Consortium (ExAC) dataset (http://exac.broadinstitute.org) with an 
allele frequency of 0.002952 (0.004401 in Europeans). Overall, this MAPT variant 
seems unlikely to have caused disease in this patient. No additional variants in dementia 
related genes were found in the other cases with novel PSEN1 or APP variants.  
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Table 3.1 Mutations carried by the individuals in the cohort  
Gene Mutation Exon Number 
of 
families 
Number of 
affected 
individuals 
(range in 
family size) 
 
Mean age at onset 
(range) 
APP p.Ala692Gly 17 1 4 46 (39-54) 
 p.Val715Ala 17 1 1 42 
 p.Val717Gly 17 1 13 50 (40-59) 
 p.Val717Ile 17 6 22 (1-8) 52 (39-59) 
 p.Val717Leu 17 1 4 49 (48-51) 
 p.Thr719Asn 
 
17 1 1 46 
PSEN1 Intron 4 
(g.23024delG) 
p.Tyr115Cys 
p.Tyr115His 
p.Thr116Asn 
p.Glu120Lys 
p.Ser132Ala 
p.Met139Val 
p.Ile143Phe 
p.Met146Ile 
p.Leu153Val 
p.Tyr154Cys 
p.Leu166Arg 
p.Leu166del 
Delta 167 
(p.Ile168del) 
p.Leu171Pro 
p.Glu184Asp 
p.Ile202Phe 
4 
 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
6 
6 
6 
 
6 
7 
7 
4 
 
2 
1 
1 
2 
1 
4 
1 
2 
1 
1 
1 
1 
1 
 
1 
3 
1 
17 (1-12) 
 
2 
4 
2 
7 (2-5) 
3 
18 (1-9) 
2 
6 (2-4) 
3 
1 
1 
1 
5 
 
5 
5 (1-2) 
2 
38 (35-45) 
 
39 (34-44) 
34 (30-36) 
34 
35 (31-39) 
59 (58-60) 
40 (35-48) 
56 (53-59) 
48 (43-50) 
35 (35-36) 
41 
40 
38 
54 (43-60) 
 
42 (40-43) 
40 (37-45) 
48 (47-48) 
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p.Gln222Pro 
p.Gly206Val 
p.Ile229Phe 
p.Leu235Val 
p.Phe237Leu 
p.Leu250Ser 
p.Ala260Val 
p.Cys263Phe 
p.Pro264Leu 
p.Pro267Ser 
p.Arg269His 
p.Arg278Ile 
p.Glu280Gly 
p.Phe283Leu 
p.Ser290Cys 
ΔE9* 
p.Arg377Met 
p.Gly378Val 
p.Gly394Val 
p.Pro436Ser 
p.Thr291Ala 
and 
p.Ala434Thr 
7 
7 
7 
7 
7 
7 
8 
8 
8 
8 
8 
8 
8 
8 
9 
9 
11 
11 
11 
12 
9 
and 
12 
1 
1 
1 
1 
1 
1 
1 
1 
2 
1 
3 
1 
3 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
3 
4 
1 
7 
1 
2 
3 (1-2) 
2 
4 (1-2) 
7 
16 (1-8) 
15 
5 
1 
1 
5 
1 
3 
1 
 
45 
30 
33 (32-34) 
52 (44-59) 
47 
52 (47-56) 
40 
59 (58-59) 
50 (44-56) 
38 
55 (50-62) 
51 (44-59) 
42 (39-49) 
46 (42-48) 
42 (41-44) 
45 
38 
44 (41-48) 
40 
46 (44-50) 
42 
 
* The exon 9 deletion (NM_000021.3:c.869-1G>T; p.Ser290Cys;Thr291_Ser319del) 
commonly referred to as ΔE9. 
 
All novel sequence variants identified were absent from 100 healthy unrelated white 
control patients. With the exception of p.Ser132Ala which was seen in one individual of 
European ancestry, none of the variants were found on the ExAC dataset. Where 
possible, when a novel sequence variant was found in the proband, genotyping of other 
affected family members was performed by sequencing the relevant exon to 
demonstrate co-segregation between the mutation and disease. However, this was not 
possible in the majority of cases as there were no other affected relatives still alive.  
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The case with the APP p.Thr719Asn variant had a family history of dementia 
suggesting autosomal dominant inheritance but there were no other living affected 
relatives in whom to demonstrate co-segregation. She developed memory symptoms 
from age 46 years, with additional word-finding and calculation difficulties and 
myoclonus. Her father was similarly affected, also from around the age of 46 years, and 
his father was also thought to have had dementia. Although there was no pathological 
confirmation of AD in this family, the proband had supportive investigations including 
a typical CSF profile with a raised tau concentration of 920 pg/ml (reference range 146-
595 pg/ml) and reduced Aβ1-42 concentration of 121 pg/ml (reference range 627-1322 
pg/ml). The affected amino acid lies close to the gamma-secretase site, is highly 
conserved between species and numerous pathogenic mutations have been reported at 
neighbouring residues. A different substitution at this residue (p.Thr719Pro) has 
previously been reported as pathogenic (Ghidoni et al., 2009). The variant is predicted 
to be probably pathogenic by our algorithm, probably damaging by Polyphen (score=1) 
and “neutral” by Provean (score=-1.521). 
 
The case with the PSEN1 p.Gln222Pro variant was adopted and knew nothing of her 
biological family. She developed memory impairment from age 46 years with word-
finding difficulties and dyscalculia. The residue is conserved between species and 
PSENs and a different substitution at this same residue (p.Gln222His) has been reported 
as pathogenic in a pathologically-confirmed FAD patient (Miklossy et al., 2003). The 
variant is predicted to be probably pathogenic by our algorithm, probably damaging by 
Polyphen (score=1) and “deleterious” by Provean (score=-5.670). 
 
The p.Phe283Leu PSEN1 variant was identified in three affected individuals and absent 
in two unaffected individuals from the same family, with AD confirmed post-mortem in 
another two affected family members. All of the mutation cases had an amnestic 
presentation, with symptom onset at age 46, 47 and 50 years. The residue is completely 
conserved between species and there are numerous pathogenic mutations in this region 
of PSEN1. The variant is classified as definitely pathogenic by our algorithm, as 
segregation was demonstrated. Polyphen predicts the variant to be probably damaging 
(score=0.999) and Provean predicts it to be “deleterious” (score=-5.378). 
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The cases with the novel p.Ser123Ala and p.Thr291Ala and p.Ala434Thr substitutions 
are described in the final part of the results section. 
 
3.3.2 Age at symptom onset 
Mean (±SD) age at onset was significantly later in individuals with APP mutations (50.4 
±5.2, range 39-59, p<0.0001) than in those with PSEN1 mutations (43.6 ±7.2, range 30-
62). There was no significant association between possession of an APOE4 allele and 
age at onset in either the PSEN1 (43.6 ±7.2 APOE4 +ve versus 42.3 ±6.7 APOE4 –ve; 
p=0.385) or APP (50.7 ±4.2 APOE4 +ve versus 50.7 ±5.3 APOE4 –ve; p=0.998) 
cohorts. In individuals with a PSEN1 mutation, age at onset (Table 3.1) was found to be 
influenced by the specific mutation, with 72% of the variance in age at onset explained 
by mutation (intra-class correlation coefficient, ICC=0.72). Mutation and family 
membership together explained 82% of the variance in age at onset (ICC=0.82). 
Mutations located before codon 200 had, on average, a younger age at onset (41.3 ±7.2) 
than mutations beyond codon 200 (45.8 ±6.4, p<0.0001), which appeared to be driven 
by a younger age at onset for mutations involving exons 5 and particularly 4 compared 
with the later exons (Figure 3.2 and Figure 3.3). Age at onset for the individual with the 
double substitution p.Thr291Ala and p.Ala434Thr is excluded from these figures as it is 
unclear whether pathogenicity is due to one or both of these amino acid substitutions. 
The intron 4 (NM_000021.3:c.338+1delG) mutation is classified as involving exon 4 as 
it is located just outside this exon. The mutation produces three different transcripts 
through aberrant splicing; two deletion transcripts resulting in truncated PSEN1 proteins 
and one insertion transcript resulting in full-length PSEN1 with an extra amino acid 
(Thr) inserted between codons 113 and 114 (PSEN1 Thr114-114ins), exon 5 begins at 
codon 114. The truncated proteins have been found to be undetectable in brain 
homogenates, indicating that the PSEN1 Thr113-114ins protein probably accounts for 
the pathogenicity of this mutation (De Jonghe et al., 1999).  
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Figure 3.2 Age at onset for individuals with mutations involving each exon of the 
PSEN1 gene.  
Each dot represents an individual’s age at onset. Within each exon, different colours 
represent each separate family and multiple families with the same mutation are 
indicated by different shades of the same colour (blue, green, purple or pink). Bars 
indicate mean age at onset for mutations involving each exon 
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Figure 3.3 Location of the mutations present in our cohort of PSEN1 mutation 
carriers, shown according to age-at-onset quartiles  
Predicted membrane topology of PSEN1, with the nine transmembrane domains (dark 
green shaded boxes) and boundaries between coding exons indicated. The sites of 
amino acid substitution (or insertion in the case of Intron 4 and deletion in the case of 
ΔE9) are indicated by coloured circles, with the colour representing the quartile that the 
mean age at onset for that variant falls within. Adapted by permission from Macmillan 
Publishers: Nature (2012) (Li et al., 2013). Codon 200 is shown within the fourth 
transmembranal domain of the protein. TM = transmembrane domain. 
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3.3.3 Cognitive-behavioural presentations 
35 of 36 individuals with APP mutations presented with typical amnestic symptoms; the 
remaining individual presented with dyscalculia but developed memory problems soon 
after. Of the 85 individuals with PSEN1 mutations, 71 (84%) presented with amnestic 
symptoms. Atypical cognitive presentations were more frequently associated with 
PSEN1 than APP mutations (p=0.037). Of the 14 PSEN1 mutation carriers with atypical 
initial cognitive features, seven (8%) presented with behavioural change, three (4%) 
with language impairment, two (2%) with dyscalculia and two (2%) with a dysexecutive 
syndrome. The PSEN1 subgroup with atypical cognitive presentations had, on average, 
a somewhat later age at onset than those with typical amnestic symptoms (46.2 vs 42.0, 
p=0.046). Prevalence of atypical cognitive presentations differed markedly between 
exons, occurring in 10 of 22 (45%) individuals with exon 8 mutations, and fewer than 
(20%) of individuals with mutations involving other exons (Figure 3.4). As a result, 
atypical presentations were significantly more common in individuals whose mutation 
was located after codon 200 (p=0.006). Individual mutations associated with atypical 
cognitive presentations are listed in Table 3.2. There was no association between 
atypical cognitive symptoms and APOE4 status. 
 
 
Figure 3.4 Cognitive presentations in APP and PSEN1 mutation carriers in our 
cohort, with presenting symptoms in the PSEN1 group shown by exon  
Number of cases: 36 APP and 85 PSEN1 mutation carriers 
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Table 3.2 Mutations associated with atypical phenotypes and additional 
neurological features in our cohort 
Phenotype Gene  Mutation Patients with 
the 
phenotype 
(n/N) 
Previous reports of the 
cases 
Behavioural 
presentation 
 
 
PSEN1 p.Met139Val 
p.Leu166Arg 
p.Pro264Leu 
p.Arg269His 
p.Arg278Ile 
p.Glu280Gly 
1/14 
1/1 
2/3 
1/2 
1/5 
1/9 
 
Language 
presentation 
PSEN1 p.Pro264Leu 
p.Arg278Ile 
1/3 
2/5 
(Mahoney et al., 2013) 
(Godbolt et al., 2004) 
Dycalculia 
presentation 
 
 
PSEN1 
 
 
APP 
Intron 4 
(g.23024delG) 
p.Leu235Val 
p.Val717Ile 
1/9 
 
1/2 
1/19 
 
Dysexecutive 
presentation 
PSEN1 p.Glu280Gly 2/9  
Myoclonus 
 
PSEN1 
 
 
 
 
 
 
 
 
 
 
 
 
Intron 4 
(g.23024delG) 
p.Tyr115Cys 
p.Tyr115His 
p.Ser132Ala 
p.Met139Val 
 
p.Met146Ile 
p.Glu184Asp 
p.Ile202Phe 
p.Gly206Val 
p.Ile229Phe 
p.Phe237Leu 
6/9 
 
1/1 
1/2 
1/1 
10/14 
 
2/3 
1/3 
1/1 
1/1 
1/1 
1/1 
 
 
 
 
 
(Kennedy et al., 1995) 
(Fox et al., 1997) 
 
 
(Ryan et al., 2014) 
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APP 
p.Leu250Ser 
p.Ala260Val 
p.Pro264Leu 
p.Arg269His 
p.Arg278Ile 
p.Glu280Gly 
p.Ser290Cys 
p.Gly278Val 
p.Gly394Val 
p.Val717Gly 
p.Val717Ile 
p.Val717Leu 
p.Thr719Asn 
1/1 
1/1 
1/3 
1/2 
3/5 
4/9 
½ 
1/1 
1/1 
5/11 
5/19 
1/4 
1/1 
 
 
 
 
 
 
 
 
 
(Kennedy et al., 1993) 
Seizures 
 
PSEN1 
 
 
 
 
 
 
 
 
 
 
 
APP 
Intron 4 
(g.23024delG) 
p.Tyr115Cys 
p.Tyr115His 
p.Met139Val 
 
p.Met146Ile 
p.Gly206Val 
p.Ala260Val 
p.Pro264Leu 
p.Pro267Ser 
p.Glu280Gly 
p.Ala692Gly 
p.Val717Gly 
p.Val717Ile 
p.Val7171Leu 
5/9 
 
1/1 
1/4 
4/14 
 
2/3 
1/1 
1/1 
2/3 
1/1 
2/9 
1/1 
5/11 
2/19 
1/4 
 
 
 
 
(Kennedy et al., 1995) 
(Fox et al., 1997) 
 
 
 
 
 
 
 
(Kennedy et al., 1993) 
Spastic 
paraparesis 
+/- other 
pyramidal signs 
PSEN1 Intron 4 
(g.23024delG) 
p.Tyr115His 
p.Glu120Lys 
1/9 
 
1/2 
1/3 
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p.Met139Val 
p.Met146Ile 
p.Leu166Arg 
p.Glu184Asp 
p.Pro264Leu 
p.Arg278Ile 
p.Glu280Gly 
p.Gly394Val 
p.Thr291Ala & 
p.Ala434Thr 
ΔE9 
1/14 
1/3 
1/1 
1/3 
1/3 
2/5 
8/9 
1/1 
1/1 
 
1/1 
 
 
 
 
 
 
(O'Riordan et al., 2002) 
Extrapyramidal 
signs 
 
PSEN1 p.Tyr115His 
p.Glu120Lys 
p.Ser132Ala 
p.Met146Ile 
p.Leu166Arg 
Delta 167 
(p.Ile168del) 
p.Arg278Ile 
p.Glu280Gly 
p.Thr291Ala & 
p.Ala434Thr 
1/3 
1/3 
1/1 
1/3 
1/1 
1/2 
 
3/5 
2/9 
1/1 
 
Cerebellar signs 
 
PSEN1 p.Tyr115Cys 
p.Glu280Gly 
p.Ser290Cys 
1/1 
1/9 
1/2 
 
(O'Riordan et al., 2002) 
 
3.3.4 Neurological features 
In the APP group, myoclonus and seizures were the only additional neurological 
features observed. In the PSEN1 group, pyramidal, extrapyramidal and cerebellar signs 
were also seen. Table 3.2 shows the mutations and proportion of cases with each of 
these neurological features. Figure 3.5 demonstrates the proportion of cases with each 
neurological feature for mutations involving each exon of PSEN1. 
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Figure 3.5 Proportion of cases with each neurological feature for mutations 
involving each of the exons of PSEN1 
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3.3.4.1 Myoclonus and seizures 
The frequency of myoclonus and seizures did not differ significantly between the 
PSEN1 and APP groups. In the APP group, 12 (33%) of 36 carriers had myoclonus and 
nine (25%) of 36 developed seizures. Of the 12 individuals with myoclonus, onset was 
early (≤5years from onset) in five (42%), late in two (17%), and uncertain in five (42%). 
Of the nine individuals with seizures, onset was early in three, late in three, and 
uncertain in three. In the PSEN1 group, 40 (47%) of 85 carriers had myoclonus and 20 
(24%) had seizures. Of the 40 individuals with myoclonus, onset was early in 28 (70%), 
late in nine (23%), and uncertain in three (7%). Of the 20 individuals with seizures, 
onset was early in six (30%), late in 10 (50%), and uncertain in four (20%). Individuals 
with myoclonus were significantly more likely to develop seizures: 40% developed 
seizures in the PSEN1 group (p=0.001) and 50% in the APP group (p=0.036). There 
was no association between myoclonus or seizures and age at onset or APOE4 status in 
either the APP or PSEN1 groups. There was no association between seizures or 
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myoclonus and APOE4 status, exon or mutation location with respect to codon 200 in 
the PSEN1 group. 
 
3.3.4.2 Pyramidal signs 
Pyramidal signs were observed in 21 (25%) of the 85 PSEN1 carriers. All of these 
individuals had spastic paraparesis, and 18 also had upper limb pyramidal signs. Of the 
21 individuals with pyramidal signs, 15 (71%) developed them early, although none 
were reported to have these signs before onset of cognitive symptoms. The remaining 
six (29%) developed them late, with an absence of pyramidal signs at earlier 
assessments. There were no associations between pyramidal signs and age at onset or 
APOE4 status in the PSEN1 cohort as a whole and insufficient numbers to investigate 
such associations at the level of individual families or mutations. Pyramidal signs were, 
however, observed more frequently in association with PSEN1 mutations after codon 
200 than before codon 200 (p=0.024), with particularly high frequency (50%) for 
mutations on exon 8 (Figure 3.5).  
 
3.3.4.3 Extrapyramidal signs 
Extrapyramidal signs were observed in 13% of the PSEN1 group and occurred early in 
the illness in 67%, late in the illness in 25% and were of uncertain onset in 8%. No 
associations were found between extrapyramidal signs and age at onset, APOE4 status, 
exon or PSEN1 mutation location compared to codon 200. 
 
Of the individuals with early extrapyramidal signs, one had markedly asymmetrical 
features consistent with a corticobasal syndrome. Two had novel PSEN1 variants; one 
presenting with a DLB phenotype. These cases are summarised below.  
 
Corticobasal syndrome secondary to the PSEN1 p.Tyr115His mutation 
This right-handed man developed memory impairment from age 34 years. Three years 
later, he gradually developed uncomfortable tingling sensations, involuntary jerks and 
stiffness of his right hand, which took up a clenched position. He then developed 
unsteadiness walking and lower limb stiffness, particularly on the right. On examination 
aged 39 years, he scored 24/30 on the MMSE and had a rigid, dystonic flexed hand with 
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frequent myoclonic jerks. There was a pyramidal and extrapyramidal component to the 
rigidity, with associated bradykinesia and limb kinetic apraxia. The lower limbs had a 
spastic increase in tone bilaterally, more prominent on the right, with sustained clonus. 
Limb reflexes were all pathologically brisk but symmetrical with flexor plantar 
responses. He had a spastic gait with decreased right arm swing. Brain MRI brain 
demonstrated strikingly focal asymmetrical left parietal atrophy. In view of the 
spasticity component a trial of Tizanidine was given, which caused a significant 
improvement in the stiffness and function of his right hand. His father had developed 
memory impairment aged 36 years followed by slurred speech and difficulty walking 
two years later. 
 
Dementia with Lewy bodies (DLB) phenotype secondary to a novel PSEN1 mutation 
p.Ser132Ala  
This man developed problems with episodic and topographical memory from age 59 
years with early symptoms of visual perceptual impairment and difficulty learning new 
tasks. He sometimes failed to recognise places or experienced déjà vu in places he had 
never visited before. Two years later he developed visual hallucinations of people and 
animals and difficulty recognising his wife and daughter, at times thinking they were 
imposters. He subsequently developed paranoid ideation, wandering and dyspraxia. He 
was first examined by a neurologist aged 64 years, at which stage he had myoclonic 
jerks, bradykinesia and increased limb tone throughout. Limb reflexes were normal and 
bilateral grasp and palmomental reflexes were present. He was too severely impaired for 
neuropsychological testing, brain MRI showed widespread atrophy. There was no past 
medical history, sulpiride had been prescribed by a psychiatrist for his behavioural 
symptoms but stopped when he developed limb stiffness. His maternal aunt and uncle 
had both died aged 65 years, having developed cognitive impairment with visual 
hallucinations, paranoia and loss of self-care at the ages of 58 years and 60 years 
respectively. His mother died following a brain haemorrhage aged 61 and experienced 
visual hallucinations of cats whilst in hospital. His maternal grandmother died in a 
psychiatric hospital in her early 70s after a ten year illness. There were no affected 
living relatives in whom to demonstrate co-segregation. He died aged 70 years.  
 
Post-mortem examination of the brain revealed severe neuritic plaque pathology in the 
CERAD consensus regions with Braak & Braak stage V neurofibrillary tangle 
 78 
pathology, indicating high likelihood AD (NIA-Reagan criteria). There was also severe 
neocortical Lewy body pathology, Braak stage 6 (Figure 3.6). In view of the severity of 
the AD pathology, McKeith criteria indicate an intermediate likelihood that the 
pathological findings are associated with a DLB clinical syndrome (McKeith et al., 
2005). 
 
Figure 3.6 Neuropathological findings in a 70 year old man with the novel PSEN1 
p.Ser132Ala mutation presenting with a Dementia with Lewy bodies phenotype 
Amyloid pathology in the hippocampus of (a) cored amyloid plaques (double arrows), 
and (b) diffuse Aβ (arrows). (c) AT8 immunoreactivity for abnormally phosphorylated 
tau of neurofibrillary tangles in the CA1 sub-region of the hippocampus, and (d) of 
neuritic plaques in the temporal cortex (arrows). (e) Alpha-synuclein 
immunohistochemistry of Lewy neurites and Lewy bodies in the CA1 sub-region of the 
hippocampus, and (f) Lewy bodies found in the dopaminergic neurons of the substantia 
nigra (arrows). Bar in a represents 60µm in a, c, d and e; 20µm in f and 10µm in b. 
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The p.Ser132Ala variant has not previously been reported. The affected amino acid is 
conserved between PSENs and located close to the second transmembrane domain. 
There are several pathogenic mutations in the surrounding region, although these all fall 
within the second transmembrane domain. The variant is predicted to be possibly 
pathogenic by our algorithm, probably damaging by Polyphen (score=0.998) and 
“neutral” by Provean (score=-0.871). 
 
Dementia with Parkinsonism and pyramidal signs in an individual with two PSEN1 
mutations: p.Thr291Ala and p.Ala434Thr  
This man of Scottish-Italian origin developed simultaneous memory symptoms and a 
gait disorder from age 42 years. His walking initially became unsteady and slow, with 
leg stiffness and frequent falls. He then developed difficulty turning and an increasingly 
small-stepped gait. He appeared more docile and withdrawn and neglected his self-care. 
From age 43 years he was noted to have slow, slurred speech and illegible handwriting. 
He had a history of treated hypertension and smoking. His father had died aged 34 years 
from a brain haemorrhage and was said to have had cognitive impairment and a 
shuffling gait prior to this event. Nothing else was known about the paternal side of his 
family. His mother died aged 73 years with no cognitive symptoms and two maternal 
half-siblings were well. There were no other affected relatives in whom to demonstrate 
co-segregation. On examination aged 44 years, he scored 17/30 on the MMSE and had 
clear pyramidal and extrapyramidal signs. He was hypomimic, bradyphrenic and 
bradykinetic with slow, dysarthric speech. Limb tone was increased throughout and 
reflexes were pathologically brisk with extensor plantar responses. He had truncal 
rigidity and walked with a stooped posture and reduced arm swing. Neuropsychometry 
demonstrated global memory impairment, anomia and executive dysfunction with 
extreme cognitive slowing, whilst visual perceptual function was intact. Brain MRI 
revealed extensive white matter hyperintensities with a posterior emphasis and 
generalised atrophy, which did not disproportionately involve the hippocampi. CSF tau 
concentration was 117 pg/ml, Aβ1-42 was 279 pg/ml. He underwent a progressive 
decline in cognition and mobility and died aged 47 years.  
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Postmortem examination of the brain revealed changes of AD with tau pathology 
corresponding to Braak & Braak stage V. The Aβ deposition was in the form of 
widespread cotton wool plaques and diffuse deposits (Figure 3.7).  
 
Figure 3.7 Neuropathological findings in a 42 year old man with a PSEN1 double 
substitution, p.Thr291Ala and p.Ala434Thr, presenting with cognitive impairment, 
pyramidal and extrapyramidal signs 
Amyloid pathology in the hippocampus of (a) cotton wool plaques and (b) capillary 
cerebral amyloid angiopathy (c) Diffuse deposits, shown in the granule cell layer of the 
cerebellum. (d) Aβ deposits in the leptomeningeal blood vessels, (e) and Aβ deposits 
shown to be in an amyloid conformational state using Congo red staining. (f) AT8 
immunoreactivity for abnormally phosphorylated tau in the CA1 sub-region of the 
hippocampus, (g) and at 40X magnification detailing the neurofibrillary tangles and 
neuropil threads. Bar in a represents 60µm in a, c, d and g; 20µm in b and e and 200µm 
in f. 
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Cotton wool plaques were observed throughout neocortical regions, hippocampus, 
amygdala, caudate, putamen, thalamus, subthalamic nucleus and in the molecular layer 
of the cerebellum. There was severe CAA in leptomeningeal and cortical vessels, 
including capillaries. Marked gliosis and diffuse microgliosis were observed throughout 
the cortex and white matter. There was no α-synuclein pathology.  
 
The p.Ala434Thr PSEN1 mutation has been reported in a Chinese patient who presented 
with hallucinations and delusions, although another affected family member had a 
typical amnestic presentation (Jiao et al., 2014). The p.Thr291Ala variant has not 
previously been reported. However, it affects a highly conserved amino acid and a 
different substitution at the same residue (p.Thr291Pro) has been reported in a French 
FAD patient who also had spastic paraparesis and dysarthria. This variant increases 
Aβ42 secretion in retrovirally transduced cells (Dumanchin et al., 2006). The 
p.Thr291Ala variant is predicted to be possibly pathogenic by our algorithm, possibly 
damaging by Polyphen (score=0.674) and “neutral” by Provean (score=-1.545). 
 
3.3.4.4 Cerebellar signs 
Cerebellar signs were observed in three (4%) of the 85 PSEN1 carriers, occurring early 
in two, and late in one. No associations were found with age at onset, APOE4 status, or 
exon or PSEN1 mutation location compared to codon 200. 
 
3.4 Discussion 
 
This study characterises the clinical spectrum of FAD in a large case series from a 
single UK centre and explores some of the factors that may influence clinical 
heterogeneity. Significant phenotypic differences were found between PSEN1 and APP 
mutation carriers, emphasising the potential importance of examining these groups 
separately in observational research and clinical trials. In addition to the well known 
younger age at symptom onset for PSEN1 compared with APP mutations, PSEN1 
mutation carriers more frequently presented with atypical cognitive symptoms and 
additional neurological features. Behavioural, language and dysexecutive presentations, 
spastic paraparesis and other pyramidal, extrapyramidal and cerebellar signs were only 
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seen in the PSEN1 cases in our cohort. Myoclonus and seizures, on the other hand, 
affected a similar proportion of individuals with APP and PSEN1 mutations. In both 
genetic groups, individuals with myoclonus were significantly more likely to develop 
seizures than those without myoclonus, highlighting the importance for clinicians of 
being vigilant for symptoms of seizure activity when myoclonus is present.  
 
Possible limitations of our study were that some atypical phenotypes, such as movement 
disorder presentations or much older onset, may not have been seen in our case series 
due to the ascertainment bias of our centre being more likely to be referred younger 
patients with cognitive symptoms. Also, not all individuals were followed to advanced 
stages of illness, so late neurological features may be more frequent than described here. 
With enrolment of individuals over a long period of time, there is the potential for 
families to have greater awareness and therefore earlier recognition of symptom onset 
with successive generations.  The relative non-diversity of individuals seen in a single 
country may also limit generalizability of the findings. However, the mean age at onset 
in our cohort was very similar to those reported in a French case series of autosomal 
dominant early onset AD cases (Wallon et al., 2012) and in recent systematic reviews of 
autosomal dominant FAD (Ryman et al., 2014, Shea et al., 2015). As in our case series, 
spastic paraparesis and extrapyramidal and cerebellar signs were seen in French PSEN1, 
but not APP, mutation carriers, usually manifesting within five years of symptom onset. 
The proportion of French individuals with PSEN1 mutations presenting with ‘frontal 
symptoms’ (11%) was also comparable to the combined proportion of individuals in our 
series whose initial cognitive symptoms were behavioural (8%) or dysexecutive (2%) 
(Wallon et al., 2012). Finally, a non-amnestic presentation was found in 16% of the 
autosomal dominant FAD cases reported worldwide (Shea et al., 2015); the same as the 
proportion of PSEN1 cases in our cohort who did not present with memory symptoms.  
 
Whilst a significant minority of the PSEN1 cases in our study presented with non-
amnestic cognitive symptoms, all but one of the APP cases had initial memory 
symptoms. The vast majority of these mutations involve codon 717. Amnesia has been 
recognised as the major neuropsychological feature of mutations at this site since the 
earliest reports (Rossor et al., 1993) and a slowly progressive pure amnestic syndrome 
lasting fourteen years before involvement of other cognitive domains occurred in one of 
these individuals with a p.Val717Gly mutation (Knight et al., 2009). Dyscalculia was 
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also observed to be an early feature of APP-associated FAD in the initial case series and 
we found 2% of the APP and PSEN1 cases to present with isolated dyscalculia, 
followed soon after by memory symptoms. Interestingly, none of our cases presented 
with a PCA syndrome. Despite the young age at onset that is typical of PCA, it has only 
once been reported in association with FAD secondary to a novel PSEN1 variant 
p.Ile211Met (Sitek et al., 2013).  
 
There has been some evidence that phenotypic differences between APP and PSEN1 
mutation carriers are reflected in differences on neuroimaging and that these may 
provide insights into differences in underlying disease mechanisms. We have previously 
reported APP mutation carriers to have greater hippocampal atrophy than PSEN1 
carriers of similar disease severity, while PSEN1 carriers show more extensive 
neocortical atrophy and white matter involvement; the latter may underlie some of the 
atypical features observed in PSEN1 (Scahill et al., 2013). PSEN1 forms the catalytic 
subunit of gamma-secretase, which processes APP, but also a large number of other 
substrates involved in various physiological functions including myelin repair, vascular 
and immune function. Gamma-secretase carries out an initial endopeptidase cleavage of 
its substrates followed by successive carboxypeptidase-like cleavages. PSEN1 
mutations all appear to decrease the efficiency of this carboxypeptidase-like activity, 
resulting in the release of longer Aβ peptides, which are more prone to aggregation. 
Most PSEN1 mutations also affect the endopeptidase activity, but to various degrees, 
potentially impacting on the processing of other substrates in addition to APP (Chavez-
Gutierrez et al., 2012, Szaruga et al., 2015). We speculate that altered processing of 
other substrates may contribute to the atypical phenotypes witnessed in association with 
some PSEN1 mutations. Supporting this notion, atypical cognitive presentations and 
pyramidal signs in participants of this study were seen more frequently in association 
with PSEN1 mutations involving exon 8. The residues encoded by exon 8 lie within the 
hydrophilic extended sequence between transmembrane domains six and seven of 
PSEN1, which is where the cleavage site processed by autocatalytic activity has been 
found (Bai et al., 2015). Furthermore, individuals with two of the most atypical 
phenotypes - the corticobasal syndrome (p.Tyr115His)  and DLB (p.Ser132Ala) 
presentations - had mutations involving hydrophilic loop 1, which has been proposed to 
form the initial substrate binding site in PSEN1, with Ser132 playing a critical role 
 84 
(Takagi-Niidome et al., 2015). Indeed, the p.Tyr115His mutation has been found to 
reduce endopeptidase efficiency due to substantially decreased affinity for the Notch 
substrate, while the affinity for APP is affected to a lesser extent (Chavez-Gutierrez et 
al., 2012). Certain mutations may therefore differentially affect the substrate specificity 
of the gamma-secretase complex and investigating whether this mechanism contributes 
to atypical phenotypes is an important direction for future work. Also important will be 
studies exploring clinicopathologic correlations in FAD. It was notable that the PSEN1 
p.Ser132Ala case with a DLB phenotype had severe neocortical Lewy body pathology. 
However, concomitant Lewy body pathology is a frequent finding in FAD (Leverenz et 
al., 2006). Large cohort studies will be important to further investigate clinical 
phenotype and clinicopathologic correlations in autosomal dominant FAD, ideally with 
unaffected family members acting as controls. 
 
Our results suggest that multiple factors may contribute to phenotypic heterogeneity in 
FAD. There was often considerable variability in the clinical features of individuals 
with the same mutation, even within a single family. Even so, we found that mutations 
before codon 200 were associated with younger age onset, whereas mutations beyond 
codon 200 were more frequently associated with later ages at onset, atypical cognitive 
presentations and pyramidal signs. Given the relatively small numbers of subjects 
manifesting each atypical feature, and the numbers of associations (although not 
independent), it is important to be cautious about nominally significant associations. 
Nonetheless, we felt it important to report them to allow replication in other cohorts. 
Indeed, a recent systematic review (Shea et al., 2015) also found that PSEN1 mutations 
before codon 200 had younger ages at onset and were more frequently associated with 
seizures and myoclonus, whilst mutations beyond codon 200 were more frequently 
associated with spastic paraparesis. Codon 200 is an arbitrary cut-off and mapping the 
mean ages at onset for different mutations to the structure of PSEN1 (Figure 3.3) 
suggests there may be certain areas of the protein where mutations cause particularly 
early-onset disease, such as the first hydrophilic loop encoded by exons four and five. 
This extracellular loop contributes to a key allosteric core that changes Aβ profiles 
through carboxypeptidase-like activity without affecting the endopeptidase function of 
gamma-secretase (Ohki et al., 2011, Takeo et al., 2014). As qualitative changes in Aβ 
profiles appear to underlie the pathogenicity of PSEN1 mutations (Chavez-Gutierrez et 
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al., 2012, Szaruga et al., 2015), one could speculate that they may be more dramatically 
altered by mutations involving this allosteric core, resulting in a more aggressive 
phenotype. 
 
We have demonstrated that a subset of individuals with FAD do not have a typical 
amnestic presentation. As atypical presentations also occur in sporadic AD, we do not 
feel that our findings challenge the idea that familial cases represent a paradigm for AD, 
but rather highlight the importance of distinguishing and investigating atypical 
phenotypes in the endeavour to understand the complex underlying mechanisms that 
may contribute to disease. The clinical features of PSEN1-associated FAD may 
erroneously suggest a diagnosis of frontotemporal or vascular dementia, corticobasal 
degeneration or DLB. However, if there is a family history or if the family history is not 
known, we suggest that it is important to consider FAD in the differential diagnosis of 
patients with young onset dementia with additional neurological features. FAD 
detection rates have, at least historically, been lower than expected based on genetic 
epidemiology data and have shown considerable variability across different regions of 
the UK (Stevens et al., 2011). Failure to identify a mutation in these families not only 
deprives the affected individual from a correct diagnosis and appropriate symptomatic 
treatment but has implications for the wider family. Individuals at risk of FAD should, 
if they wish, be given access to genetic counselling so that they may consider their 
choices in a variety of areas including predictive genetic testing and reproductive 
options such as pre-implantation genetic diagnosis. They may benefit from the peer 
support of connecting with other families affected by FAD (Walton et al., 2015) and 
from opportunities to participate in research, including preclinical treatment trials 
aiming to delay or prevent the onset of symptoms. 
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4 Genetic determinants of white matter hyperintensities and amyloid 
angiopathy in familial Alzheimer’s disease 
 
4.1  Introduction 
 
As described above, although autosomal dominantly inherited mutations in APP, 
PSEN1 and PSEN2 account for a small minority of AD cases, insights gained through 
studying FAD have contributed to our understanding of AD pathophysiology. The view 
that therapeutic success may only be possible with intervention very early in the disease 
course has motivated the development of treatment trials specifically for FAD, which 
offers the possibility of treating individuals at a preclinical disease stage (Reiman et al., 
2010, Bateman et al., 2011). The young age of patients with FAD means that co-
morbidities such as atherosclerotic cerebrovascular disease that can complicate clinical 
trials in sporadic AD are rare. However, the launch of FAD treatment trials necessitates 
a deeper understanding of the heterogeneity that exists within FAD, particularly with 
regards to CAA, which appears to be an important factor in amyloid-modifying 
therapeutic trials (Boche et al., 2008, Sperling et al., 2011, Sakai et al., 2014).     
 
As detailed in the previous chapter of this thesis there is considerable heterogeneity 
within FAD in the clinical phenotype; however there is also a recognition of 
heterogeneity at molecular and histopathological levels. Pathological findings in PSEN1 
mutation carriers have revealed considerable variability in terms of neuronal loss: the 
type, number and distribution of amyloid plaques; and the amount and distribution of 
neurofibrillary tangles (Gomez-Isla et al., 1999, Maarouf et al., 2008, Shepherd et al., 
2009). Of particular importance, marked differences in the amount of CAA have been 
observed that may possibly be driven by the precise location of the mutation within 
PSEN1. Intriguingly, mutations before codon 200 have been reported to be associated 
with many diffuse and cored plaques, few white matter plaques and only mild to 
moderate CAA, mainly confined to leptomeningeal blood vessels. By contrast, 
mutations beyond codon 200 have been described as demonstrating larger diffuse and 
cored plaques surrounding amyloid-laden arteries, with severe CAA that involves both 
leptomeningeal and intraparenchymal arteries (Mann et al., 2001). The pre- or post-
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codon distinction appears arbitrary but it may be an approximation for important 
functional differences in the PSEN1 molecule. Certainly this is the case for the APP 
molecule with certain APP mutations being associated with very severe CAA, 
particularly those that lie in very localised positions within the Aβ coding sequence 
(Revesz et al., 2003, Revesz et al., 2009, Shepherd et al., 2009) including the Flemish 
(p.Ala692Gly), Dutch (p.Glu693Gln), Arctic (p.Glu693Gly) and Iowa (p.Asp694Asn) 
mutations. Remarkably, whilst all these mutations cause prominent CAA, the 
occurrence of plaques and tangles varies, as does the clinical phenotype (Ryan and 
Rossor, 2010). The Flemish mutation presents with haemorrhages or dementia; the 
Dutch mutation typically presents with recurrent cerebral haemorrhage, usually 
followed by dementia; and the Arctic and Iowa mutations present with dementia only.  
 
Post-mortem studies of AD patients who participated in the initial, active, Aβ42 
AN1792 immunotherapy (vaccination) trial have revealed that parenchymal amyloid 
removal may be accompanied by an increase in CAA, thought to be secondary to Aβ42 
accumulation via perivascular drainage pathways (Boche et al., 2008). The era of 
disease-modifying treatment trials for FAD therefore necessitates better characterisation 
and understanding of the variable occurrence of CAA in individuals with APP and 
PSEN1 mutations. Radiological features of CAA include white matter hyperintensities 
(WMH) on T2-weighted MRI, cortico-subcortical intracerebral haemorrhages on 
gradient echo imaging; and atrophy best seen on T1-weighted imaging (Chao et al., 
2006). Whilst WMH on MRI are common in the elderly, in whom they may represent 
multiple pathologies, the young age of patients with FAD makes them less likely to 
have significant conventional vascular risk factors and MRI manifestations of 
atherosclerotic small vessel disease (Hopkins et al., 2006). Prominent WMH in this 
population are therefore much more likely to be indicative of an aspect of FAD 
pathology. The aim of the study described in this chapter was to investigate the degree 
and location of WMH in symptomatic APP and PSEN1 mutation carriers, together with 
age-matched controls, and to explore whether the reports of increased CAA in intra-
domain APP mutations and PSEN1 mutations located beyond codon 200 are reflected in 
greater WMH burden on MRI. Pathological investigations were also carried out in 10 
cases who had had post-mortem histopathological examination. 
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4.2  Materials and methods 
4.2.1 Study Subjects 
The study was conducted at the DRC, UCL Institute of Neurology at the National 
Hospital for Neurology and Neurosurgery. All symptomatic FAD subjects, who had a) 
participated in research; and b) had a confirmed pathogenic APP or PSEN1 mutation; 
and c) had had appropriate and usable (e.g. relatively free of movement or other 
artefact) imaging were included in this retrospective study. Fifty-two patients were 
studied: 13 with APP mutations; and 39 with PSEN1 mutations. In the PSEN1 cohort, 
18 subjects had pre-codon 200 mutations and 21 had post-codon 200 mutations. All 
FAD subjects were clinically affected and met criteria for probable AD at the time of 
MRI acquisition. Twenty-five healthy control subjects, mainly spouses and mutation-
negative siblings, were also recruited. All subjects gave informed consent and approval 
was received from the local ethics committee. Mutation analysis was conducted on 
genomic DNA and APOE genotype was established for all patients. All subjects with 
FAD underwent clinical assessment. In most cases, a comprehensive medical history 
was recorded and from this, the presence or absence of hypertension, diabetes, 
hyperlipidaemia, stroke, transient ischaemic attack (TIA) and coronary artery disease 
was assessed to create a composite score for vascular risk that was the sum of the 
factors present, ranging from 0 to 6 (DeCarli et al., 2004). This information was not 
available for some of the earlier historical cases and controls but could be analysed for a 
large subset (Table 4.1).  
 
4.2.2 Imaging 
All subjects underwent T2-weighted (T2 and/or FLAIR) and volumetric T1-weighted 
MRI. As this study was a retrospective analysis of individuals scanned over almost 
twenty years, images acquired on 1.5Tesla and 3Tesla scanners were included and there 
was also some variability in the parameters of the sequences used. However, an 
equivalent proportion of individuals were scanned at each magnetic field strength in 
each group.  
 
An experienced neurologist, blinded to clinical diagnosis, visually assessed all scans. 
The scans were rated using the age-related white matter change (ARWMC) scale 
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(Wahlund et al., 2001). The ARWMC scale (range 0-30) rates the degree of WMH on a 
four point scale for five different brain regions (frontal, parieto-occipital, temporal, 
infratentorial and basal ganglia including thalamus) for the right and left cerebral 
hemispheres separately. The ARWMC scale was chosen as it has been shown to provide 
robust results when applied to both CT and MRI, and therefore would be applicable to 
the T2-weighted MR images available in this study, which were acquired on a variety of 
different scanners and field strengths. T2*-weighted imaging sensitive to microbleeds 
was only available in the 12 most recently scanned patients (one APP and 11 PSEN1 
mutation carriers) and is reported in Chapter 5 (Ryan et al., 2011) so was not included 
in the current study. 
 
4.2.3 Pathology 
Brains were donated to the Queen Square Brain Bank for Neurological Disorders, UCL 
Institute of Neurology. The protocol used for brain donation was approved by a London 
Research Ethics Committee and tissue is stored for research under a license from the 
Human Tissue Authority. Tissue sections (7-µm) from a number of brain regions were 
immunostained using commercially available antibodies as described previously and in 
Appendix 11.3 (Lashley et al., 2008).  
 
Quantitation of Aβ-positive mature and diffuse plaques was performed based on 
Consortium to Establish a Registry for Alzheimer’s disease (CERAD) recommendations 
(Mirra et al., 1991). Alzheimer-type neurofibrillary tangle pathology was determined 
using Braak and Braak staging (Braak et al., 2006). The extent and severity of CAA was 
determined based on a four-tier grading system (Olichney et al., 1996, Lashley et al., 
2008), described in Appendix 11.4. Quantitation of the immunohistochemical stains was 
undertaken to assess any deep white matter changes in the occipital and parietal regions. 
Myelin loss was assessed using myelin basic protein (MBP) immunohistochemistry 
(SMI94R antibody) while changes in axonal density and/or integrity were investigated 
using the phosphorylation dependent anti-neurofilament antibody RT97. Iba1 and CD68 
immunohistochemistry was used to assess microglial response and GFAP 
immunohistochemistry was employed to study astrocytic response. CD3 and CD20 
immunohistochemical preparations were used to assess T and B lymphocytic response, 
respectively. A semi-quantitative assessment of myelin loss, gliosis and microglial 
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expression was made, described in Appendix 11.5. Stained slides were scanned using 
the Leica Slide Scanner SCN400 producing digital images of the whole section. 
Regions of interest were marked in the deep white matter and separately in the 
superficial U-fibres. The latter were used as an internal control on the basis that U-fibres 
are relatively spared in both subcortical arteriosclerotic encephalopathy (Revesz et al., 
1989) and in white matter damage due to CAA (Plant et al., 1990). Using x20 
magnification, ten random fields from the marked areas were captured using PicPick 
software (www.picpick.org). The density of immunohistochemical staining (% area 
stained) was accessed using Image J software (www.imagej.en.softonic.com). Occipital 
white matter could not be analysed for the p.Arg377Met case due to an infarct and there 
was insufficient parietal deep white matter available for region of interest analysis for 
one intron 4 (g.23024delG) case. 
 
The proportion of blood vessels affected by amyloid deposition and the severity of 
amyloid deposition were also determined; occipital sections immunostained with an 
anti-Aβ antibody were scanned and 10 random fields digitally captured as described 
above. The number of vessels containing Aβ in the leptomeninges and cerebral cortical 
parenchyma were then counted and expressed as a percentage of the total number of 
vessels analysed. The number of vessels classed as ‘severely affected’ were also 
counted. The criteria for this was the presence of degenerative vascular changes known 
to be associated with CAA (Revesz et al., 2003). In both the leptomeninges and 
parenchyma, the diameter of the blood vessel walls were measured and averaged in 10 
random fields.  
 
4.2.4 Statistical analysis 
Analysis of the association between mutation group and ARWMC score on MRI was 
carried out using bootstrapped regression with samples stratified by group, using 2000 
replications and bias-corrected confidence intervals, implemented in STATA 11 (Stata 
Corporation, College Station, Texas). Due to the use of bootstrapping, exact p-values 
are not provided; rather, p-value ranges were inferred from whether confidence intervals 
excluded zero. Mutation “group” was pre-defined as either control, APP, PSEN1 pre-
codon 200 or PSEN1 post-codon 200. Group differences in total ARWMC scores were 
assessed for each of the mutation groups compared to controls and for the two PSEN1 
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mutation groups compared to each other. Analyses were additionally adjusted for age at 
scan, presence of an APOE4 allele and vascular risk score. The vascular risk scores 
observed in this study ranged from only 0-2 and were therefore categorised as either low 
(score 0) or increased (score 1-2) risk.  
 
In the autopsy cohort, comparisons between the PSEN1 pre-codon 200 and PSEN1 post-
codon 200 mutation groups were made for the immunohistochemical stains using t-tests 
for normally distributed variables and Wilcoxon rank sum testing for categorical data. 
Paired t-tests were used for within-subject comparisons of staining in the deep white 
matter and U-fibre regions of interest. In view of the skewed distribution of the 
ARWMC scale Kendall’s tau, a non-parametric correlation coefficient, was used to 
investigate correlations between total ARWMC score on MRI and pathological findings 
in the autopsy cohort as a whole. Correlations between age at onset and the pathological 
findings were investigated using Kendall’s tau for categorical and Pearson’s pairwise 
correlations for continuous data. Pathological differences between APOE4 carriers and 
non-carriers were explored using the same methods as were used to compare the PSEN1 
pre and post-codon groups. 
 
4.3  Results 
4.3.1 Imaging cohort 
The majority of the 52 FAD patients in this study had recognised mutations but several 
subjects with novel variants were also included. The APP cohort comprised six 
p.Val717Ile, four p.Val717Gly and one each of p.Val717Leu, p.Ala692Gly (Flemish) 
and the novel p.Thr719Asn variant. The PSEN1 pre-codon 200 cohort comprised six 
intron 4 (g.23024delG) mutations, six p.Met139Val and one each of p.Ile143Phe, 
p.Leu166del, p.Leu166Arg, p.Glu184Asp, p.Tyr115His and p.Glu120Lys. The PSEN1 
post-codon 200 cohort comprised five p.Glu280Gly, three p.Arg278Ile, two each of 
p.Leu235Val and p.Pro264Leu, one each of p.Ile202Phe, p.Phe237Leu, p.Leu250Ser, 
p.Arg269His, p.Arg377Met, p.Gly394Val and the novel variants p.Gln222Pro and 
p.Phe283Leu. The final subject had pathologically confirmed AD with two post-codon 
200 PSEN1 substitutions; p.Ala434Thr (Jiao et al., 2014) and the novel p.Thr291Ala 
variant. All novel sequence variants identified were absent from 100 healthy unrelated 
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white control patients and none of the variants were found in the Exome Aggregate 
Consortium (ExAC) browser (http://exac.broadinstitute.org). The novel variants 
included in this study have recently been reported (Ryan et al., 2016) and their likely 
pathogenicity is discussed in chapter 3 of this thesis  
 
Baseline characteristics are shown in Table 4.1, including ARWMC scores. The groups 
were well matched for gender. The mean age of the control group (54y) was similar to 
the APP patient group (54y). The mean age of all PSEN1 subjects at 48 years was, as 
expected, younger than the APP group. The PSEN1 post-codon 200 group was 
significantly older than the PSEN1 pre-codon 200 group both at the time of scan (51 vs 
44y; p < 0.001) and age at symptom onset (47 vs 39y; p < 0.001). The three patient 
groups had similar disease durations. None of the groups had clinically significant 
levels of conventional vascular risk factors. There was a borderline increased vascular 
risk score in the PSEN1 post-codon 200 compared with PSEN1 pre-codon 200 group 
(p=0.06), although neither group differed from controls (both p>0.1). 
 
4.3.1.1 White matter hyperintensities and mutation position 
Results from analyses of ARWMC score are presented in Table 4.1, with the mean total 
ARWMC score at each mutation position shown in Table 4.2. The PSEN1 post-codon 
200 group had a higher total ARWMC score than the PSEN1 pre-codon 200 group 
(estimated difference in score 2.1 (95% CI 0.4 to 3.8), p<0.01) and controls (estimated 
difference in score 2.8 (95% CI 1.4 to 4.4), p<0.005), after adjusting for age. The 
difference between the PSEN1 subgroups appeared to be driven by differences in the 
parieto-occipital ARWMC score (estimated difference in score 1.4 (95% CI 0.5 to 2.3), 
0.005<p<0.01, after adjusting for age); there was no evidence of a difference in total 
score after excluding this component (p>0.1, after adjusting for age). There was no 
evidence that individuals with mutations in the APP gene or PSEN1 gene pre-codon 200 
differed from controls in terms of their ARWMC score (both p>0.1, after adjusting for 
age). Only one APP subject had a mutation within the amyloid-β coding domain 
(p.Ala692Gly, Flemish). As expected, this individual’s total ARWMC score (14) was 
disproportionately higher than the median score for the APP group (0), the remainder of 
which had mutations at positions 717 and 719.  
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Table 4.1 Subjects’ characteristics and total age-related white matter change 
(ARWMC) scores 
Subject group 
 
 
 
 
 
 
Controls 
 
 
APP 
 
 
PSEN1 
pre-
codon 
200 
 
 
 
PSEN1 
post-
codon 
200 
 
 
 
p-value 
for 
PSEN1 
pre-codon 
200 vs 
post-
codon 200 
 
p-value 
for 
control vs 
PSEN1 
post-
codon 200 
No. of subjects 
 25 13 18 21 
  
Gender 
M/F 13/12 6/7 9/9 10/11 
  
Age (y) at scan 
Mean (sd) 
53.5 
(10.6) 
53.8 
(3.5) 
43.5 
(7.0) 
51.1 
(5.9) 
 
0.0007* 
 
 
0.4* 
Disease 
duration in 
years 
Mean (sd) 
N/A 
5.9 
(5.6) 
4.3 
(1.8) 
4.4 
(2.5) 
 
0.9* 
 
N/A 
Age at onset 
Mean (sd) N/A 
47.9 
(5.3) 
39.2 
(6.2) 
46.8 
(6.1) 
 
0.0005* 
 
N/A 
MRI scan 
Teslaa 
1.5T/3T 
16/9 12/1 12/6 16/5 
 
0.5** 
 
0.8** 
Proportion 
carrying 
APOE4 allele 
N/A 38% 22% 38% 
 
0.3+ 
 
N/A 
No. of subjects 
with vascular 
risk known 
19 10 16 21 
  
Proportion 
with increased 
vascular risk 
score 
21% 30% 0% 24% 
 
0.06+ 
 
1.0+ 
Total ARWMC 
score 
Median 
Mean 
(interquartile 
range) 
 
0 
0.9 
(0-1) 
 
0 
1.8 
(0-2) 
 
0 
1.1 
(0-1) 
 
3 
3.6 
(0-7) 
 
 
<0.01§ 
 
 
<0.005§ 
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*T-test     **Pearson chi-squared test +Fisher’s exact test    §Bootstrapped regression 
 
a) One subject only (in the PSEN1 post-codon 200 group) had a 1.0T MRI scan, so was 
included in the 1.5T group. 
 
Table 4.2 Mean total white matter hyperintensity score for each PSEN1 
mutation in the cohort 
 
PSEN1 mutation 
 
No of subjects 
 
Mean total ARWMC 
score 
Intron 4 (g.23024delG) 6 0 
p.Met139Val 6 1 
p.Ile143Phe 1 0 
p.Leu166del 1 2 
p.Leu166Arg 1 8 
p.Glu184Asp 1 1 
p.Tyr115His 1 1 
p.Glu120Lys 1 0 
p.Ile202Phe 1 8 
p.Gln222Pro 1 0 
p.Leu235Val 2 5 
p.Phe237Leu 1 0 
p.Leu250Ser 1 0 
p.Pro264Leu 2 3 
p.Arg269His 1 4 
p.Arg278Ile 3 8 
p.Glu280Gly 5 2 
p.Phe283Leu 
p.Arg377Met 
1 
1 
4 
0 
p.Gly394Val 1 1 
p.Thr291Ala & p.Ala434Thr 
 
1 7 
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Figure 4.1 shows representative MR images for subjects in the PSEN1 cohort; some of 
the WMHs had an atypical appearance, with U-fibre involvement. 
 
Figure 4.1: Example MR images from subjects with (A) p.Glu120Lys (B) Intron 4 
(g.23024delG) (C) p.Met139Val (D) p.Ile202Phe (E) p.Leu235Val (F) p.Glu280Gly 
(G) and (H) p.Arg278Ile and (I) p.Pro264Leu mutations, whose location within the 
PSEN1 gene is indicated.  
 
 
 
In some cases, particularly those with the p.Arg278Ile mutation (G and H), some of the 
WMH have an atypical appearance with extension into the U-fibres. Green stars 
indicate mutation positions where the mean age-related white matter change score was 
four or more. Figure adapted from (Dillen and Annaert, 2006) and reprinted from (Ryan 
et al., 2015), with permission.. FAD-linked mutations are indicated in red, while non-
pathogenic mutations are marked in orange. Interaction domains with APP/TLN or 
NCT/APH-1/PEN-2 are marked in blue, as well as the conserved residues D257 and 
D385 forming the putative catalytic site. Interactions of the C-terminal domain and the 
hydrophilic loop domain with proteins such as the brain G-protein Go, calsenilin, the 
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PSEN1-associated protein, b- and d-catenin, p0071 and PLD1, are shown in dark green. 
The endoproteolytic cleavage site separating PSEN1-NTF and -CTF in the seventh 
hydrophobic region, the SPP cleavage site in the ninth TMD and the caspase cleavage 
site in the hydrophilic loop domain are indicated by yellow arrows.  
 
APH: Anterior pharynx-defective; CTF: C-terminal fragment; NTF: N-terminal 
fragment; PEN: Presenilin enhancer; PLD: Phospholipase D; NCT: Nicastrin; SPP: 
Signal peptide peptidase; TLN: Telencephalin; TMD: Transmembrane domain. 
 
4.3.1.2 White matter hyperintensities and vascular risk  
Accounting for vascular risk weakened the difference in ARWMC score between the 
PSEN1 pre-codon 200 and PSEN1 post-codon 200 group (estimated difference in score 
1.5 (95% CI -0.3 to 3.1), 0.09<p<0.1). However, there was still strong evidence for a 
difference between the PSEN1 post-codon 200 group and controls (estimated difference 
in score 2.8 (95% CI 1.5 to 4.4, p<0.005). The model provides evidence that vascular 
risk and mutation position were both independent predictors of ARWMC score. 
Increased vascular risk score was associated with an estimated difference in ARWMC 
score of 2.7 (95% CI 0.5 to 5.5, 0.01<p<0.05), after adjusting for age and mutation 
group. 
 
4.3.1.3 White matter hyperintensities and APOE4 status 
There was no evidence that APOE status was associated with ARWMC score (after 
adjusting for group and age, p>0.2) and there was no difference in the proportion of 
subjects carrying an APOE4 allele between the PSEN1 pre-codon 200 (22%) and 
PSEN1 post-codon 200 groups (38%, p=0.3). Only one subject in each patient group 
was APOE4 homozygous: these were individuals with an APP p.Val717Ile mutation 
(ARWMC score 0): a PSEN1 pre-codon 200 intron 4 (g.23024delG) mutation 
(ARWMC score 0): and a PSEN1 post-codon 200 p.Ile202Phe mutation (Church et al., 
2011) (ARWMC score 8). It was the PSEN1 p.Ile202Phe patient’s baseline scan (shown 
in Figure 4.1) that was rated for this study. However, it should be noted that further 
imaging after a period of clinical deterioration three years later demonstrated floridly 
increased WMH with extension into the U-fibres and oedema suggesting CAA-related 
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inflammation (CAA-ri), which was confirmed at post-mortem and is described in 
Chapter 5 (Ryan et al., 2014). 
 
4.3.2 Pathology cohort 
Of the 10 subjects in the imaging study who underwent post-mortem examination, five 
had PSEN1 pre-codon 200 mutations (p.Glu120Lys and four intron 4 (g.23024delG) 
mutations) and five had PSEN1 post-codon 200 mutations (p.Ile202Phe, p.Leu235Val, 
p.Arg278Ile, p.Arg377Met and the double substitution p.Thr291Ala & p.Ala434Thr). In 
the autopsy subgroup, as in the larger cohort, age at onset was significantly later for 
those with PSEN1 post-codon 200 compared to PSEN1 pre-codon 200 mutations (43.6 
vs 36.6y, p=0.02), although disease duration was similar (Table 4.3). The mean interval 
between MRI and post-mortem was five years. Three subjects in the autopsy cohort had 
ARWMC scores greater than 0; all were in the post-codon 200 group. 
 
4.3.2.1 Amyloid and tau pathology 
All autopsy cases demonstrated Braak stage VI tau pathology. The severity of Aβ-
positive mature, diffuse or cotton wool plaques did not differ between the PSEN1 pre-
codon 200 and post-codon 200 groups. The grade of CAA showed little difference 
between the two groups for any region other than the cerebellum, where the median 
CAA score was marginally higher in the PSEN1 post-codon 200 than pre-codon 200 
group (3 vs 2, p=0.05). However, it should be noted that the average CAA grade for 
each region was at least 2 or 3 in both groups, and that the post-codon 200 group had an 
average score of 3 for all regions, reflecting widespread CAA. The mean proportion of 
blood vessels affected by amyloid deposition was nominally higher in the PSEN1 post-
codon 200 than pre-codon 200 group in cortical parenchyma (47.6% vs 28.6%) and 
leptomeninges (78.2% vs 72.2%). However, differences between the two mutation 
groups were not statistically significant for these, nor any other aspects of the blood 
vessel analysis (Table 4.3). 
 
 
 
 98 
Table 4.3. Autopsy cohort subject demographics and results of CAA grading and 
blood vessel analysis 
 All PSEN1 
cases 
(N=10) 
PSEN1 
pre-codon 
200  
(N=5) 
PSEN1 
post-codon 
200 (N=5) 
p value for 
PSEN1 pre-
codon 200 vs 
post-codon 
200 
Disease duration 
Mean (sd) 
10.6 
(4.6) 
9.4 
(4.4) 
 
11.7 
(5.1) 
 
0.4* 
Age at onset 
Mean (sd) 
40 
(5.1) 
36.6 
(4.2) 
43.6 
(3.8) 
 
0.02* 
 
Years from MRI to post-
mortem 
Mean (sd) 
 
5.0 
(3.8) 
4.2 
(3.2) 
5.8 
(4.5) 
0.6 
APOE status Two 44, 
one 34, 
seven 33 
One 44, 
four 33 
One 44, one 
34, 
three 33 
1.00** 
CAA grade 
Median (range) 
Frontal 
Temporal 
Parietal 
Occipital 
Cerebellar 
 
 
2.5 (0-3) 
2 (0-3) 
2.5 (0-3) 
3 (3) 
3 (2-3) 
 
 
 
2 (1-3) 
2 (0-2) 
2 (1-3) 
3 (3) 
2 (2-3) 
 
 
3 (0-3) 
3 (0-3) 
3 (0-3) 
3 (3) 
3 (3) 
 
 
1.0+ 
0.4+ 
1.0+ 
. 
0.05+ 
Proportion of blood 
vessels affected by amyloid 
deposition 
Mean (SD) percentage 
 
Cortical 
Cortical ‘severely affected’ 
Leptomeningeal 
Leptomeningeal ‘severely 
affected’ 
 
Vessel diameter 
Cortical vessel diameter 
Leptomeningeal vessel 
diameter 
 
 
 
 
 
 
38.1 (37.3) 
27.2 (36.5) 
75.2 (32.3) 
44.6 (28.5) 
 
 
 
19.0 (4.2) 
17.1 (3.4) 
 
 
 
 
 
28.6 (41.3) 
21 (36.7) 
72.2 (36.4) 
38.6 (29.6) 
 
 
 
18.1 (2.9) 
17.7 (2.9) 
 
 
 
 
 
47.6 (34.5) 
33.4 (39.4) 
78.2 (31.5) 
50.6 (29.3) 
 
 
 
19.8 (5.5) 
16.5 (4.1) 
 
 
 
 
 
0.5* 
0.6* 
0.8* 
0.5* 
 
 
 
0.6* 
0.6* 
 
*T-test  ** Fisher’s exact test   +Wilcoxon rank sum test 
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4.3.2.2 White matter pathology 
Semi-quantitative assessment of myelin loss, gliosis and microglial expression in the 
deep white matter (Table 4.4) suggested a pattern, whereby cases with minimal or no 
white matter pallor tended to have more active microglia and gliosis, whereas cases with 
white matter pallor had minimal gliosis and activated microglia. There was some 
evidence that the PSEN1 pre-codon 200 group had more white matter pallor than the 
PSEN1 post-codon 200 group on HE (haematoxylin and eosin) staining of parietal 
(p=0.02) and occipital (p=0.07) sections, and more severe gliosis in the parietal white 
matter on GFAP immunohistochemistry (p=0.06). The mean density of staining (% area 
stained) for each immunohistochemical marker in parietal and occipital deep white 
matter and U-fibre regions of interest is presented in Figure 4.2. 
 
Figure 4.2 Mean density of immunohistochemical staining in parietal and occipital 
white matter.   
Error bars indicate standard errors. Reprinted from (Ryan et al., 2015), with permission.  
 
 
 
In the PSEN1 cohort as a whole, the only differences between deep white matter and U-
fibres were in RT97, which demonstrated lower axonal density/integrity in the deep 
white matter compared to U-fibres in occipital (53.9% vs 78.7%, p=0.02) and parietal 
(52.5% vs 71.3%, p=0.04) areas. When the pre-codon 200 group was analysed 
separately, there were still trends for the density of RT97 to be lower in deep white 
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matter compared to U-fibres in occipital (53.4% vs 78.9%, p=0.06) and, to a lesser 
extent, parietal (44.8% vs 64.3%, p=0.1) areas. There was also a slightly higher density 
of CD3-positive T-lymphocytes in occipital deep white matter compared to U-fibres 
(1.4% vs 0.7%, p=0.04) in the pre-codon 200 group. In the post-codon 200 group, none 
of the stains showed significant differences between deep white matter and U-fibres. 
However, there was weak evidence that the density of Iba1-positive microglia was 
somewhat higher in parietal U-fibres than deep white matter (4.3% vs 3.0%, p=0.07). 
Direct comparisons between the pre and post-codon 200 groups for the overall density 
of staining in each region and the ratio of staining in deep white matter to U-fibres 
demonstrated no significant differences.  
 
4.3.2.3 Pathological features and white matter hyperintensities  
In the autopsy cohort as a whole, there was a correlation between ARWMC score on 
MRI and grade of severity of CAA in the temporal lobe (p=0.02) and to a lesser extent 
frontal and parietal lobes (both p=0.09). ARWMC score was also associated with 
severity of cotton wool plaques in the occipital (p=0.03) and temporal, parietal and 
cerebellar (all p=0.04) regions (Figure 4.3). There was a trend towards a negative 
correlation between ARWMC score and mature plaque severity in the parietal lobe 
(p=0.06). Borderline associations were found between ARWMC score and the 
proportion of cortical blood vessels affected by amyloid deposition (p=0.07) and the 
proportion of leptomeningeal vessels that were classified as severely affected by CAA 
(p=0.09). ARWMC score was also associated with leptomeningeal blood vessel 
diameter (p=0.03). There was some evidence that higher ARWMC scores were 
associated with a lower density of CD68-positive microglia in the parietal deep white 
matter (p=0.04) and U-fibres (p=0.09). 
 
4.3.2.4 Pathological features and APOE4 status 
Three of the ten autopsy subjects carried an APOE4 allele; one (E44) in the pre-codon 
200 group and two (one E44, one E34) in the post-codon 200 group. As in the larger 
cohort, there was no association between ARWMC score and APOE status. Although 
the APOE4 carrier group was very small, hence results should be interpreted with 
caution, the proportion of cortical blood vessels affected by amyloid deposition was 
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significantly greater in APOE4 carriers than non-carriers (84.0% vs 18.4%, p<0.002), as 
was the proportion of cortical vessels classified as severely affected (66.0% vs 10.6%, 
p=0.02). The proportion of leptomeningeal blood vessels affected by amyloid 
deposition was higher than the proportion of cortical blood vessels affected in both 
APOE4 carriers (99%) and non-carriers (65%) and did not significantly differ between 
the two APOE groups (p=0.13). However, there was borderline evidence that the 
proportion of leptomeningeal blood vessels classified as severely affected was higher in 
APOE4 carriers than non-carriers (70.0% vs 33.7%, P=0.06). The degree of parietal or 
occipital capillary CAA showed no association with ARWMC score and did not differ 
between the pre and post-codon 200 groups, nor between APOE4 carriers and non-
carriers. APOE4 carriers demonstrated an increased T lymphocytic response in the 
parietal U-fibres (3.8% vs 1.0%, p=0.01). In contrast, APOE4 non-carriers demonstrated 
higher staining of CD68 for activated microglia in occipital U-fibres (1.9% vs 1.0%, 
p=0.03). 
 
4.3.2.5 Pathological features and age at symptom onset 
In the pathology cohort as a whole, there was some evidence that younger ages at onset 
were associated with greater immune/inflammatory responses in the deep white matter. 
Negative correlations were found between age at onset and density of Iba1-positive 
microglia in parietal deep white matter (absolute counts and ratio compared to U-fibres, 
both r=-0.7, p=0.03). The ratio of CD20 in occipital deep white matter compared to U-
fibres also negatively correlated with age at onset (r=0.7, p=0.04) although CD20 
staining was minimal in all cases. Younger ages at onset were associated with more 
severe gliosis on HE staining of parietal deep white matter (r=-0.5, p=0.02) and with 
lower axonal density/integrity in parietal deep white matter (r=0.6, p=0.06) and U-fibres 
(r=0.7, p=0.04) on RT97 immunohistochemistry. 
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Table 4.4 Semi-quantitative assessment of white matter pallor, gliosis and 
microglial expression in parietal and occipital deep white matter 
The deep white matter in the occipital (occ) and parietal (par) lobes were semi-
quantitatively assessed for white matter pallor (HE, MBP, RT97), gliosis (GFAP) and 
microglial expression (Iba1). This was based on a four-tier grading system where ‘0’ 
represented no change in the white matter, no gliosis or microglial activation; ‘+’ 
represented mild pallor of the white matter, mild gliosis and the minimal presence of 
activated microglia (Figure 4.3,K); ‘++’ represented a moderate degree of white matter 
pallor, gliosis and microglial activation (Figure 4.3, L); ‘+++’ represents severe pallor 
of the white matter, severe gliosis and severe microglial activation; ‘++++’ represents 
very severe microglial activation where the majority of the microglial cells are 
highlighted using immunohistochemical methods (Figure 4.3, M).  
 
Mutation 
 
 
 
Location 
 
 
 
Age 
at 
onset 
 
Duration 
(years) 
 
 
Block 
 
 
 
HE 
 
 
 
MBP 
 
 
 
RT97 
 
 
 
GFAP  
 
 
 
Iba1 
 
 
 
Intron 4  Pre 200 35 16.9 Par +++ + + ++ + 
(g.23024delG)    Occ + + + + + 
Intron 4  Pre 200 39 8.1 Par + + + ++ ++ 
(g.23024delG)    Occ 0 0 0 + +++ 
Intron 4  Pre 200 36 5.6 Par + + + ++ + 
(g.23024delG)    Occ + + + + + 
Intron 4  Pre 200 42 9.7 Par 0 0 0 +++ ++++ 
(g.23024delG)    Occ + 0 0 ++ ++ 
p.Glu120Lys Pre 200 31 6.9 Par + 0 + +++ ++++ 
    Occ 0 0 0 ++ +++ 
p.Ile202Phe Post 200 48 12.3 Par 0 + + + ++ 
    Occ 0 0 0 + ++ 
p.Leu235Val Post 200 44 9.3 Par 0 0 0 + ++ 
    Occ 0 + 0 + ++ 
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p.Arg278Ile Post 200 46 19.6 Par 0 0 0 ++ ++ 
    Occ 0 0 0 ++ ++ 
p.Arg377Met 
 
Post 200 
 
38 11.6 Par 
 
0 
 
0 
 
0 
 
++ 
 
+++ 
 
p.Thr291Ala  Post 200 42 5.9 Par 0 0 0 ++ ++ 
& 
p.Ala434Thr 
 
  
Occ 0 0 0 ++ +++ 
 
 
 
Figure 4.3 Pathological analysis of familial Alzheimer’s disease with PSEN1 
mutations.   
Aβ immunohistochemistry demonstrates prominent mature amyloid plaques (A) and 
mild CAA (B) in a case with a PSEN1 mutation located before codon 200 and no white 
matter hyperintensities on MRI. In PSEN1 cases with mutations beyond codon 200 and 
white matter hyperintensites on MRI, there was severe CAA both in the parenchyma 
(C), showing double barrelling, and the leptomeninges (D). Some of these post codon 
200 cases also contained ‘cotton wool like’ Aβ plaques (E) with severe CAA 
involvement in the occipital cortex where  Aβ  deposition severely affected the 
capillaries (F). CD68 (G) and Iba1 (H) were used to assess any alterations in microglia 
response between the deep white matter and ‘U’ fibres. In the PSEN1 pre-codon 200 
group, lower axonal density was observed in the deep white matter (I,) compared to the 
‘U’ fibres (J). The semiquantitative assessment suggested a trend for cases with white 
matter pallor to show only a minimal (K) or moderate (L) degree of microglial 
activation, whilst cases with normal-appearing white matter showed moderate to very 
severe (M) microglial activation. Reprinted from (Ryan et al., 2015), with permission. 
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4.4  Discussion   
 
Individuals with PSEN1 post-codon 200 mutations had significantly more parieto-
occipital WMH on T2-weighted MRI and also a later age at onset than those with 
PSEN1 pre-codon 200 mutations. WMH may be caused by a variety of pathological 
processes including ischaemia, infarction, demyelination and oedema. In older patients, 
they commonly result from the ischaemia caused by cerebrovascular disease secondary 
to conventional vascular risk factors (Prins and Scheltens, 2015). Given the young age 
and relative lack of co-morbidities in the subjects in this study, their WMH are much 
more likely to reflect an aspect of FAD pathology.  
 
It has previously been reported that PSEN1 mutations beyond codon 200 show more 
prominent CAA than mutations situated pre-codon 200 (Mann et al., 2001). MRI 
manifestations of CAA include WMH, cortico-subcortical intracerebral haemorrhages 
including microbleeds and atrophy (Chao et al., 2006). Our finding of a greater WMH 
‘burden’ on MRI in the PSEN1 post-codon 200 mutation group is therefore consistent 
with at least a proportion of these individuals having more severe CAA. The 
predominantly parieto-occipital location of the WMH further supports the hypothesis 
that they relate to CAA. CAA, which is present to at least some degree in 70%-100% of 
AD brains at post-mortem (Bergeron et al., 1987, Ellis et al., 1996), has a particular 
predilection for the occipital lobes (Thal et al., 2002, Alafuzoff et al., 2009) and a 
posterior distribution of WMH has been shown to predict pathologically confirmed 
CAA (Thanprasertsuk et al., 2014). Although only one of the APP subjects had a 
mutation within the amyloid-β coding domain, their ARWMC score was considerably 
higher than the median for the APP group, consistent with pathological reports of severe 
CAA in cases with intradomain APP mutations. There was also one outlier in the 
PSEN1 pre-codon 200 group (p.Leu166Arg), whose total ARWMC score of 8 was 
considerably higher than the median for the group (0). This subject also carried the 
p.Arg62His PSEN2 variant. It was previously unclear whether this variant represents a 
novel mutation or non-pathogenic polymorphism (Cruts et al., 1998). Although it seems 
increasingly likely that it is not pathogenic (Guerreiro et al., 2010), the possibility 
remains that it may have an influence on the clinico-pathological phenotype.  
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The pathology results in the patients who came to post-mortem offer some support that 
the WMH are related to CAA, as there was indeed a positive correlation between 
ARWMC score on MRI and severity of CAA in the temporal and to a lesser extent 
frontal and parietal lobes. Occipital CAA was the maximum grade of severity in all 
cases, preventing detection of any association with ARWMC score. Although the actual 
grade of CAA showed little difference between the pre and post-codon 200 groups for 
any region other than the cerebellum, where it was marginally higher in the PSEN1 
post-codon 200 group, it should be noted that in the small number of subjects with post-
mortem examination, CAA was relatively severe in the majority of cases.  
 
An alternative explanation for the increased WMH in the PSEN1 post-codon 200 cohort 
is that they reflect another aspect of FAD pathology, independent of or related to CAA, 
which also varies according to mutation position. For example, inflammatory mediated 
pathology. Vascular amyloid may be associated with a variety of inflammatory 
reactions (Miao et al., 2005, Chung et al., 2011) including perivascular inflammation 
surrounding amyloid-laden blood vessels and granulomatous or non-granulomatous 
angiitis in which there is also inflammation and necrosis within the vessel wall (Eng et 
al., 2004, Harkness et al., 2004, Scolding et al., 2005). The clinical and 
neuroradiological manifestations of these inflammatory responses do, however, appear 
to be relatively consistent and WMH are a common feature. WMH typically spare the 
U-fibres when they are caused by ischaemic cerebrovascular disease secondary to either 
arteriolosclerosis or CAA (Chao et al., 2006). However, WMH extending into the U-
fibres have been described in cases of CAA-ri (Chao et al., 2006). In some of the 
PSEN1 post-codon 200 cases in our study, the WMH showed a degree of extension into 
the U-fibres, including those with the p.Arg278Ile mutation, as demonstrated in Figure 
4.1. The p.Arg278Ile mutation is associated with selective overproduction of Aβ43 and 
mice carrying this mutation show accelerated Aβ pathology, accompanied by an 
inflammatory response with massive astrocytosis surrounding amyloid plaques (Saito et 
al., 2011).  
 
Our alternative hypothesis that WMH may reflect secondary inflammatory mediated 
pathology led us to investigate microglial, astrocytic and lymphocytic responses in the 
autopsy cases. At a group level, there was weak evidence that the density of Iba1-
stained microglia was higher in the U-fibres than deep white matter in the PSEN1 post-
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codon 200 group and the autopsy cohort included the p.Ile202Phe case with CAA-ri that 
has been reported elsewhere (Ryan et al., 2014). However, the pathological analysis 
suggested that inflammatory responses might if anything be more prominent in the 
PSEN1 pre-codon 200 cohort and that this may be related to the younger ages at onset. 
The pre-codon 200 group had more severe gliosis and a greater T lymphocytic response 
and decreased axonal density in deep white matter compared to U-fibres. In the 
pathology cohort as a whole, younger ages at onset were associated with greater 
immune/inflammatory responses and lower axonal density/integrity. Furthermore, 
higher ARWMC scores were associated with a lower density of microglia in parietal 
deep white matter and, on semi-quantitative assessment, cases with white matter pallor 
were noted to have minimal activated microglia. ARWMC scores also showed positive 
correlations with the severity of cotton wool plaques in occipital, parietal, temporal and 
cerebellar regions and a negative correlation with mature plaque severity in the parietal 
lobe. These observations require corroboration in larger studies but may all be 
connected. Cotton wool plaques are immunoreactive for Aβ but lack the dense amyloid 
cores, neuritic responses or microglial associations seen with mature plaques (Crook et 
al., 1998). Their aetiology remains unknown but it has been speculated that they may 
result from the combination of particularly high Aβ production (Houlden et al., 2000) 
and low clearance by the immune system (Tabira et al., 2002). Of potential relevance to 
the imaging findings, cotton wool plaques have sometimes been noted to encroach into 
superficial subcortical white matter (Shrimpton et al., 2007). The idea that PSEN1 
mutations located before codon 200 may be associated with a more aggressive disease 
course was also suggested by Mann et al., who reported younger ages at onset and 
shorter disease durations in these cases (Mann et al., 2001). 
 
Different genetic risk factors may interact to determine the severity and pathological 
consequences of CAA. In sporadic AD, the APOE4 allele is associated with CAA 
severity (Greenberg et al., 1995, Kalaria et al., 1996, Premkumar et al., 1996, Chalmers 
et al., 2003). We found that, even in FAD, APOE4 carriers have a greater proportion of 
leptomeningeal and, in particular, cortical blood vessels severely affected by CAA. 
APOE4 is also a risk factor for CAA-ri (Eng et al., 2004, Kinnecom et al., 2007) and for 
the amyloid-related imaging abnormalities (ARIA), thought to relate to vascular 
amyloid, observed in amyloid immunotherapy trials (Sperling et al., 2011, Barakos et 
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al., 2013). It is therefore noteworthy that the only APOE4 homozygote with a PSEN1 
post-codon 200 mutation in this study went on to develop clinical, radiological and 
pathological features of CAA-ri (Ryan et al., 2014). In the autopsy cohort, APOE4 
carriers showed a higher T lymphocytic response in parietal U-fibres, however there 
was also some evidence for a greater microglial response in non-carriers so the 
relationship between APOE status and inflammation was not clear-cut. We found no 
association between APOE4 status and WMH in our cohort. A previous study of 
sporadic AD also found that APOE4 homozygosity was not associated with WMH, 
although it was associated with multiple microbleeds (Goos et al., 2009). The authors of 
this study found particularly low ARWMC scores in APOE4 homozygous AD patients 
with multiple microbleeds, prompting them to suggest that separate pathophysiological 
mechanisms may underpin microbleeds presenting with and without WMH. T2*-
weighted imaging sensitive to microbleeds was only available in 12 of the patients in 
this study and is reported in Chapter 5 (Ryan et al., 2011). The prevalence of one or 
more microbleeds in this subset of FAD patients was 25%, which is comparable to the 
proportion of microbleeds found in patients with sporadic AD (Cordonnier and van der 
Flier, 2011, Whitwell et al., 2015). Interestingly, the only patient with multiple 
microbleeds had both a post-codon 200 PSEN1 mutation (p.Arg269His) and the APOE 
genotype 3/4  (see Chapter 5).  
 
CAA typically affects cortical and leptomeningeal small and medium-sized arteries and 
arterioles, with veins and capillaries involved less frequently (Revesz et al., 2003). 
When the cortical capillaries are involved there are sometimes associated dyshoric 
changes, where amyloid deposits spread beyond the vessel wall into the surrounding 
neuropil (Richard et al., 2010). An association has been observed between APOE4 and 
capillary CAA, particularly with associated dyshoric changes (Thal et al., 2002). 
Furthermore, capillary CAA has been found to provoke a strong inflammatory response, 
which does not usually occur in large vessel CAA (Richard et al., 2010). This could 
perhaps provide a unifying explanation for how APOE4 status appears to increase the 
risk of developing both microbleeds and inflammation as a consequence of CAA. 
Although we did not find associations between capillary CAA and APOE status or 
ARWMC score in our pathology cohort, subject numbers were small and this would be 
an interesting issue to explore in larger studies.   
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It is possible that other vascular risk factors also play a role in the manifestation of CAA 
in FAD. Our results suggested that increased age and the presence (albeit very minor) of 
conventional vascular risk factors may contribute to some of the difference in ARWMC 
observed between the PSEN1 pre- and post-codon 200 groups. However, these factors 
could not account for the differences between the PSEN1 post-codon 200 group and 
controls. It is noteworthy that the vascular risk scores in subjects with increased 
vascular risk were still very low - 1 or 2 at most- signifying the presence of only mild 
hypertension and/or hypercholesterolaemia in most cases. It seems highly unlikely that 
this minor increased vascular risk could wholly explain the severity of WMH seen in 
many of the PSEN1 post-codon 200 patients’ scans. Furthermore, the occurrence of 
increased vascular risk scores in the PSEN1 post-codon 200 group could have been 
biased by the imaging findings themselves. Patients with FAD and WMH may be more 
thoroughly investigated for vascular risk factors than patients lacking such imaging 
features. Smoking history was not known for all of the subjects in this study. Although 
smoking status is not included in the system for scoring vascular risk that we used 
(DeCarli et al., 2004), the absence of this information should be considered a limitation.  
 
An important but inevitable limitation of this retrospective study is the lack of T2* 
imaging in all subjects, which is due to the fact that the scans were collected over a 
twenty year period, with the majority having been acquired before the introduction of 
gradient echo imaging to our protocol. A further limitation of the current study is that, 
although it is one of the largest pre-morbid imaging investigations of FAD with post-
mortem neuropathological correlation, the number of autopsy cases is small. Due to the 
limited sample size, we did not include correction for multiple comparisons in our 
analysis of the data, which should be considered exploratory and requires corroboration 
in larger datasets. 
 
Investigation of why PSEN1 mutations located after codon 200 should be associated 
with increased CAA and/or a different inflammatory response is an important area for 
future research, with the potential to reveal how other functions of PSEN1 may be 
affected by mutations at different sites. For example, certain post-codon 200 PSEN1 
mutations may interfere with the role of PSEN1 in Notch processing, resulting in 
vulnerability of the vascular wall (Mann et al., 2001). Indeed, the functionally important 
residues of the PSEN1 endoproteolytic cleavage site lie at or around amino acid 298. By 
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contrast, recent work on γ-secretase modulators has highlighted the importance of an N-
terminal, predominantly pre-codon 200 region of PSEN1, in the carboxypeptidase-like 
activity that alters Aβ profiles (Ohki et al., 2011, Takeo et al., 2014). One could 
speculate that mutations involving this allosteric core may alter more dramatically the 
Aβ profiles and cause a more aggressive phenotype. Another potential source of 
variability in the pathological consequences of different PSEN1 mutations is their role 
in calcium homeostasis, which could have implications for vascular, immune and 
neuronal function. The function of presenilins as calcium leak channels in the 
endoplasmic reticulum appears to be impaired by most PSEN1 mutations (Nelson et al., 
2011). However, calcium leak function is preserved with certain mutations, particularly 
those in a cluster located beyond codon 200 in exons 8-9 (Nelson et al., 2010), which 
tend to be associated with cotton wool plaque pathology. Further work investigating 
functionally relevant differences between mutations at different sites will be important 
to refine our understanding of how mutation position influences pathology and 
phenotype, beyond the simple dichotomy of pre or post-codon 200 location.  
 
In conclusion, we observed increased posterior WMH and later ages at onset in the 
PSEN1 post-codon 200 group. WMH correlated with severity of CAA and cotton wool 
plaque pathology at post-mortem. In contrast, the PSEN1 pre-codon 200 group had 
younger ages at onset and greater axonal loss, gliosis and T-lymphocytic response in the 
deep white matter. A significantly later age at onset in cases with PSEN1 mutations 
beyond codon 200 cases was also reported in Mann’s study (Mann et al., 2001). It may 
suggest that some degree of protection is conferred by the source of the WMH in the 
post-codon 200 group, whether this is preferential deposition of amyloid in the 
vasculature, differing inflammatory responses, plaque species or a combination. 
Pathological studies have found an inverse relationship between the severity of capillary 
CAA and the density of amyloid plaques surrounding these capillaries, which has been 
interpreted as providing support for the idea that Aβ may be transported between the 
neuropil and circulation (Richard et al., 2010). A similar observation, of increased CAA 
in areas of decreased amyloid plaque burden, was also made at post-mortem in brains of 
some of the AD patients who received Aβ immunisation (Boche et al., 2008). The 
findings of a decrease in both CAA and plaques in immunised patients who survived 
longer led to the suggestion that this vascular amyloid may be cleared over time (Boche 
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et al., 2008). What remains an unknown and critical issue for clinical trials in FAD, is 
how an individual’s baseline propensity for developing CAA may influence the 
processes by which amyloid may be cleared after immunotherapy or other amyloid 
depleting strategies.  
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5 Amyloid-related imaging abnormalities (ARIA) in familial 
Alzheimer’s disease 
 
The term ‘ARIA’ was proposed to describe the amyloid-related MRI abnormalities 
observed in a number of patients participating in various amyloid-modifying therapy 
trials for AD (Sperling et al., 2011, Coric et al., 2012, Ostrowitzki et al., 2012, Sperling 
et al., 2012, Salloway et al., 2014). ARIA refers to a spectrum of imaging changes and 
may be subdivided into: ARIA-E, describing increased signal on fluid-attenuated 
inversion recovery (FLAIR) and other T2-weighted MRI sequences, thought to 
represent cerebral oedema and effusion or extravasated fluid in sulcal spaces; and 
ARIA-H, denoting microbleeds and superficial siderosis evident on gradient echo (T2*-
GRE) sequences. Although a detailed understanding of the pathogenesis of ARIA 
remains to be elucidated, the imaging features are thought to reflect changes involving 
vascular amyloid. This chapter comprises two short reports on the subject of ARIA in 
FAD.  
 
As discussed in Chapter 4, a number of strands of evidence suggest that amyloid-
modifying therapy may provoke increased amyloid in the vasculature and the launch of 
trials of such therapy for FAD therefore raises particular interest in the imaging 
manifestations of CAA in mutation carriers. The previous chapter focused on white 
matter hyperintensities on MRI as a potential marker of CAA. Other MRI 
manifestations of CAA include cortical superficial siderosis, enlarged perivascular 
spaces in the centrum semiovale and cerebral microbleeds (Yamada, 2015). This 
chapter begins by considering cerebral microbleeds and describes a study investigating 
their prevalence in a small cohort of FAD mutation carriers. I then move from ARIA-H 
to ARIA-E, describing the first reported case of ARIA-E developing spontaneously 
during the course of PSEN1-associated FAD, in an APOE4 homozygote. Potential risk 
factors for the development of ARIA in FAD are discussed and I argue that monitoring 
for ARIA and identifying individuals at increased risk of developing them should play 
an important role in FAD clinical trials. 
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5.1 Cerebral microbleeds (ARIA-H) in familial Alzheimer’s disease 
 
Determining the relevant contributions of atherosclerotic cerebrovascular disease 
(related to conventional risk factors including hypertension) and CAA to microbleeds 
identified on T2*-weighted imaging of AD patients is an important issue, which may 
lead to new insights into the pathology and pathogenesis of AD.  However, one of the 
difficulties in attempting to delineate the relative contributions of conventional 
cerebrovascular and CAA pathology in sporadic AD is that multiple pathologies are 
common at more advanced ages. An alternative strategy is to study patients with FAD; 
such individuals can be diagnosed definitively during life and, having a younger age at 
symptom onset, are much more likely to have “pure” AD without co-existing 
cerebrovascular disease. This study is the first to assess the frequency of microbleeds in 
FAD.  
 
5.1.1 Methods 
 
All individuals with genetically confirmed FAD who had undergone T2*-weighted MRI 
as part of the longitudinal study of FAD at the DRC were included in this study. A total 
of 12 patients with FAD (mean age: 49.4, range: 35.8 – 63.4 yrs; mean disease duration: 
4.0, range: 1.1 – 6.7 yrs; 75% male) were eligible. 11 patients had a mutation in the 
PSEN1 gene (three Intron 4 (g.23024delG) mutations and one each of p.Leu166Arg, 
p.Tyr115His, p.Glu120Lys, p.Leu250Ser, p.Pro264L, p.Arg269His, p.Arg278Ile, 
p.Glu280Gly), and one patient carried the Val717Ile APP mutation. 12 controls (mean 
age: 59.8; range: 46.9 – 66.5 yrs; 50% male) were also studied. All mutation carriers 
were symptomatic and fulfilled criteria for AD dementia at the time of scanning.  T2* 
gradient echo sequences (TR/TE 625/20ms, flip angle 20°, field of view 240x240, 
matrix 256x320, slice thickness 5mm) were acquired on the same 3T Siemens MRI 
scanner. All subjects gave written informed consent according to the Declaration of 
Helsinki, and the study was approved by the local ethics committee. All scans were 
assessed by one experienced neuroradiologist, blinded to mutation status, to evaluate the 
presence, number and location of microbleeds. Microbleeds were defined as small (2-
10mm diameter), round and homogenous foci of low signal intensity on T2*-weighted 
MRI. Microbleed mimics including basal ganglia mineralization, vessel flow voids in 
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the subarachnoid space and artefacts at air-bone interfaces were excluded in line with 
standardized criteria (Gregoire et al., 2009). The number and location of microbleeds 
was assessed in the following regions: cortical/cortico-subcortical (frontal, temporal or 
parieto-occipital), infratentorial (brainstem and cerebellum) and the basal ganglia 
(including thalamus). 
 
5.1.2 Results 
 
Microbleeds were found in three out of 12 patients and in none of the control subjects. 
Two PSEN1 mutation carriers had 1 microbleed each (p.Leu166Arg right parieto-
occipital; Intron 4 (g.23024delG) left infratentorial). Only one patient had multiple, 
predominantly cortical/cortico-subcortical microbleeds (over 30 in total) and fulfilled 
Boston Criteria for probable CAA (Greenberg et al., 1996, van Rooden et al., 2009). 
This individual, a 59-year-old man harbouring the p.Arg269His PSEN1 mutation, had a 
one-year history of cognitive decline at the time of referral and recruitment to the study. 
He was adopted and had no siblings. There was no significant past history and no 
hypertension or other vascular risk factors. The neurological examination revealed 
finger myoclonus but was otherwise unremarkable. The MMSE was 24/30. Cognitive 
testing revealed him to have little insight into his problems, a pronounced dysexecutive 
syndrome, mild episodic memory impairment, and relative preservation of parietal lobe 
function. 3D-T1-weighted images showed mild generalised volume loss without 
predominance of medial temporal lobe atrophy. T2 FLAIR MRI depicted mild-
moderate white matter disease (Figure 5.1). T2*-weighted imaging revealed prominent 
cerebellar, parieto-occipital and temporal lobar microbleeds (Figure 5.2). 
 
5.1.3 Discussion 
 
Although CAA is found at post-mortem in up to 90% of patients with sporadic AD, 
only around 23% of patients with AD have identifiable microbleeds on MRI 
(Cordonnier and van der Flier, 2011). It is possible that microbleeds only occur when 
CAA is particularly severe; or it may be that patients with AD and microbleeds 
represent a subgroup in whom the pathological process is somewhat different. 
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Pathological studies of FAD confirm that whilst CAA is seen in the context of 
mutations in APP, PSEN1 and PSEN2 and also in APP duplications, the degree of 
pathological CAA in FAD is also highly variable. Thus for example in PSEN1-
associated FAD, mutations beyond codon 200 appear to be associated with particularly 
severe CAA (Mann et al., 2001). CAA, when present, may also be associated with 
different clinical correlates: some mutations within the Aβ coding domain of APP 
leading to significant pathological CAA burden are associated with recurrent cerebral 
haemorrhage, whilst others can present with a purely cognitive phenotype (Ryan and 
Rossor, 2010) (see Chapter 1.3). 
 
Figure 5.1 3T T2-weighted FLAIR coronal MRI shows white matter lesions, but no 
significant medial temporal lobe atrophy in a patient with the p.Arg269His PSEN1 
mutation. 
Reprinted from (Ryan et al., 2012), with permission. 
 
  
 
Our data confirm that microbleeds are not an inevitable feature of even “pure” 
genetically confirmed AD. Although numbers are small, the 25% prevalence of one or 
more microbleed in our series is comparable with the pooled proportion of 23% 
reported in a meta-analysis of studies of microbleeds in sporadic AD (Cordonnier and 
van der Flier, 2011). It is striking that only one individual with a PSEN1 mutation had 
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microbleeds sufficient to fulfil criteria for probable CAA, and that this patient had a 
mutation (p.Arg269His) which has been associated both with relatively late age at onset 
and with conspicuous amyloid overproduction (Gomez-Isla et al., 1997). We 
hypothesize that the atypical phenotype with a prominent early dysexecutive syndrome 
in this case might in part relate to the presence of significant CAA (Arvanitakis et al., 
2011).  
 
Figure 5.2 3T T2* MRI shows multiple lobar hypointensities consistent with 
microbleeds in a patient with the p.Arg269His PSEN1 mutation. 
Reprinted from (Ryan et al., 2012), with permission. 
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Interest in the relationship between AD and microbleeds is particularly timely in light of 
the findings of amyloid immunotherapy trials for AD, which have indicated that Aβ 
immunotherapy may lead to accumulation of Aβ42 in perivascular drainage pathways, 
with an associated increase in CAA and cerebral microbleeds (Boche et al., 2008). It 
seems that clearance of this plaque-derived Aβ42 can occur over time, but both the 
efficacy of the process and risk of vasogenic oedema varies and may be influenced by 
the degree of pre-existing CAA. With the recent launch of prevention trials for 
presymptomatic mutation carriers (Bateman et al., 2011), a deeper understanding of the 
relationship between CAA and microbleeds in different FAD mutations becomes 
increasingly relevant. Large, multi-centre studies of FAD such as DIAN, and newer 
scan sequences such as susceptibility-weighted imaging (SWI), potentially more 
sensitive to microbleeds, will be ideally placed to address these issues. 
 
 
5.2 Spontaneous ARIA-E and cerebral amyloid angiopathy related 
inflammation in PSEN1-associated familial Alzheimer’s disease 
 
Although a detailed understanding of the pathogenesis of ARIA remains to be 
elucidated, the imaging appearances are certainly thought to reflect changes involving 
vascular amyloid. Recognition that the clinical and neuroimaging features of ARIA are 
similar, although in general milder, to those of the spontaneously occurring condition 
CAA-related inflammation (CAA-ri), supports the hypothesis that an immunological 
response to vascular amyloid, with increased vascular permeability, may be a common 
underlying pathophysiological mechanism (Piazza et al., 2013). The observation of 
changes resembling ARIA-E in a small number of cases undergoing screening for 
clinical trials or participating in longitudinal imaging research studies suggests that it 
may rarely occur during the natural history of AD (Carlson et al., 2011, Raman et al., 
2014). Its prevalence, however, is unknown and to our knowledge this is the first 
reported case of ARIA-E developing spontaneously during the course of PSEN1-
associated FAD.  
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5.2.1 Case Report of ARIA-E in PSEN1-FAD 
 
The patient developed gradual impairment of episodic memory from age 48. She was an 
ex-smoker with a history of treated hypercholesterolaemia and depression. On initial 
assessment, aged 53, she had finger myoclonus bilaterally and scored 25/30 on the 
MMSE. Neuropsychological assessment revealed significant impairment of immediate 
and delayed recall memory with language function at the lower limit of normal. 
Visuospatial and executive functions were relatively intact. A lumbar puncture (LP) 
demonstrated acellular CSF with a protein level of 0.4g/L. As a similar illness had 
affected her father from the age of 67 and two of her sisters from their early 50s, genetic 
testing was carried out. This identified the novel PSEN1 p.Ile202Phe mutation in the 
patient and her affected siblings (Church et al., 2011). Her APOE genotype was e4 
homozygous. She was treated with a cholinesterase inhibitor and the first nine years of 
her illness followed a gradually progressive course. At the age of 57, she underwent a 
sub-acute deterioration in cognition and behaviour over a period of several weeks, 
becoming more emotionally labile and losing the ability to dress herself or hold a 
conversation. There were no associated headaches, seizures or signs of systemic 
infection. An MRI scan at this stage demonstrated florid white matter hyperintensities, 
particularly in a parieto-occipital distribution where they extended to involve the U-
fibres and were associated with marked focal loss of sulcal spaces suggestive of oedema 
(Figure 5.3). The imaging abnormalities were bilateral but more prominent in the left 
hemisphere. T2*-GRE sequences were not acquired. The prospect of a further LP and 
steroid treatment was discussed with her family but a conservative approach was 
chosen. Her agitation improved on quetiapine and the course of her cognitive 
impairment appeared to return to the gradual rate of decline which it had previously 
followed. A follow up MRI nine months later showed that there had been some 
spontaneous improvement in the severity of white matter change and oedema. 
Unfortunately, she was unable to tolerate scanning long enough to acquire T2-FLAIR 
and T2*-GRE sequences on this occasion. Two months after the final scan she 
developed visual hallucinations and misperceptions, motor stereotypies and worsened 
agitation. An empirical trial of Prednisolone was given for a month; the family felt that 
this was associated with some functional improvement initially but it was not sustained 
and she couldn’t tolerate increased doses. She continued to deteriorate, developed 
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seizures and was admitted to a Nursing Home. She died 10 months after her final scan 
and 11 years after the onset of her illness.  
 
Figure 5.3 Serial MRI scans demonstrating the appearance and then subsequent 
partial resolution of ARIA  
Reprinted from (Ryan et al., 2014), with permission from IOS press. 
 
 
 
Her brain was donated to the Queen Square Brain Bank for Neurological Disorders 
where tissue is stored under a licence from the Human Tissue Authority. Brain weight 
was 1038g and macroscopic investigation confirmed severe cerebral atrophy, reduction 
in bulk of the hemispheric white matter, marked reduction in size of the hippocampus 
and amygdala and pallor of the locus coeruleus. Microscopic investigation of 
histological slides from representative regions of the right hemisphere of the brain 
demonstrated end-stage AD pathology with severe neurofibrillary tangle pathology 
(Braak and Braak stage VI) and extensive mature and diffuse Aβ-positive parenchymal 
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plaques (Thal phase 5). Tau immunohistochemistry confirmed the presence of 
‘frequent’ neuritic plaques in all CERAD (Consortium to Establish a Registry for AD) 
cortical regions.  Aβ immunohistochemistry also revealed ‘severe’ CAA with focal 
collections of mononuclear inflammatory cells, mostly CD3-positive T lymphocytes 
and CD68-positive macrophages, around some of the leptomeningeal and cortical blood 
vessels. One leptomeningeal small arteriole showed invasion of its thickened walls by 
CD3-positive T-cells (Figure 5.4), but no multinucleated giant cells were identified. 
Using special staining (MSB method) no fibrinoid necrosis of the walls of this or other 
leptomeningeal or cortical blood vessels could be demonstrated. A sparse diffuse 
chronic inflammatory cell infiltrate was present in the leptomeninges. In addition, there 
was marked diffuse increase of CD68-positive microglia/macrophages in the 
parenchyma of both cerebral cortex and subcortical white matter, which was slightly 
more severe in the temporal, parietal and occipital areas than in the frontal region. No 
haemorrhagic changes were seen. Some of the macrophages were observed to contain 
pigment, however this was negative for haemosiderin on Perls stain. As the MRI 
changes were more prominent in the left hemisphere, frozen tissue from the left parietal 
and occipital cortices was also examined. This demonstrated a small, cavitating infarct 
in the left occipital cortex and subcortical white matter invaded by macrophages and T 
lymphocytes. Macrophages and microglia were focally numerous in the surrounding 
brain parenchyma surrounding the infarct. a-Synuclein immunohistochemistry 
demonstrated amygdala predominant Lewy pathology.  
 
Figure 5.4 Neuropathological analysis  
Macroscopic observation of coronal slices confirmed cerebral atrophy and dilatation of 
the lateral ventricle with a reduction in bulk of the deep white matter and size of the 
hippocampus (A; arrow). Aβ immunohistochemistry showed numerous plaques (B) 
both cored (C) and diffuse. Severe CAA was found in the parenchyma (B, arrow) and 
leptomeninges (D) and was also found to affect capillaries in the occipital cortex (E). 
Numerous neurofibrillary tangles and neuropil threads were highlighted with tau 
immunohistochemistry (F) in the CA1 hippocampal subregion. Severe gliosis was 
observed throughout all cortical regions with GFAP immunohistochemistry (G) together 
with increased numbers of reactive microglia (H). Additional Lewy body and Lewy 
neurite pathology was seen in the amygdala (I). Some leptomeningeal blood vessels 
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were surrounded by focal collections of mononuclear inflammatory cells, mostly CD3-
positive T lymphocytes and CD68-positive macrophages (K), with one leptomeningeal 
small arteriole showing invasion of its thickened walls by CD3-positive T-cells (L). B-I 
and K and L are immunohistochemical preparations, B-E: Ab peptide; F: Tau (AT8 
antibody); G: GFAP; H and K: CD68; I: a-Synuclein; L: CD3; J: Haematoxylin and 
eosin. Bar in B represents 100µm in B, D; 50 µm in H, J, K and L; 20µm in C,E, F and 
I.  Reprinted from (Ryan et al., 2014), with permission from IOS press. 
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5.2.2 Discussion 
 
The appearance of ARIA-E in this patient coincided with a period of clinical 
deterioration. As there was an interval of almost two years between this episode and the 
post-mortem examination, the exact cause of the imaging abnormalities can only be 
hypothesised. However, the pathological findings do support the idea that an 
immune/inflammatory response to vascular amyloid was implicated. There was severe 
CAA, with a chronic inflammatory infiltrate surrounding some of the cortical and 
leptomeningeal blood vessels. One leptomeningeal arteriole also showed transmural 
inflammation indicative of vasculitis. This case therefore adds further support to a 
growing body of literature linking CAA-ri to radiological features described as ARIA 
(Greenberg and Frosch, 2011). Whilst the precise underlying pathogenetic mechanisms 
are not yet fully understood, previous observations of CD68+ macrophages and CD4+ T-
cell recruitment at sites of Aβ-related angiitis (Melzer et al., 2012, Bogner et al., 2014) 
and CSF anti-Aβ autoantibodies in patients with spontaneous CAA-ri (DiFrancesco et 
al., 2011, Piazza et al., 2013) support the notion of an autoimmune response against 
vascular Aβ, which may act to trigger a posterior reversible encephalopathy syndrome 
(Greenberg and Frosch, 2011). 
 
Several factors may have predisposed the patient to developing this complication. 
PSEN1 mutations located beyond codon 200 have been reported to cause particularly 
severe CAA (Mann et al., 2001), and her APOE-e4 homozygosity may have increased 
her risk of developing CAA-ri. In clinical trials of the humanized anti-Aβ antibody 
bapineuzumab, the frequency of ARIA-E increased with APOE-e4 gene dose (Sperling 
et al., 2012, Salloway et al., 2014) and spontaneous CAA-ri is also associated with 
APOE-e4 homozygosity (Eng et al., 2004, Kinnecom et al., 2007). Capillary CAA, 
observed in the occipital cortex of this patient, may play an important role here as it has 
been found to both associate with the APOE-e4 allele (Thal et al., 2002) and to provoke 
a particularly strong inflammatory response, unlike larger vessel CAA (Richard et al., 
2010). This individual’s vascular risk factors may have rendered her further vulnerable 
to developing blood-brain barrier dysfunction and increased vascular permeability.  
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The development of ARIA-E should be further evaluated as a possible cause of sub-
acute deterioration in patients with established AD. Recognition that it may arise 
spontaneously during the course of FAD is particularly timely with amyloid-modifying 
therapy trials for FAD underway. Although many of the participants in these trials will 
be presymptomatic, certain genetic factors may increase the risk of developing ARIA, 
even prior to the onset of clinical disease. This has been illustrated by a case report of 
ARIA developing spontaneously in a cognitively normal APP duplication carrier 
(Chamard et al., 2013). Monitoring for ARIA, investigating the underlying 
pathophysiological mechanisms and identifying individuals at increased risk of 
developing them will be a crucial part of both natural history studies and treatment trials 
in AD. 
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6 MRI evidence for presymptomatic change in thalamus and caudate 
in familial Alzheimer’s disease 
 
6.1 Introduction 
 
A wealth of evidence now indicates that the symptoms of AD are preceded by a long 
period of gradual accrual of pathological change (Price and Morris, 1999, Bateman et 
al., 2012). FAD, although rare, provides a unique opportunity to gain insights into the 
earliest stages of the disease, through prospective study of mutation carriers (MCs), who 
are genetically destined to develop the disease. FAD MCs also represent a cohort in 
whom treatment may be initiated at a presymptomatic stage and a number of such trials 
are currently underway (Reiman et al., 2010, Bateman et al., 2011). As the individuals 
participating in these trials will have little or no cognitive impairment, there is a need to 
understand the trajectory of biomarker changes in presymptomatic FAD, in order to 
both assess disease progression and look for therapeutic effects. 
 
Results from the large international DIAN study indicate that CSF biomarker changes 
are evident over two decades before an individual’s expected age at symptom onset, as 
determined by their parental age at onset (Bateman et al., 2012). Reduced 
concentrations of CSF amyloid-beta (Aβ)42 and increased concentrations of CSF tau 
were detected at 25 and 15 years from expected symptom onset respectively. Aβ 
deposition on PIB-PET scans (Klunk et al., 2004) and hippocampal volume loss were 
apparent at 15 years and cerebral hypometabolism at 10 years prior to expected 
symptom onset. Presymptomatic hippocampal atrophy has also been detected in 
longitudinal studies, which have followed smaller cohorts through the presymptomatic 
stage to age at symptom onset. At a group level, MCs showed hippocampal and whole 
brain volume loss compared with controls at three and one year before symptom onset 
(Ridha et al., 2006). However, longitudinal measures were able to detect changes 
earlier, with differences in hippocampal and whole brain atrophy rates observed at 5.5 
and 3.5 years before symptom onset in MCs (Ridha et al., 2006, Knight et al., 2011).  
 
Prior volumetric imaging studies have mainly focussed on the neocortex and 
hippocampus, in view of the well-recognised roles that these structures play in higher 
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cognitive functions and memory, and their apparent vulnerability to AD pathology. 
However, PIB-PET studies have indicated that prominent amyloid deposition first 
appears in the striatum and thalamus in presymptomatic FAD (Klunk et al., 2007, 
Knight et al., 2011). These subcortical structures have received relatively little attention 
from volumetric imaging studies in AD. They are known to be significantly atrophied 
mild-moderate sporadic AD but it is not known how early this atrophy occurs (de Jong 
et al., 2008).  A previous FAD study reported decreased volumes of thalamus, caudate 
and putamen in presymptomatic mutation carriers (PMCs) who were on average 15 
years younger than their family’s median age at dementia diagnosis, with a trend 
towards increasing caudate size in those with memory deficits who were ten years 
younger (Lee et al., 2013). Increased caudate volumes were reported in another cohort 
of PMCs who were approximately a decade younger than their expected age at 
symptom onset (Fortea et al., 2010). This study also included diffusion imaging and 
found associated changes in mean diffusivity in the caudate of PMCs. 
 
Although the thalamus and striatum are structures that are not conventionally associated 
with AD, it has long been known that they are affected by AD pathology (Braak and 
Braak, 1990, Braak and Braak, 1991). It is also becoming increasingly recognised that, 
given their dense connections with the cortex, they are involved in a variety of neural 
networks subserving complex cognitive and behavioural functions (Middleton and 
Strick, 2000). The caudate, for example, appears to play a key role in supporting the 
planning and execution of behaviour needed to achieve complex goals (Grahn et al., 
2008), whilst thalamic nuclei are involved in declarative memory function at a number 
of different levels (Van der Werf et al., 2003). There is a growing appreciation of the 
idea that AD, and indeed neurodegenerative diseases in general, should be considered as 
network disorders in which there is selective degeneration of vulnerable neuronal 
circuits (Warren et al., 2012). It therefore seems appropriate to investigate the 
subcortical grey matter regions involved in such networks, as well as the cortical areas 
and their connecting white matter.  
 
DTI allows assessment of alterations in tissue microstructure in specific brain regions 
and can be used to examine the integrity of connecting white matter pathways (Basser et 
al., 1994). DTI exploits the fact that water molecules show preferential diffusion along 
the major axis of a white matter fibre bundle (anisotropy), due to barriers hindering 
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perpendicular diffusion including axonal membranes and the myelin sheath. The effects 
of a pathological process on white matter tracts can be explored by investigating 
whether there are associated changes in the overall magnitude of diffusion (mean 
diffusivity; MD) or the degree of its directionality (fractional anisotropy; FA). 
Examining the component eigenvalues of the diffusion tensor, from which FA is 
derived, provides further information on how diffusion is altered in both the principal 
direction of the tract (axial diffusivity; AxD) and in the plane perpendicular to this 
(radial diffusivity; RD). If there are changes in AxD and RD which are proportional, 
there will be no corresponding change in FA, making it important to examine these 
components separately (Acosta-Cabronero et al., 2010). DTI can be used to characterise 
grey matter microstructure too (Bozzali et al., 2002, McKinstry et al., 2002) with MD a 
commonly used metric (Benedetti et al., 2006). In fibre-rich structures such as the 
thalamus and striatum, FA may also be a useful indicator of pathological change 
(Ciccarelli et al., 2001, Tovar-Moll et al., 2009, Bohanna et al., 2011). Many DTI 
studies of sporadic AD have now been published, reporting decreased FA and increased 
MD in various tracts, most notably the cingulum, corpus callosum and white matter of 
the parahippocampal gyrus (Chua et al., 2008, Stebbins and Murphy, 2009). There has 
been just one previous DTI study of presymptomatic FAD, which examined FA only 
and found it to be globally reduced in the white matter of PMCs, most strikingly in the 
fornix (Ringman et al., 2007). 
 
The study reported in this chapter investigates a cohort of PSEN1 PMCs who are 
relatively close to their expected age at symptom onset, together with groups of 
symptomatic MCs (SMCs) and controls. Region of interest (ROI) analyses are used to 
examine volumetric and diffusivity differences in the subcortical structures that are the 
main focus of this study, and altered diffusivity in white matter tracts of interest. 
Automated whole brain analysis techniques; voxel-based morphometry (VBM) and 
tract-based spatial statistics (TBSS), are also used to provide whole-brain assessments 
of group differences in volume and DTI indices respectively.  
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6.2 Materials and methods 
6.2.1 Subjects 
20 PSEN1 MCs were included in this study, all of whom had pathogenic mutations 
which have previously been reported elsewhere. Ten of these were PMCs: three 
p.Met146Ile, two p.Glu184Asp and one each of p.Met139Val, p.Tyr115Cys, Intron 4 
(g.23024delG), p.Leu171Pro, p.Leu262Phe. Ten were SMCs: three Intron 4 
(g.23024delG), two p.Glu280Gly and one each of p.Tyr115His, p.Glu120Lys, 
p.Pro264Leu, p.Arg269His, p.Arg278Ile. A group of 20 healthy controls (including two 
gene-negative siblings) was also studied. All subjects in the study underwent 
assessment with the Mini-Mental State Examination (MMSE). The PSEN1 MCs also 
underwent neurological examination and detailed neuropsychological assessment. The 
neuropsychological test battery comprised measures of general intellectual functioning 
(Wechsler Abbreviated Scale of Intelligence (WASI)), estimated premorbid IQ 
(National Adult Reading Test (NART); verbal and visual recognition memory 
(recognition memory test (RMT) for words and faces); naming (Graded Naming Test 
(GNT)); calculation (Graded Difficulty Arithmetic Test (GDA)); visuoperceptual skills 
(object decision test from the Visual Object and Space Perception battery); speed and 
executive function (Stroop Test). All MCs identified a close informant who was 
interviewed separately to gain a collateral history; specific enquiry was made regarding 
cognitive symptoms in each domain, anxiety and depression. MCs were defined as 
symptomatic if consistent symptoms of cognitive decline were reported by the subject 
and/or their close informant. If there was a discrepancy between the opinion of the 
subject and their informant, the perspective of the informant was favoured as insight 
may not always be preserved in FAD. Estimated time to onset was calculated for the 
PMCs by subtracting the participant’s current age from the age at which their parent 
first developed symptoms of progressive cognitive decline. The participants were 
recruited from an ongoing longitudinal study of FAD at the Dementia Research Centre, 
UCL Institute of Neurology. Some of the subjects had participated in our prior imaging 
studies of FAD (Ridha et al., 2006, Knight et al., 2011, Knight et al., 2011) but the data 
used for this study have not been reported elsewhere. All of the subjects in this study 
were aware of their mutation status, having undergone clinical diagnostic or predictive 
genetic testing at approved clinical centres separately to their involvement in research. 
All subjects gave written informed consent according to the Declaration of Helsinki and 
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approval was received from the local ethics committee. Consent was taken by a 
clinician experienced in the assessment of patients with cognitive impairment and all 
subjects were considered to have capacity to consent according to the Mental Capacity 
Act of 2005. Subject demographics are detailed in Table 6.1.   
 
6.2.2 MRI acquisition 
All subjects were scanned on the same 3T Siemens TIM Trio scanner using a 32-
channel phased array head-coil (Siemens, Erlangen, Germany). A sagittal 3D 
magnetisation prepared rapid gradient echo T1 weighted volumetric MRI (TE/TR/TI = 
2.9/2200/900ms, dimensions of 256x256x208, voxel size of 1.1x1.1x1.1mm) and a 
coronal T2 FLAIR sequence (TE/TR/TI = 87/9000/2500 ms, voxel size of 
0.9375x0.9375x5mm) were acquired. Two 64-direction DTI sequences were acquired 
with a single shot, spin-echo echo planar imaging (EPI) sequence (FOV 240 mm; matrix 
96x96; yielding an isotropic voxel size of 2.5x2.5x2.5mm; 55 contiguous axial slices; 
TR: 6800 ms; TE: 91 ms; b value: 1000 s/mm2), augmented with parallel imaging 
acceleration (GRAPPA). Nine acquisitions without diffusion weighting were acquired 
(b = 0 s/mm2). For all subjects, volumetric T1, DTI and T2 FLAIR images were 
assessed visually in all planes to ensure adequate coverage and to exclude significant 
motion, artefacts or unexpected pathology.  
 
6.2.3 Grey matter region of interest volumetric analysis 
ROI segmentation in T1-weighted space was used to investigate the volumes of the 
subcortical structures of interest in this study; namely the thalamus, caudate, putamen 
and hippocampus. The Multi-Atlas Propagation and Segmentation (MAPS) technique 
was used (Keihaninejad et al., 2011), which was previously developed for hippocampal 
segmentation and has been used in brain extraction (Leung et al., 2010, Leung et al., 
2011). In MAPS, all of the atlases in a template library are first compared to the target 
image. Our template library consisted of 30 subjects (median age of 31 ± 8 years, 15 
women) whose MRI scans had been manually segmented into 83 anatomical structures 
(Hammers et al., 2003). Multiple best-matched atlases are then selected, and the labels 
in the selected atlases are propagated to the target image after non-linear image 
registration. Label fusion is then applied to combine the labels from different atlases to 
 130 
create a consensus segmentation in the target image. We applied MAPS to 30 atlas 
images in a leave-one-out approach in order to determine the number of best-matched 
atlases (7-9) and the optimal label fusion technique (simultaneous truth 
and performance level estimation (STAPLE)) (Warfield et al., 2004) required to 
produce accurate individual ROIs by comparing them to the manually delineated 
regions. We used the optimised MAPS technique to generate individual ROIs for each 
subject in our data set (Figure 6.1). The anatomical validity of the segmentations was 
confirmed by two consultant neuroradiologists.  
 
Figure 6.1 Regions of interest 
Grey matter regions of interest (top): Segmentations of thalamus (blue), caudate (green), 
putamen (pink) and hippocampus (purple) overlaid on the T1 image of a single subject. 
White matter tracts of interest (bottom): Segmentations of the fornix (pale blue), right 
cingulum (purple), left cingulum (green), genu (yellow), body (red) and splenium (dark 
blue) of the corpus callosum, overlaid on the study-specific template. Reprinted from 
(Ryan et al., 2013), with permission. 
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6.2.4 Grey matter region of interest diffusion tensor imaging analysis 
All DTI acquisitions were registered to the first b=0 image using 12 degrees of freedom 
FLIRT (FSL) (Jenkinson et al., 2002) for motion and eddy current correction and 
realigning diffusion-weighting directions appropriately. Tensor fitting was performed 
using Camino (Cook et al., 2006). For each subject, the T1-weighted image was 
registered to the first (b=0) DTI image using a 12-parameter affine registration 
algorithm (Ourselin et al., 2001). The ROIs defined using MAPS were transferred to the 
DTI space using nearest-neighbour interpolation. The overall average FA and MD 
values were calculated by averaging values for the entire individual ROI.  
 
6.2.5 White matter tract of interest diffusion tensor imaging analysis 
White matter tract of interest analysis was performed using DTI-TK to create a study-
specific template using iterative tensor-based registration, which takes into account 
local fiber orientation (Zhang et al., 2006, Keihaninejad et al., 2012). In particular, all 
linear and non-linear registrations on the tensor images were performed using DTI-TK, 
which has been shown to outperform more conventional tools (Wang et al., 2011). FA, 
mean, axial and radial diffusivity maps were created for the study-specific template and 
registered images. The ICBM-DTI-81 white matter labels and tracts atlas, developed by 
Johns Hopkins University (JHU) was used to locate the white matter tracts of interest 
(Mori et al., 2005). The FA map of the JHU atlas was linearly and non-linearly 
registered to the study-specific template FA map (Ourselin et al., 2001, Modat et al., 
2010). This transformation was used to warp the labels from the white matter atlas to 
the template FA image through nearest neighbour interpolation. In this study, we 
focused on six white matter tracts of interest: the genu, body, and splenium of the 
corpus callosum, fornix and left and right cingulum (Figure 6.1).  
 
6.2.6 Statistical tests for non-voxelwise analyses 
Baseline characteristics and neuropsychological test results (which were converted to z 
scores, based on published normative data) were compared using t-tests for normally 
distributed variables and Wilcoxon ranksum testing for the MMSE. Linear regression 
was used to factor out age effects on neuropsychological tests where no detailed age 
corrections were available (RMT, GNT, GDA and Object Decision).  For the ROI 
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analyses, groups were compared using separate linear regressions for each outcome 
measure, in each ROI. The ROI volumetric analyses were adjusted for age, gender and 
total intracranial volume (TIV). The ROI DTI analyses for grey and white matter were 
adjusted for age and gender. TIV correction is not required for DTI as it assesses 
microstructural properties that are not expected to be associated with macroscopic head 
size. All results are reported as statistically significant if p < 0.05. 
 
6.2.7 Voxel-based morphometry analysis of volumetric imaging 
VBM processing was carried out using SPM8 (Statistical Parametric Mapping, version 
8; Wellcome Trust Centre for Neuroimaging, London, UK). The T1-weighted scans 
were segmented into grey and white matter using the new segment toolbox with default 
settings (Weiskopf et al., 2011). Segmentations were produced with rigid alignment to 
standard space (Montreal Neurological Institute (MNI) space) and re-sampled to 1.5mm 
isotropic voxels for use with DARTEL (Ashburner, 2007). DARTEL then iteratively 
registered the grey and white matter segments to an evolving estimate of their group-
wise average (Ashburner and Friston, 2009). The native space tissue segments were 
then normalised to MNI space using the DARTEL transformations, modulated to 
account for volume changes. A smoothing kernel of 6mm full width at half maximum 
was applied. TIV was calculated for each subject using Jacobian integration of 
deformation fields created by the new segment toolbox (Ridgway et al., 2011). Voxel-
wise statistical analysis was performed with non-parametric permutation-testing using 
the FSL randomise programme (as used for the TBSS statistical analysis, described 
below). Grey and white matter images were modelled separately in terms of group 
(control, presymptomatic, symptomatic), age, gender and TIV (all mean centred). 
Statistical significance of differences between groups was assessed using threshold-free 
cluster enhancement (TFCE) (Smith and Nichols, 2009), controlling family-wise error 
(FWE). Results for symptomatic patients are shown thresholded at FWE p < 0.05; 
presymptomatic differences are shown at a less stringent level of FWE p < 0.1, with 
effect-maps (difference between adjusted group means as a percentage of the control 
mean) provided for a fuller characterization of the atrophy pattern. 
 
 133 
6.2.8 Voxel-wise diffusion tensor imaging analysis using tract-based spatial 
statistics 
The DTI data were also analysed with TBSS to investigate whole-brain white matter 
microstructural abnormalities (Smith et al., 2006). In this study the modified TBSS 
protocol was used by incorporating a group-wise atlas as the registration target; GW-
TBSS (Keihaninejad et al., 2012). In the GW-TBSS pipeline, a group-wise atlas is first 
created based on the subset subjects’ FA images using the method described in 
Keihaninejad et al., 2012. The voxel-wise statistical analysis was performed by the FSL 
randomise program (5000 random permutations) with correction for multiple 
comparisons to control FWE (p < 0.05) using TFCE. Age and gender were entered into 
the analysis as covariates.  
 
6.3  Results 
 
The subjects’ demographic, neuropsychological and clinical data are summarised in 
Table 6.1. The presymptomatic (PMC) group was, as expected, younger than the 
symptomatic (SMC) group, and was on average 5.6 years below the expected age at 
symptom onset. The mean age of the control group (44.3) fell between that of the PMCs 
(37.8) and the SMCs (49.0) and age was used as a covariate in all analyses, as was 
gender. There was no clinically relevant difference in MMSE score between the 
controls and PMCs; SMCs had significantly lower MMSE scores than both groups as 
expected. The PMC and SMC groups were well matched for educational level and 
estimated pre-morbid IQ. Figure 6.2 shows mean and standard error z scores for the 
PMC and SMC groups on neuropsychological tests. The PMC group showed no 
significant deficit on any neuropsychological measure. The SMC group had 
significantly poorer performance than the PMC group on all tests except naming (GNT) 
and object perception. 
 
The clinical data showed that neuropsychiatric symptoms were common in the SMC 
group; 40% had anxiety and 60% had depression. In the PMC group, 10% had anxiety 
and 20% had depression. The two PMCs with symptoms of anxiety and/or depression 
were both within two years of their expected age at onset; both had a long history of 
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recurrent psychiatric symptoms since their teenage years and required psychiatric 
review and medication changes at the time of their current assessment. None of the 
subjects had seizures but 60% of the SMCs and 40% of the PMCs had myoclonus on 
neurological examination. Myoclonus was the only abnormal sign present on 
examination of the PMCs but 20% of the SMCs had extrapyramidal signs and 60% had 
pyramidal signs, typically a symmetrical spastic increase in lower limb tone with hyper-
reflexia.  
 
Figure 6.2 Mean and standard error z scores for presymptomatic and symptomatic 
mutation carriers on standard neuropsychological tests. 
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Table 6.1 Subject demographics, neuropsychological and clinical data.  
Mean (SD) 
 
Presymptomatic 
MCs 
(4M, 6F) 
 
 
 
Symptomatic 
MCs* 
(6M, 4F) 
 
 
 
Control 
(9M, 
11F) 
 
 
 
 
p value 
Age/ yrs 
 
 
 
37.8 (4.7) 
 
 
 
49 (9.4) 
 
 
 
44.3 
(12.7) 
 
 
0.27 a (SMC vs 
control)  
0.04 a (PMC vs 
control)  
Years from estimated age at 
onset 
5.6 (7) 
  
N/A 
  
 N/A 
 
< 0.01 a (PMC 
vs SMC)  
 
 
Disease duration/ yrs 
 
 N/A 
 
4.3 (1.7) 
 
 N/A 
 
 
 MMSE/ 30 (range) 
 
 
 
 
29 (28-30) 
 
 
 
 
19 (13-24) 
 
 
 
 
29.9  
(29-30) 
 
 
 
<0.01 b (SMC 
vs control 
0.02 b (PMC vs 
control) 
 
Years of education 
 
 
13 (2.5) 
 
12 (1.7) 
 
 
 
N/A 
 
<0.01 b  (PMC 
vs SMC) 
0.20 a 
NEUROPSYCHOLOGY     
NART estimated IQ 100.2 (12.9) 100.1 (12.5) N/A 0.98 a 
WASI Verbal IQ 101.7 (18.0) 81.2 (17.5) N/A 0.02 a 
WASI Performance IQ 106.7 (17.1) 69.0 (15.0) N/A <0.01 a 
RMT words (/50) 45.9 (3.5) 30.0 (8.1) N/A <0.01c 
RMT faces (/50) 42.6 (5.3) 32.4 (7.5) N/A <0.01 c 
Graded naming test (/30) 19.0 (5.0) 13.1 (7.8) N/A 
 
0.5 c 
Graded difficulty arithmetic 
(/24) 12.9 (6.4) 2.4 (2.4) N/A 
 
<0.01 c 
Object decision (/20) 18.2 (2.1) 15.6 (3.2) N/A 0.06 c 
Stroop colour (s) 36.2 (14.8) 63.3 (18.3) N/A <0.01a 
Stroop word (s) 23.1 (8.4) 49.1 (22.1) N/A <0.01 a 
Stroop ink colour (s) 58.7 (20.5 124.4 (30.9 N/A <0.01 a 
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CLINICAL**    
 
Anxiety 10% 40% N/A  
Depression 20% 60% N/A  
Seizures 0% 0% N/A  
Myoclonus 40% 60% N/A  
Pyramidal signs 0% 60% N/A  
Extrapyramidal signs 0% 20% N/A  
 
*n = 9 for all neuropsychological measures except WASI PIQ (N=10), NART (N=7) 
and Stroop colour ink interference (n = 5), with all reductions in n reflecting participants 
being untestable on specific tasks. Data for the complete cohort were available for all 
other statistical tests. 
 **Percentage in group manifesting the clinical feature 
a Unpaired t-test, 2-tailed test b Wilcoxon ranksum test  
c  Linear regression with group and age as independent variables 
 
 
The grey matter ROI volumetric analysis demonstrated significant atrophy of the left 
thalamus in PMCs compared with controls (p = 0.023), together with significant atrophy 
of both left caudate (p = 0.025) and right caudate (p = 0.001) (See Table 6.2 for all the 
grey matter ROI volumetric and DTI results). No areas of significant grey or white 
matter volume loss were seen in the PMC group versus controls in the VBM analysis 
after correction for multiple comparisons at the conventional level of FWE p<0.05. 
However, atrophy in the bilateral thalamic region was near significant (FWE p = 0.061, 
at MNI coordinates of [4.5, -13.5, 12] mm). Results thresholded at FWE p<0.1, together 
with an unthresholded effect map are shown in Figure 6.3. All of the grey matter ROIs 
were significantly atrophied in the SMC group compared to controls. The VBM results 
for the SMC versus control group comparison demonstrated grey matter volume loss in 
bilateral hippocampus and posterior cortical areas but the most significant volume loss 
was seen in the region of bilateral striatum and thalamus. Extensive loss of white matter 
volume was also observed in the SMCs compared with controls (Figure 6.4). 
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Figure 6.3 VBM results showing (top left) areas of grey matter reduction in PMCs 
compared with controls after correction for multiple comparisons at FWE < 0.1 
and the effect-map for the PMC versus control group comparison.  
In the effect-map, regions showing reduced grey matter in the PMC group are shown in 
red and in controls in blue. Differences between the two adjusted group-means are 
overlaid on a mean study-specific template. Images shown in radiological convention 
(right on left). Reprinted from (Ryan et al., 2013), with permission. 
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Figure 6.4. VBM results showing (top) grey matter reduction and (bottom) white 
matter reduction in SMCs compared with controls.  
Results are shown overlaid on a mean study-specific template and are FWE- corrected 
for multiple comparisons. Images shown in radiological convention (right on left). 
Reprinted from (Ryan et al., 2013), with permission. 
 
 
 
In the presymptomatic group, no significant hippocampal atrophy was evident, although 
the right hippocampus did show significantly decreased MD (p = 0.046) in the grey 
matter ROI DTI analysis relative to controls. Although not reaching significance, there 
was also a trend towards decreased MD in all the other subcortical structures in PMCs. 
This contrasts with the findings in the SMCs, who demonstrated increased MD in all the 
subcortical grey matter structures assessed; the pattern of change in diffusivity that is 
more typically observed in neurodegenerative disease. In the PMCs, FA was increased 
in the left thalamus (p = 0.016), right thalamus (p = 0.036) and left caudate (p = 0.004). 
FA was also increased in SMCs in left putamen (p = 0.032) and right putamen (p = 
0.020), but did not differ significantly from controls in the other grey matter structures 
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assessed. In the white matter tract of interest analysis, PMCs demonstrated decreased 
MD (p = 0.043) and AxD (p = 0.011) in the right cingulum only (Table 6.3).  
Significantly decreased FA with increased MD, AxD and RD was seen in all the white 
matter tracts of interest in the SMCs. The TBSS analysis demonstrated widespread 
decreased FA and increased MD, AxD and RD in the white matter of SMCs. As 
demonstrated in Figure 6.5, the fall in FA in the fornix and cingulum of the SMC group 
appeared to be driven by an increase in radial diffusivity; very little difference in AxD 
was seen in these structures between the SMCs and controls. No significant differences 
in any of the DTI indices were seen in the TBSS analysis for PMCs vs controls. 
 
Figure 6.5 TBSS results demonstrating areas of significantly decreased FA and 
significantly increased axial, radial and mean diffusivity in SMCs compared to 
controls.   
Results are FWE-corrected for multiple comparisons using TFCE. Reprinted from 
(Ryan et al., 2013), with permission. 
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Table 6.2  Mean ± sd volumes and diffusivity indices in the grey matter regions of 
interest.  
The differences in adjusted means between the MC and control group (95% confidence 
interval) are shown in italics. Significant results at p < 0.05 are indicated by an asterisk 
in the shaded cells. 
 		 Controls	 Pre-symptomatic	MCs	 Symptomatic	MCs	Volume	Right	Thalamus	(mm3)	 7792	±			550	 7676	±		747				275	(-152,	703)	 6103	±	543			1620	(1294	,1947)*		Volume	Left	Thalamus	(mm3)	 7177	±			652	 6962	±	604					428	(64,	792)*	 5520	±	404			1533	(1216,	1849)*	Volume	Right	Caudate	(mm3)	 4689	±				512	 4273	±	553		605	(293,	917)*	 3832	±		525					746	(438,	1053)*	Volume	Left	Caudate	(mm3)	 4743	±				506	 4376	±	610					466	(63,	868)*	 3748	±		588					940	(537,	1343)*	Volume	Right	Putamen	(mm3)	 5210	±				656	 5234	±	695					144	(-250,	537)	 4228	±	473						920	(555,	1285)*	Volume	Left	Putamen	(mm3)	 5035	±				680	 4989	±		775				194	(-232,	620)	 3847	±		655					1142	(736,	1548)*	Volume	Right	Hippocampus	(mm3)	
3131	±				304	 3153	±	483					
-1.76	(-233,	230)	 2295	±		477					868	(632,	1103)*	
Volume	Left	Hippocampus	(mm3)	
3014	±				278	 3118	±	423					
-116	(-345,	112)	 2302	±		459							769	(546,	991)*	
FA	Right	Thalamus	 .352	±	.017	 .367	±	.019		-.017	(-.032,	-.001)*	 .346	±		.031										.006	(	-.014,.025)				FA	Left	Thalamus	 .332	±	.013	 .343	±	.008				
-.013	(-.023,	-.003)*	 .327	±		.031										.007	(	-.011,.025)	
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FA	Right	Caudate	 .229	±		.024	 .239	±		.030								
-.017	(-.038,.004)	 .243	±		.034										-.013	(	-.037,.010)	FA	Left	Caudate	 .226	±		.017	 .248	±	.026		
-.025	(-.041,	-.009)*	 .236		±		.027										-.011	(-.029,.008)	FA	Right	Putamen	 .222	±		.016	 .227	±			.013						
-.009	(	-.021,.003)	 .242	±	.020			-.017	(-.031,	-.003)*	FA	Left	Putamen	 .212	±			.011	 .214	±			.010				
-.005	(-.013,.003)	 .228	±	.021				-.014	(-.027,	-.001)*	FA	Right	Hippocampus		 .184	±			.016	 .193	±			.022				-.006	(-.0214,.009)	 .176	±		.032											.004	(-.014,.023)	FA	Left	Hippocampus	 .178	±			.019	 .192	±				.020					-.012	(-.029,.005)	 .167	±			.033										.007	(-.013,.028)	MD	Right	Thalamus	 .824	±		.030	 .794		±			.043				.022	(-.006	,.049)	 .912		±	.089				-.075	(-.119,-.032)*	MD	Left	Thalamus	 .838	±		.029	 .815		±		.037			
.016	(	-.010,	.042)	 .915		±	.069				-.070	(-.108,-.032)*	MD	Right	Caudate	 .956	±			.071	 .949		±		.068				
.005	(-.057,	.066)	 1.075	±	.111			-.113	(-.185,-.040)*	MD	Left	Caudate	 .993	±			.081	 .955		±		.066			
.013	(-.045,	.071)	 1.058	±		.072							-.052	(-.112,	.008)	MD	Right	Putamen	 .761	±			.026	 .740		±		.028						.016	(-.006,	.038)	 .840		±	.060				-.075	(-.108,-.041)*	MD	Left	Putamen	 .773	±				.040	 .752	±				.021			
.012	(-.016,	.039)	 .838	±	.061				-.061	(	-.010,-.022)*	MD	Right	Hippocampus	 .958		±				.033	 .907	±		.073			.044	(.002,	.087)*	 1.094	±	.073			-.139	(-.181,-.096)*	MD	Left	Hippocampus	 .952		±				.052	 .921	±				.053					.027	(-.017,	.072)	 1.113	±	.096			-.163	(-.221,-.104)*	
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Table 6.3.  Mean ± sd diffusivity indices in the white matter tracts of interest.  
The differences in adjusted means between the MC and control group (95% confidence 
interval) are shown in italics. Significant results at p < 0.05 are indicated by an asterisk 
in the shaded cells. 
		 Control	 Presymptomatic	MCs	 Symptomatic	MCs	FA	Genu	of	corpus	callosum	 	.610			±	.026										.621	±		.040						.010	(-.017,	.037)	 	.570	±		.010				-.040	(-.059,	-.021)*	FA	Body	of	corpus	callosum	 .612			±	.026				 .613	±		.045					-.000(	-.029,	.028)		 .559	±		.012						-.054	(-.074,-.034)*	FA	Splenium	of	corpus	callosum	 .684			±	.020							.691	±		.028					.005	(	-.015,	.025)	 .639	±		.020						-.045	(-.063,-.027)*	FA	Fornix		 .426			±	.044																	.458 ±		.094					
.017	(	-.036,	.069)	 .332	±		.046						-.092	(-.130,-.054)*	FA	Right	Cingulum	 .481			±	.033																			.503 ±			.059				
.018	(	-.018,	.054)	 .402	±		.019				-.078	(	-.102,	-.054)*	FA	Left	Cingulum			 .457			±	.035																		.467 ±			.050				
.011	(	-.023,	.044)	 .385	±		.018					-.073	(-.098,-.047)*	MD	Genu	of	corpus	callosum	 .849	±	.043	 .835	±		.057					.010	(	-.031,	.052)	 .942	±		.026							.090	(	.058	,.122)*	MD	Body	of	corpus	callosum	 .858	±		.039	 .855	±			.052			-.000(	-.038,	.037)	 .966	±		.041							.105	(	.071,	.139)*	MD	Splenium	of	corpus	callosum	 .855	±	.040	 .847	±		.068				.002	(	-.042,	.046)	 .974	±		.068						.117	(	.073,	.160)*	MD	Fornix		 1.718	±	.199	 1.642	±		.388		
.007	(	-.214,	.229)	 2.107	±		.147				.369	(	.215,	.523)*	MD	Right	Cingulum		 .821	±	.043	 .776	±		.047			
.040	(	.001,	.078)*	 .980	±		.049						.157	(	.119,	.196)*	MD	Left	Cingulum		 .776	±	.050	 .752	±		.062				
.019	(	-.028,	.066)	 .911	±		.040							.132	(	.092,	.172)*	
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AxD	Genu	of	corpus	callosum	 1.543	±.038	 1.528	±	.041		.010	(	-.023,	.044)	 1.636		±	.031					.088	(	.059,.118)*	AxD	Body	of	corpus	callosum	 1.569	±.040	 1.562	±		.021			.003	(	-.027,.033)	 1.661	±	.041						.087	(	.054,.120)*											AxD	 Splenium	 of	corpus	callosum	 1.662	±.043	 1.653	±		.075		.004	(	-.044,	.052)	 1.795	±		.078					.130	(	.082,.178)*	AxD	Fornix		 2.536	±.188	 2.454	±		.335		
.021	(	-.177,.219)	 2.832	±		.136					.279	(	.134,.424*)	AxD	Right	Cingulum		 1.291	±	.046	 1.248	±	.020		
.042	(	.010,.074)*	 1.394	±		.054					.102	(.062,.142)*	AxD	Left	Cingulum			 1.188	±.049	 1.161	±		.039			
.018	(	-.021,.057)	 1.281	±		.043					.088	(	.049,.128)*	RD	 Genu	 of	 corpus	callosum	 .503	±				.048	 .488	±	.068					.010	(	-.037,	.057)	 .595	±		.026							.090	(.055,.125)*	RD	 Body	 of	 corpus	callosum	 .503	±				.043	 .502	±		.069				-.002	(	-.047,	.043)	 .618	±		.042								.114	(.078,.151)*	RD	 Splenium	 of	corpus	callosum	 .451	±	.041	 .444	±		.066				.001	(	-.042,.044)	 .563	±		.064						.110	(.068,.152)*	RD	Fornix	 1.310	±	.206	 1.236	±		.416			
.001	(	-.234,		.235)	 1.744	±		.155					.415	(.255,	.575)*	RD	Right	Cingulum		 .585	±				.050	 .540	±		.073				
.039	(	-.012,	.089)	 .772	±		.048							.185	(.143,.227)*	RD	Left	Cingulum		 .569	±			.057	 .547	±		.079		
.019	(	-.036,	.075)	 .725	±				.043						.154	(.109,	.198)*	
 
As a supplemental analysis, ROI measures for the PMC versus SMC groups were 
compared. Significantly decreased FA with increased MD, AxD and RD was found in 
all white matter ROIs in SMCs. All grey matter ROIs except from the caudates had 
significantly smaller volumes in SMCs compared to PMCs. Whereas FA did not differ, 
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MD was significantly increased in all grey matter ROIs of SMCs except right thalamus 
and left caudate, where the increase was of borderline significance (p = 0.061 and p = 
0.075 respectively). 
 
6.4  Discussion 
 
It has been established from PIB-PET imaging studies that the striatum and thalamus 
are affected early in the presymptomatic stage of FAD by amyloid deposition (Klunk et 
al., 2007, Knight et al., 2011). We demonstrated atrophy of the caudate and thalamus in 
a cohort of PMCs who were on average 5.6 years prior to their expected age at onset. It 
is therefore likely that many if not all would be expected to have amyloid deposition in 
these regions. In fact half of these PMCs had participated in a prior PIB-PET study, 
which found increased thalamic and striatal amyloid deposition compared to controls 
(Knight et al., 2011). The findings of presymptomatic FAD studies will clearly depend 
on how far from symptom onset the individuals in the study are. A previous study 
examining the caudate in presymptomatic FAD interestingly demonstrated an 
unexpected increase in the volume of the caudate, precuneus and parietotemporal areas 
in PMCs who were on average 9.9 years from expected age at onset (Fortea et al., 
2010). The authors of this paper speculated that reactive neuronal hypertrophy and/or 
inflammatory processes early in the presymptomatic stage may account for an initial 
increase in the volume of these structures, which then undergo progressive atrophy as 
the disease progresses. Although their findings, like ours, need to be replicated in larger 
longitudinal studies, it is quite possible that pathological processes early in the 
presymptomatic stage cause dynamic changes in the volume of affected structures, 
which alter in terms of the direction of change as symptom onset is approached. Their 
DTI results, like ours, showed a widespread increase in MD in SMCs and a contrasting 
decrease in MD in the PMCs. 
 
Increased MD and decreased FA are thought to reflect loss of integrity of cellular 
structures and are commonly observed in neurodegenerative diseases, as was the case 
with the SMCs in our study. The PMCs, on the other hand, showed significantly 
decreased MD in the right hippocampus and a trend towards decreased MD in the other 
subcortical structures studied. Decreased MD may reflect earlier pathological changes 
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in the pathway towards neurodegeneration, such as microglial activation/accumulation 
and swelling of neurons and glia. In a triple transgenic mouse model of AD the 
appearance of neuritic plaques is associated with hippocampal astrogliosis and 
microglial activation and is preceded by an increase in the density of resting microglia 
(Olabarria et al., 2010, Rodriguez et al., 2010). A DTI study of the APPsw transgenic 
mouse found that the time of significant amyloid plaque accumulation coincided with a 
fall in the magnitude of diffusion in hippocampus and cerebral cortex (Sun et al., 2005).  
Microglial activation PET studies have demonstrated increased thalamic binding 
following traumatic brain injury (Ramlackhansingh et al., 2011) and middle cerebral 
artery infarction (Pappata et al., 2000), with decreased thalamic MD seen initially in 
acute stroke (Herve et al., 2005), perhaps supporting the hypothesis that gliosis accounts 
for the low MD observed in PMCs. Microglia undergo persistent activation at sites of 
white matter damage (Wilson et al., 2004), which may explain why they are observed in 
densely connected subcortical structures. In animal models of axonal injury, APP is 
upregulated in white matter at the site of trauma but is later seen in the dorsal thalamus 
(Spain et al., 2010), where neuronal atrophy, but not cell death, has been observed 
(Lifshitz et al., 2007). Support for the idea that subtle, subclinical but widely-distributed 
neuronal injury may result in microglial activation in the thalamus comes from an early 
microglial activation PET study, which demonstrated an age-dependent increase in 
thalamic binding of the tracer PK11195 in healthy controls (Cagnin et al., 2001). By 
contrast, sporadic AD patients in this study showed increased regional PK11195 
binding in the entorhinal, cingulate and temporoparietal cortex.  
 
The PMC group in our study showed increased FA in bilateral thalamus and left caudate 
and, in the SMC group, increased putamen FA was seen bilaterally. FA reflects the 
degree of directionality (anisotropy) of diffusion of water molecules within a structure; 
it is therefore highest in white matter tracts, lower in grey matter and lowest in CSF. 
The anisotropy of the thalamus and striatum is probably due to their compartmentalised 
cytoarchitectural organisation, together with the large number of white matter fibres 
passing through them (Wiegell et al., 2000). Similar to our findings, a pattern of 
increased FA in the thalamus and basal ganglia has been observed in patients with 
multiple sclerosis (MS) (Ciccarelli et al., 2001, Tovar-Moll et al., 2009). It has been 
suggested that this may be due to the selective degeneration of white matter fibres 
connecting these subcortical structures with cortical areas combined with the relative 
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preservation of anisotropic intrinsic connections between the structures themselves. This 
may result in an overall increase in the FA of the subcortical structures. By the same 
presumed mechanism, increased FA was found in a group of patients with mild 
cognitive impairment compared with controls in the centrum semiovale, due to 
degeneration of association fibres of the superior longitudinal fasciculus where they 
cross with intact motor projection fibres (Douaud et al., 2011).  
 
Decreased MD and AxD were observed in the right cingulum of the PMC group, 
whereas increased MD, AxD and RD occurred in all white matter ROIs of the SMCs. 
This pattern of events also conforms with the findings of pathological studies of axonal 
damage. Axonal injury initially causes swelling, beading and fragmentation of axons 
with an associated fall in AxD, probably because intracellular diffusion is hindered by 
the damaged membranes whilst axonal swelling and beading impedes diffusion in both 
the intracellular and extracellular space (Budde and Frank, 2010). Following subsequent 
clearance of membrane fragments, the decreased axonal density permits increased 
parallel diffusion in the extra-axonal space and therefore increased AxD, together with 
increased RD secondary to myelin degradation (Song et al., 2003, Concha et al., 2006). 
In the APPsw transgenic mouse DTI study, decreased AxD was seen diffusely in the 
white matter from the time of amyloid plaque accumulation, with increased RD 
occurring in the corpus callosum at a later stage (Sun et al., 2005). Although each 
variable was examined separately the TBSS results in our study suggest a more 
prominent increase in RD than AxD in SMCs compared to controls, particularly in the 
fornix and cingulum, which may be because of this gradual transition of AxD from 
decreased to increased with advancing axonal degeneration. Other studies of early AD 
have also found more prominent increases in RD than AxD, with AxD decreased in 
some tracts (Huang et al., 2007).  
 
Several pathogenic pathways are likely to contribute to the axonal degeneration 
witnessed in AD, including defects in fast axonal transport resulting from enhanced 
production of Aβ (Kanaan et al., 2013). Neurons, having longer dendrites and axons 
than any other cell type, are particularly vulnerable to impaired fast axonal transport, 
which may be why FAD-causing mutations selectively affect neurons despite being 
ubiquitously expressed in cells throughout the body. It may also explain why short 
interneurons tend to be relatively spared in AD compared to long projection neurons 
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(Mattson and Magnus, 2006), an observation which could well underlie our finding of 
increased FA in the thalamus and caudate in presymptomatic FAD. The cingulum 
bundle, where we observed presymptomatic diffusivity changes, is composed of 
particularly long-coursing white matter tracts, arising from the thalamus, cingulate 
gyrus and cortical association areas. It is the major route for projections from the 
anterior thalamus to cingulate cortex, hippocampus and retrohippocampal regions; a 
network that is thought to play a key role in memory and spatial orientation (Neave et 
al., 1997). These cognitive functions are often impaired early in AD, perhaps because 
neurons lose their functional connections with increasing axonal damage. Eventually, 
once the damage has reached a stage where trophic signalling is no longer available, 
overt neurodegeneration may occur.  
 
A number of strands of evidence suggest that a network of limbic neurons undergoes 
selective degeneration in early AD, including PET findings of hypometabolism in the 
thalamus, mamillary bodies, hippocampus and posterior cingulate (Nestor et al., 2003). 
Along with the cingulum findings, our observation of presymptomatic thalamic atrophy 
and increased thalamic FA in FAD adds further support to this notion. The few 
pathological studies of thalamic involvement in AD have demonstrated extracellular 
amyloid deposits in almost all thalamic nuclei (Braak and Braak, 1991) and significant 
thalamic atrophy, thought largely to be due to loss of axons, dendrites and synaptic 
structures or glial cell changes (Xuereb et al., 1991).  
 
The striatum of AD patients at post-mortem has also been found to contain abundant 
amyloid deposits with loss of large cholinergic neurons (Oyanagi et al., 1987, Braak and 
Braak, 1990), which potentially underlies our findings of striatal atrophy in FAD. The 
majority of striatal nerve cells appear to resist the development of neuritic change 
(Braak and Braak, 1990) despite the presence of abundant amyloid, which is intriguing 
given that striatal involvement on PIB-PET scans is evident over a decade prior to 
symptom onset in FAD. One possible hypothesis relates to differences in mechanisms 
of calcium homeostasis in different neuronal populations. It has been found that 
Presenilins act as calcium leak channels in the endoplasmic reticulum (ER) of 
hippocampal neurons and many PSEN1 mutations impair this leak function, resulting in 
ER calcium overload and supranormal calcium release. In medium spiny striatal 
neurons (the major neuronal cell type in the striatum), the ER is much less leaky for 
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calcium and Presenilins show less involvement in calcium homeostasis (Nelson et al., 
2010).  
 
The idea that widespread white matter degeneration occurs in FAD is supported by the 
imaging findings in our SMC cohort. Volume loss of the white matter appeared to be 
more widespread than that of the grey matter in the VBM analysis, and the TBSS results 
showed very diffuse microstructural white matter abnormalities in the SMC cohort. A 
variety of PSEN1 mutations are known to be associated with spastic paraparesis and 
some individuals with the phenotype have white matter hyperintensities visible on brain 
MRI (O'Riordan et al., 2002, Ryan and Rossor, 2010). It would not, therefore, be 
surprising if microstructural damage to the white matter gave rise to more subtle 
pyramidal signs and our observation that 60% of the SMCs had lower limb spasticity 
and hyper-reflexia may well relate to this white matter pathology. It is not clear whether 
there are clinical correlates of the presymptomatic thalamic and caudate changes we 
observed. Although extrapyramidal signs, often associated with striatal pathology, were 
seen in 20% of the SMCs they were not seen presymptomatically. Presymptomatic 
myoclonus was observed, as has been detected in prior studies (Godbolt et al., 2004). 
The origin of this myoclonus is unknown but it is possible that thalamocortical networks 
are implicated, as they are in other conditions such as juvenile myoclonic epilepsy 
(Gerschlager and Brown, 2009).   
 
Neuropsychologically, the SMC cohort showed deficits in widespread domains at the 
time they were studied, with verbal recognition memory worst affected and perhaps 
some relative preservation of naming and object perception, as has been observed 
previously (Warrington et al., 2001, Godbolt et al., 2004). No significant 
neuropsychological deficits were observed in the PMC group, although 20% of these 
subjects and 60% of the SMCs had symptoms of depression and/or anxiety. Anxiety and 
depression are relatively common in both sporadic and familial AD and it is 
understandable that these symptoms may occur in PMCs who are aware of their 
mutation status and approaching the age at which they saw their parent develop 
symptoms. However, it is worth noting that limbic circuits are well known to be 
involved in emotional expression and lesions to anterior thalamic nuclei have been 
found to cause a variety of neuropsychiatric symptoms including sadness, agitation and 
flattened affect, in addition to amnesia (Schmahmann, 2003). Disentangling whether 
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presymptomatic psychiatric symptoms are related more to psychological factors or 
disease effects will require longitudinal study of large cohorts of at risk individuals, 
comprising both mutation positive and negative individuals, who are unaware of their 
mutation status but exposed to the same anxieties about the possibility of developing 
symptoms. Collaborative studies such as DIAN will be ideally placed to address these 
issues and ascertain whether our findings are reproducible in larger FAD cohorts. The 
relatively small number of subjects was an important limitation of our study, as it limits 
power and may have accounted for the fact that reduced thalamic volume and increased 
caudate FA only reached statistical significance on the left in the PMC ROI analysis. 
Larger cohorts will be required to investigate whether the onset of subcortical imaging 
changes is indeed asymmetrical.  
 
In summary, we demonstrated presymptomatic thalamic and caudate volume loss and 
increased FA, with decreased mean diffusivity in the right hippocampus and cingulum, 
in PSEN1 MCs who were approximately 5.6 years from expected age at onset. We 
propose that axonal degeneration is an early event in FAD pathogenesis and that 
amyloid accumulation, atrophy and diffusivity changes are seen early on in the thalamus 
and striatum due to the large number of white matter tracts that these structures are 
connected with. Involvement of a subcortical structure like the thalamus, which forms a 
key node in a vulnerable neuronal network, could potentiate the propagation of 
pathology through that network. The most striking degeneration may then be observed 
in connected neuronal populations, such as those of the hippocampus. How 
generalizable our findings are to sporadic AD is an important question. There is some 
evidence of early white matter tract degeneration in sporadic AD from DTI studies of 
MCI (Chua et al., 2008, Stebbins and Murphy, 2009) and thalamic atrophy has also 
been demonstrated in MCI (Pedro et al., 2012). In healthy controls at increased risk of 
sporadic AD due to possession of an APOE4 allele, decreased FA has been found in 
several white matter tracts including the cingulum (Smith et al., 2010) and volume loss 
of the hippocampus, but not thalamus or striatum, has been observed (O'Dwyer et al., 
2012). The same neuronal network appears to disintegrate in both sporadic and familial 
AD but it may be that different nodes of this circuit are particularly vulnerable to 
different risk factors for the disease. The development of more sensitive diffusion 
imaging techniques such as high-angular-resolution diffusion imaging (HARDI) 
(Haroon et al., 2011) and neurite orientation dispersion and density imaging (NODDI) 
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(Zhang et al., 2012), and their application to the longitudinal study of individuals at risk 
of both familial and sporadic AD, may allow us to further investigate just how early 
microstructural abnormalities become evident and when is the optimal time for 
therapeutic intervention. 
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7 Thesis summary and conclusions 
 
7.1 Summary 
 
This thesis describes studies of FAD undertaken with the broad objectives of 
investigating heterogeneity in the clinical and neuroimaging features of FAD, and 
exploring imaging changes in the preclinical phase of FAD, in order to gain insights 
into underlying disease mechanisms. The work was strongly motivated by the launch of 
presymptomatic treatment trials for FAD, which necessitate characterisation of the full 
clinical spectrum of the disease, investigation of factors contributing to phenotypic 
heterogeneity and identification of presymptomatic biomarkers of the disease. In this 
final chapter, the main findings of the thesis are described and discussed, along with 
limitations of the studies, implications for clinical practice and future directions for 
FAD research.  
 
Introductory chapters 1 and 2 reviewed the literature on the clinical phenotype of FAD 
and on imaging biomarkers of AD, particularly presymptomatic FAD. In chapter 3, the 
clinical spectrum of FAD was investigated through analysis of all symptomatic cases 
studied at our centre since identification of the first mutation twenty-five years ago. 
Significant phenotypic differences between individuals with PSEN1 and APP mutations 
were identified, highlighting the potential importance of considering these genetic 
groups separately in clinical research and trials. In addition to having younger ages at 
symptom onset, PSEN1 mutation carriers were much more likely to have a non-
amnestic cognitive presentation, which occurred in 16% of PSEN1 cases. Additional 
neurological features of pyramidal, extrapyramidal and cerebellar signs were only 
observed in the PSEN1 group and there could be considerable phenotypic variability 
between different PSEN1 mutations. Atypical cognitive presentations, pyramidal signs 
and later ages at symptom onset were seen more frequently in association with PSEN1 
mutations located beyond codon 200. A previous study had reported that 
neuropathological differences may also be evident between PSEN1 mutations located 
before and after codon 200, with more severe CAA seen in association with post codon 
200 mutations (Mann et al., 2001). In chapter 4, potential differences between pre and 
post codon 200 PSEN1 mutations were further investigated with an imaging study of 
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white matter hyperintensities (WMH) on MRI, which are a key imaging manifestation 
of CAA. This study demonstrated increased posterior WMH in the PSEN post-codon 
200 mutation group and found that, in the subset of cases with post-mortem 
examination, WMH burden correlated with the severity of CAA and cotton wool plaque 
pathology. In contrast, the PSEN1 pre-codon 200 group had younger ages at onset and 
greater axonal loss, gliosis and T-lymphocytic response in the deep white matter. These 
studies demonstrate that mutation site contributes to the phenotypic and pathological 
heterogeneity witnessed in FAD and motivate future work investigating functional 
differences between mutations at different sites of PSEN1. Chapter 5 continued to 
explore the topic of CAA in FAD with reference to ‘ARIA’, the term coined to describe 
amyloid-related imaging abnormalities’ of microbleeds (ARIA-H) on T2*-GRE MRI 
and oedema or extravasated fluid on T2-FLAIR MRI (ARIA-E), which have been 
observed in amyloid-modifing therapy trials for AD and are thought to reflect vascular 
amyloid. A study of microbleeds in symptomatic subjects with FAD mutations is 
described, which is the first to assess the prevalence of microbleeds in FAD and finds 
this to be similar to that reported in sporadic AD. The first reported case of ARIA-E 
developing spontaneously during the course of PSEN1-associated FAD is then 
presented. The post-mortem findings of CAA-related inflammation (CAA-ri) in this 
case add further support to a growing body of literature linking CAA-ri to ARIA, and 
suggest that APOE4 homozygosity and a post-codon 200 PSEN1 mutation may have 
rendered the individual particularly vulnerable to developing this complication. 
Monitoring for ARIA and identifying risk factors for their development will form a 
crucial part of preclinical treatment trials for FAD. These trials drive a need to better 
understand the trajectory of biomarker changes prior to symptom onset in FAD and 
Chapter 6 investigates volumetric and diffusivity changes in subcortical grey matter 
structures and their connecting white matter tracts in presymptomatic and symptomatic 
mutation carriers. The thalamus and striatum are included as regions of interest as they 
show early amyloid deposition in FAD and the study finds that they do indeed 
demonstrate atrophy and altered diffusivity in the presymptomatic phase. Altered 
diffusivity in the cingulum and hippocampus are also seen, but at a stage when 
hippocampal atrophy is not evident. Axonal degeneration may therefore be an early 
event in presymptomatic FAD and it may be owing to their dense connectivity that 
imaging changes are seen first in the thalamus and striatum, which then progress to 
involve other regions in a vulnerable neuronal network. 
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7.2 Imaging manifestations of familial Alzheimer’s disease pathology 
 
Work described in this thesis contributes to a growing interest in the imaging 
manifestations of AD pathology, particularly in the preclinical stage of the disease, and 
highlights a number of unresolved issues. Firstly, brain atrophy on MRI is typically 
thought to be a biomarker of neuronal loss, which is considered to be a very 
downstream element in the amyloid cascade hypothesis of AD pathogenesis. Our 
finding of caudate and thalamic atrophy in presymptomatic FAD mutation carriers, at a 
stage when hippocampal atrophy was not yet evident, therefore raises a number of 
questions. What is the relationship between this atrophy and the early striatal and 
thalamic amyloid deposition observed on PIB-PET imaging of FAD mutation carriers? 
Does the atrophy represent neuronal injury induced by amyloid or by amyloid 
independent mechanisms? Is the atrophy due to neuronal injury at all, or does it reflect 
non-neuronal cellular changes, for example involving the glia? Furthermore, our 
observations highlight the broader issue that it is not yet clear what pathological 
processes do account for the volume or other MRI-based changes that may be witnessed 
in the presymptomatic phase of AD. Whilst there are numerous clinicopathological 
studies correlating atrophy on MRI with neuronal loss, Braak neurofibrillary tangle 
stage and tau burden in patients with established symptomatic AD (Zarow et al., 2005, 
Whitwell et al., 2008) this information is lacking for the presymptomatic stage. Various 
different processes may give rise to changes in the volume of brain structures, some of 
which may be dynamic. There may potentially be both increases in volume (for 
example, relating to inflammation) and decreases in volume (for example, due to 
neuronal loss), and this uncertainty should be taken into account in hypothetical 
biomarker models of presymptomatic AD. 
 
I speculate in chapter 6 that axonal injury and subsequent degeneration may account for 
the thalamic and caudate atrophy observed in our cohort of presymptomatic mutation 
carriers. Support for this hypothesis came from the associated changes in diffusivity 
indices found in these subcortical grey matter structures and in the cingulum and from 
one of the few autopsy studies to have specifically examined the thalamus in AD 
(Xuereb et al., 1991). Xuereb et al. noted that, although there was significant loss of 
thalamic volume in cases with Alzheimer’s disease, the amount of neuronal loss was 
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insufficient to account for the degree of atrophy. They suggested that the atrophy must 
instead be due to loss of axons, dendrites and synaptic structures or to glial cell changes. 
In the Discussion of chapter 6, I mainly focused on the potential role that axonal 
degeneration may play in the development of subcortical atrophy. However, it is also 
important to consider the possibility that glial cell changes may contribute to the 
volumetric MRI changes evident in presymptomatic FAD. Studies in a triple transgenic 
mouse model of AD have revealed complex changes in astroglial morphology during 
the early stages of the disease. Prior to the appearance of neuritic amyloid plaques 
hippocampal astrocytes have been observed to undergo atrophy, but once the plaques 
arise, those in close vicinity become gliotic whilst those further away remain atrophied 
(Olabarria et al., 2010). One can envisage that altering glial numbers or morphology 
might be reflected in dynamic changes in the volume and diffusion characteristics of the 
affected brain structures when studied with MRI at different time-points in the 
presymptomatic stage. If immune-mediated mechanisms do play a role that is reflected 
in dynamic regional brain volume changes this could therefore potentially explain the 
contrasting findings from a previous study of caudate enlargement in presymptomatic 
FAD mutation carriers (Fortea et al., 2010). A recent longitudinal multitracer PET 
imaging study of FAD mutation carriers offers some indirect support for this idea 
(Rodriguez-Vieitez et al., 2016). Astrocytosis was measured using the PET tracer 11C-
deuterium-L-deprenyl (11C-DED), which binds specifically to monoamine oxidase B 
(MAOB) located primarily in activated astrocytes. In this study, striatal amyloid 
deposition detected using PIB-PET imaging was evident approximately 17 years prior 
to expected age at symptom onset in mutation carriers, with astrocytosis significantly 
elevated around this time. With disease progression, there was an increase in amyloid 
deposition accompanied by a decline in astrocytosis, with the steepest decline in 
astrocytosis observed in the caudate and thalamus (Rodriguez-Vieitez et al., 2016). 
 
Another important question that follows on from our work is how specific to the 
autosomal dominant familial form of AD are early striatal and thalamic imaging 
changes and, if they are not such a feature of sporadic AD, what may these differences 
in the topography of pathology teach us about differences in the underlying disease 
process? It is logistically harder to study the preclinical stage of sporadic AD as 
individuals who will go on to develop the disease could not, until recently, be identified 
with a high degree of certainty. However, some studies of MCI patients who 
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subsequently converted to AD have demonstrated atrophy of the thalamus (Morbelli et 
al., 2010, Dukart et al., 2013) or caudate (Liu et al., 2010, Madsen et al., 2010), but at a 
stage when volume loss involving the hippocampus and/or parahippocampal cortex was 
also evident. Similarly, striatal amyloid deposition has been seen on PIB-PET imaging 
of MCI patients who subsequently converted to AD (Koivunen et al., 2011, Koivunen et 
al., 2012) and of cognitively normal APOE4 carriers with a family history of AD 
(Reiman et al., 2009), but the striatal deposition has not appeared to be more prominent 
than the amyloid deposition also observed in cortical areas in these subjects. In contrast, 
individuals with Down syndrome, who invariably develop AD pathology if they live 
long enough, have been found to have prominent early striatal amyloid deposition on 
PIB-PET imaging (Handen et al., 2012, Lao et al., 2016). In Down syndrome, the 
striatum is the first brain region to become PIB-positive, at around 40 years of age, and 
the appearance of abnormal PIB retention is strongly associated with cognitive decline 
(Annus et al., 2016). The long period of latency between the appearance of striatal 
amyloid and the onset of clinical symptoms seen in FAD due to autosomal dominant 
mutations may be reduced in Down syndrome, and it has been speculated that this may 
relate to reduced cognitive reserve in these individuals (Annus et al., 2016). 
 
In FAD due to autosomal dominantly inherited mutations and Down syndrome the 
presumed shared mechanism of amyloid deposition is overproduction of longer 
aggregation-prone species of Aβ, whereas impaired clearance may be a more relevant 
mechanism in sporadic AD. The striatal predominance on amyloid imaging studies of 
FAD and Down syndrome but not sporadic AD suggests that the striatum may be 
particularly vulnerable to developing amyloid deposition in conditions of 
overproduction. To investigate this issue, enzyme-linked immunosorbent assays 
(ELISA) have been used to assess the regional distribution of Aβ accumulation and 
molecules related to Aβ metabolism in post-mortem brain tissue from individuals with 
familial and sporadic AD (Shinohara et al., 2014). This study found that there was 
disproportionate accumulation of Aβ42 in subcortical areas in FAD compared with 
sporadic AD and that in FAD, the regional pattern of Aβ42 deposition correlated with the 
normal distribution of APP and β-C-terminal fragment of APP. Disproportionate 
accumulation of tau was also observed in the striatum in FAD compared with sporadic 
AD. As the authors of this study speculate, this may suggest that the regional 
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distribution of APP and its processing drives the disproportionate subcortical 
accumulation of Aβ42 and subsequently tau in FAD (Shinohara et al., 2014).  
 
There have been relatively few detailed histopathological studies of thalamic and striatal 
involvement in AD. Those that have focussed on the thalamus have shown that 
extracellular amyloid deposits are observed in almost all thalamic nuclei and that the 
thalamus undergoes significant atrophy in AD, but that the only nucleus to show 
striking nerve cell loss is the anterodorsal nucleus (Braak and Braak, 1991, Xuereb et 
al., 1991). In addition to being the only thalamic nucleus to show nerve cell loss, the 
anterodorsal nucleus appears to be the most severely affected by neurofibrillary tangles. 
This nucleus receives its main input from the subiculum; both directly through the 
fornix and indirectly via the mamillothalamic tract, it projects to the retrosplenial limbic 
area, which in turn projects to the presubiculum. The entorhinal region receives 
presubicular inputs and itself projects to the hippocampus. The anterodorsal nucleus 
therefore occupies a central role in the so-called circuit of Papez. A key unresolved 
question for future research is what renders the neurons in this network vulnerable to 
AD and, in the case of the thalamus, why does neurofibrillary tangle formation and cell 
loss only occur in certain nuclei when amyloid deposits are seen so diffusely? Recent 
work has demonstrated further how the pattern of neurofibrillary tangle pathology in the 
thalamus reflects the nuclei with reciprocal projections to the hippocampus and in fact 
mirrors the distribution of cytoskeletal pathology in interconnected cortical areas (Rub 
et al., 2016). Limbic nuclei of the thalamus were consistently found to have severe tau 
immunoreactive cytoskeletal pathology in AD, whilst nuclei involved in associative 
networks were only mildly affected and motor and sensory nuclei tended to be spared 
(Rub et al., 2016). Studies of the striatum have also found that regions connected with 
the limbic system seem to be particularly vulnerable to AD pathology. Amyloid 
deposits are abundant in the striatum of AD patients but are mainly diffuse and non-
neuritic (Braak and Braak, 1990). The density of diffuse plaques has been found to be 
consistently higher in the caudal putamen, which connects with limbic and prefrontal 
regions, than in the rostral putamen, which receives input from sensorimotor cortex 
(Brilliant et al., 1997). Compact amyloid deposits and dystrophic neurites, when 
present, tend to be concentrated in the ventral striatum, which receives dense projections 
from the amygdala and hippocampus (Suenaga et al., 1990).  
 
 157 
7.3 White matter involvement in familial Alzheimer’s disease 
 
Observations from post-mortem studies add support to the idea that AD should perhaps 
be viewed as a network disorder in which there is selective degeneration of vulnerable 
neuronal circuits, with critical involvement of the limbic thalamus (Aggleton et al., 
2016). The notion that neurodegenerative diseases result from disintegration of 
distributed neural networks is a popular theme in contemporary neuroscience. The term 
‘molecular nexopathy’ has been proposed to describe the conjunction of pathogenic 
protein and intrinsic network characteristics that may give rise to the specific network 
involvement of different neurodegenerative diseases (Warren et al., 2013). According to 
this paradigm, pathogenic proteins may promote degeneration of a neuronal network by 
a variety of different mechanisms including disrupting the function or maintenance of 
synapses, disturbing axonal transport or repair and interfering with cellular signalling or 
trophic support. The resulting disease effects depend on specific characteristics of the 
network involved, such as patterns of protein expression or the nature of interactions 
across neuronal circuits. For example, short-range dendritic or interneuronal 
connections may be particularly vulnerable to certain molecular insults whilst long-
range widely distributed projections may be more sensitive to others. Long-coursing 
white matter tracts appear to be particularly sensitive to defects in axonal transport and 
it has been shown in transgenic animal models that intraneuronal accumulation of Aβ 
not only triggers neuronal loss but also causes an axonopathy with disturbed neuronal 
trafficking, which is apparent even when signs of tau pathology are absent (Wirths et 
al., 2006). White matter tract degeneration may therefore be an early event in AD 
pathogenesis; a hypothesis that is supported by our finding of altered diffusivity in the 
cingulum in presymptomatic PSEN1 mutation carriers, reported in chapter 6 (Ryan et 
al., 2013). Altered white matter integrity has also been found in cognitively normal 
individuals who have evidence of presymptomatic amyloid pathology: amyloid 
deposition on PIB-PET imaging (Rieckmann et al., 2016) or reduced CSF Aβ42 
(Molinuevo et al., 2014). A variety of different mechanisms may contribute to white 
matter damage in AD, including neuroinflammation, microvascular changes and 
Wallerian degeneration. The relative importance of these different processes and the 
temporal relationship between degeneration of grey matter regions and their associated 
white matter tracts is still a matter of debate. What is clear, however, is that AD is not 
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exclusively a grey matter disease and that white matter degeneration is a feature of both 
familial and sporadic AD. Furthermore, microstructural damage to the white matter 
revealed by DTI typically appears to be far more extensive than may be expected based 
on the degree of cortical atrophy (Caso et al., 2015, Caso et al., 2016).  
 
With increased appreciation of the importance of white matter pathology, there has been 
growing interest in the role of white matter hyperintensities (WMH) in the disease. It 
has long been recognised that WMH on MRI are associated with increased risk, and 
progression, of AD in sporadic disease, although typically they are thought to reflect 
atherosclerotic small vessel disease and had historically been presumed to contribute to 
cognitive impairment in an independent albeit additive manner. However, the study 
described in chapter 4 of this thesis contributes to a growing body of evidence that 
WMH can reflect AD pathology (Ryan et al., 2015). Further supporting this notion, a 
large study from the Dominantly Inherited Alzheimer Network (DIAN) has recently 
reported greater WMH burden (volume of WMH) in FAD mutation carriers; WMH 
burden appears to increase around six years prior to expected age at symptom onset 
(Lee et al., 2016). As in our data, these effects were most prominent in the parietal and 
occipital lobes, raising the possibility that they reflect CAA, which shows a predilection 
for posterior brain regions. The precise pathological basis for WMH in CAA remains 
undetermined and is likely heterogeneous. As the increased signal on T2 or FLAIR MRI 
that accounts for WMH simply represents an increase in free tissue water content, it 
may have a variety of pathological substrates, including loss of axons and myelin, 
dilated perivascular spaces and gliosis. One hypothesis is that WMH arise because 
damage to small medullary perforating arteries results in ischaemic injury and blood-
brain barrier breakdown in the vulnerable deep white matter regions that they supply. 
Another explanation that has been proposed is that WMH reflect impaired perivascular 
drainage of interstitial fluid from the white matter, due to deposition of Aβ in the 
basement membranes of cerebral arteries (Weller et al., 2015).  APOE is thought to act 
as a transport molecule for Aβ and there is some evidence that Aβ transport along 
perivascular pathways is less efficient in the presence of APOE4 than APOE3 (Hawkes 
et al., 2012), potentially explaining why APOE4 carriers appear to have more severe 
CAA and are therefore more susceptible to side-effects from therapeutic efforts to 
remove Aβ from the brain.  
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7.4 Heterogeneity in the familial Alzheimer’s disease phenotype 
 
Interest in how genetic variability within FAD influences heterogeneity in the 
neuropathological, imaging and clinical manifestations of the disease has emerged as a 
central theme of this thesis. One of the benefits of studying individuals with FAD is 
that, as they are generally young, they tend not to have major co-morbidities or 
significant cerebrovascular disease due to conventional vascular risk factors, which can 
impact upon the clinical presentation. One therefore has the opportunity to study “pure” 
disease, and phenotypic differences observed between carriers of different mutation 
types may offer genuine insights into differences in underlying disease mechanism. For 
example, a striking difference that we observed in the clinical phenotype of FAD due to 
autosomal dominant APP and PSEN1 mutations was that spastic paraparesis only 
appears to develop in association with PSEN1 mutations. This was the case in the study 
of our FAD cohort reported in chapter 3 of this thesis (Ryan et al., 2016) and also in a 
systematic review of the world literature (Shea et al., 2015). APP and PSEN1 mutations 
share a common underlying disease mechanism of causing qualitative shifts in the Aβ 
profiles generated from APP and, if this process underpinned the pathogenesis of spastic 
paraparesis, one might expect that this neurological sign would sometimes be seen in 
the context of APP mutations. On the other hand, some mutations in PSEN1 (but not 
APP) appear to affect processing of substrates in addition to APP (Chavez-Gutierrez et 
al., 2012) so a possible hypothesis for the specific association of spastic paraparesis 
with PSEN1 mutations is that it results from effects of PSEN1 mutations on substrates 
other than APP. Our observation that spastic paraparesis shows a particular association 
with mutations involving exon 8 of PSEN1 further supports this idea as the residues 
encoded by exon 8 lie in the region of PSEN1 where the cleavage site processed by 
autocatalytic activity resides. Additional substrates of PSEN1, such as Notch, N-
cadherin, ErbB4 and the B cell maturation antigen (BCMA), are involved in diverse 
physiological processes including myelination, vascular and immune function. 
Perturbation of the processing of these additional substrates in the context of a PSEN1 
mutation could, therefore, well be envisaged to have detrimental effects upon the white 
matter.  
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7.5 Limitations  
 
In drawing conclusions from the work presented in this thesis, it is important to consider 
potential limitations of the studies undertaken. In chapter 3 I investigated the clinical 
phenotype of autosomal dominant FAD in a large UK case series, which included 
patient data gathered since identification of the first mutation over 25 years ago. 
Although this is, to our knowledge, one of the largest single centre studies of FAD, 
which included families recruited from across the UK and Ireland, it is possible that 
some atypical phenotypes may not have been seen due to ascertainment issues. As our 
clinical and research centre specialises in young onset dementia, we may not have been 
referred individuals with more atypical phenotypes such as presentation with movement 
disorders, stroke or late onset cognitive symptoms. Nonetheless, having demonstrated 
the wide clinical spectrum of familial Alzheimer’s disease (Ryan et al., 2016), we hope 
that our work will contribute to increased awareness amongst clinicians of the possible 
atypical presentations of the disease. With increased genetic testing for FAD mutations 
in patients with atypical dementia syndromes, we may find that the phenotype broadens 
further. 
 
An important limitation of the imaging studies reported in this thesis was the relatively 
small number of subjects, particularly for the studies that utilised newer MR 
acquisitions of T2*-GRE and diffusion tensor imaging. This is an inevitable issue when 
studying a rare genetic condition and is the motivation for our current international 
collaboration with other centres in the DIAN study. Despite the small number of 
subjects, the imaging studies reported in this thesis have demonstrated a number of 
insights into FAD, which have subsequently been replicated in larger studies utilising 
DIAN data. Our finding of presymptomatic thalamic atrophy, reported in chapter 6 
(Ryan et al., 2013), was followed by a voxel-based morphometry study of the DIAN 
cohort demonstrating a trend for decreased grey matter in the thalamus for mutation 
carriers closer to their expected age at onset (Cash et al., 2013). Both of these studies 
have the limitation that parental age at onset was used to estimate how far from 
symptom onset the mutation carriers were. Although age at onset does correlate with 
parental age at onset, there can be substantial variation in some families (Ryman et al., 
2014), so it is important to remember that this metric does only provide an estimate of 
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how far through the preclinical stage an individual is at the time of scanning. 
Longitudinal studies that follow mutation carriers long enough to ascertain their actual 
age at symptom onset will be important to understand the time course of 
presymptomatic volumetric changes in more detail. The other finding reported in this 
thesis (chapter 4), which has subsequently been replicated in DIAN data, is that 
autosomal dominant FAD can be associated with prominent white matter 
hyperintensities (WMH), particularly in a parieto-occipital distribution (Ryan et al., 
2015, Lee et al., 2016). Our study was a retrospective analysis of all FAD mutation 
carriers who had undergone appropriate imaging for the assessment of WMH. As this 
included data collected over a long period of time, a limitation was that there was some 
variability in the scanning sequences used. However, a strength was that some of the 
more historical cases had subsequently undergone post-mortem examination, allowing 
correlation of imaging and pathological features.  
 
7.6 Clinical implications  
 
Research reported in this thesis has a number of important clinical implications. Our 
observation of the wide clinical spectrum of autosomal dominant FAD, presented in 
chapter 3, highlights the importance for clinicians of considering genetic testing in 
young patients with dementia and additional neurological features, particularly when 
there is a family history or when the family history is censored. Furthermore, our 
findings reported in chapter 4 indicate that the appearance of prominent WMH on 
imaging should alert a clinician to the possibility of FAD, particularly if vascular risk 
factors are lacking. As discussed in chapter 5, MRI with gradient echo (T2*-GRE) 
sequences can provide valuable additional information in the investigation of patients 
with young onset dementia as the presence of cortical microbleeds may indicate that 
there is underlying CAA and that testing for FAD mutations is warranted. However, as 
microbleeds only appear to be present in around 25% of patients with familial or 
sporadic AD, their absence should not dissuade a clinician from making a diagnosis of 
AD.  
 
Findings presented in this thesis also highlight some potential problems that may arise 
in patients with established FAD, which clinicians should be aware of in order to allow 
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appropriate investigation and management. Seizures were found to be relatively 
common, affecting around a quarter of individuals with APP or PSEN1 mutations in our 
cohort. In both genetic groups, individuals with myoclonus were significantly more 
likely to develop seizures than those without myoclonus, highlighting the importance of 
being vigilant for symptoms of seizure activity when myoclonus is present. In chapter 5, 
I reported a case of ARIA-E arising during the course of FAD and argued that these 
imaging changes may have reflected the development of CAA-related inflammation 
(CAA-ri), and that this should be further evaluated as a possible cause of sub-acute 
deterioration in patients with established AD. Recent work focussed on characterising 
patients with the spontaneously occurring condition CAA-ri has validated clinico-
radiological criteria and emphasised the importance of making this diagnosis in clinical 
practice due to the high response rate to prompt immunosuppressive treatment (Auriel et 
al., 2016). An important direction for future research will be to investigate possible 
areas of overlap and difference in the pathogenic mechanisms underlying CAA-ri and 
the ARIA that have been observed in AD immunotherapy trials and, more rarely, have 
arisen spontaneously during the natural history of sporadic or familial AD.  
 
Finally, our imaging findings of early thalamic atrophy and white matter involvement in 
FAD may have clinical implications regarding the neuropsychological tests that are 
used in clinical and research assessments of individuals at risk of FAD. The imaging 
evidence that these areas of the brain undergo changes during the presymptomatic phase 
indicates that sensitive assessment of the cognitive functions they subserve may be 
needed in order to detect subtle signs of clinical impairment. In this context, it is 
noteworthy that a study reporting the baseline neuropsychological characteristics of 
individuals in the DIAN study found that performance by cognitively normal mutation 
carriers who were closer to their expected age of symptom onset was poorer on both 
immediate and delayed recall of logical memory, the digit symbol test and the switch 
block of trials from a test of attention (Storandt et al., 2014). These test scores may be 
capturing subtle deficits in episodic memory, speed of cognition and executive function 
respectively, perhaps reflecting early pathological involvement of subcortical regions 
and/or white matter in addition to the hippocampus. In further work, it would be 
interesting to investigate potential correlations between these separate 
neuropsychological tests scores and different imaging measures such as hippocampal, 
thalamic and WMH volume and DTI metrics. Reliable automated methods for 
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segmenting WMH have now been developed (Sudre et al., 2015), and it is increasingly 
feasible to analyse longitudinal data quantitatively in order to study the relationship 
between WMH accrual and the progression of regional brain volume and cognitive 
changes in presymptomatic FAD. 
 
7.7 Directions for future research 
 
Work reported in this thesis opens up a number of different avenues for future research. 
From an imaging perspective, it would of great interest to further investigate the 
thalamic atrophy we observed in presymptomatic FAD mutation carriers by examining 
whether volume loss is driven by loss of grey or white matter and whether specific 
nuclei show differential involvement on imaging, as has been indicated by studies of 
post-mortem tissue. Advances are being made in multi-modal segmentation techniques, 
which incorporate information from both T1 MRI and diffusion-weighted imaging, in 
order to segment and parcellate structures of interest like the thalamus and it’s 
constituent nuclei and white matter tracts (Stough et al., 2014). Furthermore, advanced 
diffusion MRI techniques such as neurite orientation dispersion and density imaging 
(NODDI) are allowing the microstructural complexity of neurites to be probed in 
greater detail (Zhang et al., 2012). Applying such methods to the study of 
presymptomatic FAD would be an exciting direction for future research. This would be 
particularly informative if the same participants were to also undergo molecular 
imaging of amyloid and tau deposition using PET. Insights into the temporal and spatial 
relationships between amyloid and tau deposition in presymptomatic FAD will be 
anxiously awaited by the field. Ultimately, it is likely to be the longitudinal analysis of 
multiple time-point multimodal data and ascertainment of rates of change that will 
reveal the most information about underlying pathological mechanisms. 
 
Further investigation of the neuropathological and molecular mechanisms 
underlying phenotypic variability between different mutations is another important 
direction for future work.  Forty-three FAD patients from families assessed at the 
Dementia Research Centre have now come to post-mortem, providing a unique 
opportunity to investigate neuropathological underpinnings of phenotypic 
heterogeneity. We plan to assess how the severity and type of amyloid plaque 
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(cored, diffuse and cotton wool), CAA (cortical and leptomeningeal), tau pathology, 
white matter degeneration (axonal loss and demyelination) and microglial response 
varies between different PSEN1 and APP mutations and whether these pathological 
features associate with particular mutation positions, APOE genotypes, disease 
duration, age at symptom onset and specific neurological features such as spastic 
paraparesis. It will also be of interest to analyse whether different plaque species 
observed in FAD are associated with specific Aβ isoform profiles, whether these 
vary between different brain regions and how they relate to clinical presentation. 
 
Future studies of the molecular mechanisms involved in FAD will be aided by, and 
may further inform, recent developments in our understanding of the function and 
atomic structure of gamma-secretase (Bai et al., 2015, Szaruga et al., 2015). In 
chapter 3, our exploration of clinical heterogeneity between different PSEN1 
mutations suggested that mutation position may have an influence on phenotype. 
Particularly early ages at onset were observed for a cluster of mutations before 
codon 200 involving PSEN1’s first hydrophilic loop, which is known to contribute 
to the carboxypeptidase-like activity of PSEN1 that alters Aβ profiles. Mapping 
mutations to the 3-dimensional structure of PSEN1 could extend these observations 
further. This would allow visualisation of whether mutations associated with 
particularly early onset of disease do indeed involve the site where Aβ undergoes 
successive carboxypeptidase cleavages when the protein takes up its 3-dimensional 
conformation. We also found that atypical cognitive presentations and spastic 
paraparesis were associated with PSEN1 mutations beyond codon 200, particularly 
involving exon 8. I speculated that this may relate to involvement of this region of 
PSEN1 in the endopeptidase activity of gamma-secretase, which processes APP and 
a variety of substrates. In future experimental work, this hypothesis could be tested 
by analysing how different PSEN1 mutations impact upon gamma-secretase 
processing of a variety of substrates. Detergent resistant membranes (DRMs) 
prepared from brain tissue are a source of gamma-secretase for in vitro activity 
assays where, importantly, the lipid composition of its native environment (the 
membrane) is maintained. Analysing gamma-secretase activity in brain tissue from 
individuals who manifested specific phenotypic features during life may therefore 
offer valuable insights into how different mutations alter processing of APP and 
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other substrates (Szaruga et al., 2015). Gamma-secretase processing can also be 
analysed in DRMs extracted from induced pluripotent stem cell-derived neurons, 
which have been generated from patient fibroblasts. We have been developing a 
unique resource of skin biopsies harvested from individuals with FAD mutations to 
establish fibroblast cell lines carrying specific PSEN1 and APP mutations (Wray et 
al., 2012). This will allow future investigation of numerous processes, including 
differential Aβ isoform production and gamma-secretase processing of substrates 
involved in myelin repair, vascular and immune function in cells derived from FAD 
patients with specific clinical and pathological features.  
 
7.8 Implications for clinical trials 
 
As discussed in the opening chapter of this thesis, FAD families have played a profound 
role in shaping the concept of AD that exists today, with the discovery of an APP 
mutation as the first genetic cause of AD contributing to the “amyloid cascade 
hypothesis” of AD pathogenesis (Ryan et al., 2015). However, as also discussed in 
chapter 1, concepts of disease are dynamic and constantly evolving; influenced by 
developments in the forms of knowledge and technology available at the time and by 
the objectives of the various groups in society who are interested in a disease. The 
amyloid cascade hypothesis, which posits that Aβ accumulation is the initiating event in 
AD pathogenesis and direct cause of progressive neurodegeneration, has provided the 
main theoretical foundation for AD research for over 20 years. It has also motivated, 
and continued to justify, ongoing efforts by the pharmaceutical industry to develop 
drugs targeting Aβ, with the hope that removing Aβ from the brain may slow or prevent 
neurodegeneration. A series of high profile drug trial failures, most recently of 
Solanezumab in patients with mild AD, have fostered the view that treatment may need 
to be extremely early in the disease process in order to be effective and results from the 
ongoing DIAN-TU (currently of Solanezumab and Gantenerumab in presymptomatic 
and mildly affected FAD mutation carriers) will be anxiously awaited. With the 
disappointing results of AD immunotherapy trials, some researchers have urged the 
field to take a more holistic view of the disease. Arguing that the model provided by the 
amyloid cascade hypothesis is too linear and neuron-centric, they have called for a shift 
in focus towards the prodromal “cellular phase of AD”, when complex responses and 
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interactions between neuronal networks, microglia, astroglia, oligodendrocytes and the 
vasculature allow the brain to compensate for decades until homeostasis can no longer 
be maintained and the clinical phase of the disease ensues (De Strooper and Karran, 
2016). In this view, Aβ and tau accumulation would be considered risk factors; 
proteopathic stressors that initiate the cellular phase of AD, in which additional cellular 
factors then determine evolution towards the clinical phase. The hope is that studying 
AD from this conceptual framework could shed light on new drug targets in addition to 
Aβ, with the possibility that multiple therapeutic strategies may be needed to address 
different aspects of the disease.  
 
7.9 Applying findings from familial Alzheimer’s disease to sporadic 
Alzheimer’s disease 
 
Some might argue that a theoretical construct for AD that moves focus beyond the 
amyloid cascade hypothesis might challenge the idea that familial cases represent a 
paradigm for AD. On the contrary, work presented in this thesis highlights the degree of 
heterogeneity that exists within FAD and the possible contributions of diverse 
processes, including white matter degeneration, vascular and immune responses, to 
clinical presentation. Observations from FAD may not always necessarily generalise to 
sporadic AD. However, sporadic AD is itself a heterogeneous disease. Gaining insights 
into the variable mechanisms by which different FAD mutations cause disease may 
therefore have relevance for understanding clinical and pathological heterogeneity in 
sporadic AD. It may also have relevance for the interpretation of FAD treatment trials 
as different mutations may vary in their response to certain therapeutic interventions. 
Moreover, investigating the influence of genotype on neuropathological, neuroimaging 
and clinical manifestations of disease may potentially inform our understanding of 
factors influencing the efficacy, and associated risks, of different treatment strategies in 
sporadic AD. 
 
In future work, in order to further explore a more holistic conceptualisation of AD that 
gives prominence to a prodromal “cellular phase”, it will be important to study FAD 
mutation carriers with a variety of biomarkers in addition to amyloid and tau imaging 
and CSF measures of amyloid and tau. Advances in technology often lay the ground for 
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new ways of thinking about diseases. For example, DTI is now allowing AD to be 
studied as a disorder of distributed neuronal networks and, with increasing 
methodological developments, it may allow us to gain deeper insights into the nature of 
microstructural change in different cellular compartments. Work described in this thesis 
has demonstrated how a variety of MRI sequences can shed light on different aspects of 
AD pathogenesis and multi-modal MRI is likely to continue playing a central role in the 
investigation of presymptomatic AD. Given that immune and vascular mechanisms 
appear to be involved in both the early disease process, and in strategies used to combat 
it with amyloid-immunomodulatory agents, particular effort should perhaps be invested 
in understanding how such processes can be imaged, and how they affect other imaging 
biomarkers. A variety of techniques may play a role here including microglial and 
astrocyte activation studies, as may the insights gained from imaging of animal models. 
Much valuable work has been done to formulate hypothetical models of AD biomarkers 
using evidence gathered from studies of sporadic AD, MCI and normal ageing (Jack et 
al., 2013), but we must keep an open mind to the complex and potentially unpredictable 
changes that may occur during the prodromal phase of AD. The challenge now is to use 
longitudinal studies of FAD mutation carriers, combined with insights from 
neuropathology and molecular biology, to better understand the temporal evolution of 
biomarker changes during the whole natural history of FAD, so that hypothetical 
models may be further refined and the optimal time for therapeutic intervention may be 
guided. 
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11 Appendix 
11.1 Neurological presentations of familial Alzheimer’s disease 
Neurological symptoms and signs occur commonly in FAD and may, more rarely, 
represent the initial clinical features. This table summarises mutations that were 
reported to present with neurological features, identified from a literature review 
undertaken when work towards this thesis began (Ryan and Rossor, 2010). 
 
 
Clinical 
Feature 
 
Mutation 
 
Unusual pathology 
 
Seizures and 
myoclonus 
 
 
 
PSEN1 p.Asn135Ser 
PSEN1 p.Leu166Pro 
PSEN1 p.Leu235Pro 
APP p.Val717Ile 
APP p.Thr714Ala 
APP duplication 
 
 
 
 
 
 
Cerebral amyloid angiopathy & Lewy 
body pathology 
Spastic 
paraparesis 
 
PSEN1 
p.Ile83_Met84del 
PSEN1 Δexon9 
PSEN1 p.Tyr154Asn   
PSEN1 p.Phe237Ile 
PSEN1 p.Val261Phe 
PSEN1 p.Pro264Leu 
PSEN1 p.Gly266Ser 
PSEN1 p.Arg278Lys  
PSEN1 p.Arg278Thr 
PSEN1 p.Glu280Gly 
PSEN1 p.Pro284Leu 
PSEN1 p.Pro436Gln 
 
 
Cotton wool plaques 
Cotton wool plaques 
 
 
 
Cotton wool plaques 
 
 
 
Cotton wool plaques 
Cotton wool plaques 
Cotton wool plaques 
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Extrapyramidal 
signs 
 
PSEN1 p.Ser170Phe 
PSEN1 p.Gly217Asp 
 
PSEN1 p.Met223Val 
PSEN1 p.Thr440del 
 
PSEN2 p.Ala85Val 
 
Lewy body pathology 
Cotton wool plaques & cerebral amyloid 
angiopathy 
Lewy body pathology 
Cotton wool plaques & Lewy body 
pathology 
Lewy body pathology 
Cerebellar 
signs 
 
PSEN1 p.Pro117Ala 
PSEN1 p.Ser170Phe 
PSEN1 p.Glu280Ala 
 
 
Severe Purkinje cell loss 
Focal 
neurological 
symptoms & 
signs 
APP p.Glu693Gln 
APP p.Ala692Gly 
Cerebral amyloid angiopathy with 
recurrent cerebral haemorrhages 
 
11.2 Genetics methods 
Genomic DNA was prepared from peripheral blood leukocytes using a Nucleon BACC3 
extraction kit (GE Healthcare).  Mutation analysis was done on genomic DNA by direct 
sequencing of both strands of PCR-amplified coding exons. Primer sequences were 
designed according to Genbank entries and are available on request.  Amplification was 
done using a standard protocol and PCR products were purified using MicroClean 
(Microzone).  Sequencing reactions were carried out using the BigDye® Terminator 
v1.1 Cycle Sequencing Kit (Life Technologies) the products were run out on the 3730xl 
DNA Analyzer (Life Technologies).  Confirmation of missense mutations was carried 
out by differential enzymatic restriction digests, by an allele discrimination method 
using TaqMan 5’ nuclease assay (Life Technologies) or by allele-specific oligo 
hybridisation.  
 
Cases that were found to have novel variants in PSEN1 or APP were then assessed for 
the presence of additional mutations in other dementia related genes using the Ion 
Torrent Dementia Chip. For this, sequencing was carried out using Ion Torrent(tm) 
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technology (Thermo Fisher Scientific):  A custom primer panel was designed using Ion 
AmpliSeq(tm) Designer comprising 17 dementia related genes including exon flanking 
regions and some untranslated sequence.  Sample libraries were prepared using Ion 
AmpliSeq(tm) kits, transferred to the Ion OneTouch(tm) 2 system for template 
preparation (emulsion PCR) and then sequenced using the Personal Genome Machine(r) 
System.  Assessment of C9orf72 gene expansions and alteration of the octapeptide 
repeat motif of PRNP was carried out by repeat-primed PCR and DNA size 
fractionation respectively. 
 
List of sequenced genes: 
 
APP 
C9ORF72* 
CHMP2B 
CSF1R 
FUS 
GRN 
ITM2B 
MAPT 
NOTCH3 
PRNP 
PSEN1 
PSEN2 
SERPINI1 
SQSTM1 
TARDBP 
TREM2 
TYROBP 
VCP 
 
*Gene not sequenced but simply assessed for expansions using repeat-primed PCR.  
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11.3 Immunohistochemical methods in the pathology cohort 
Paraffin sections were dewaxed in xylene. Endogenous peroxidase activity was blocked 
with 0.3% H2O2 in methanol and non-specific binding with 10% dried milk solution. 
Immunohistochemistry required pressure cooker pretreatment in citrate buffer (pH 6.0) 
for all antibodies unless otherwise stated. Tissue sections were incubated with the 
primary antibodies for one hour at room temperature, followed by biotinylated anti-
rabbit IgG (1:200, 30 min; Dako) or biotinylated anti-mouse IgG (1:200, 30 min; Dako) 
and Avidin–biotin complex (30 min; Dako). Colour was developed with di-
aminobenzidine/H2O2. Antibodies to the following proteins were used: amyloid-β (Aβ) 
(Dako, 1:100), requiring formic acid pretreatment before pressure cooking; tau (AT8 
clone; Autogen Bioclear, 1:600); Iba1 (Wako, 1:1000); glial fibrillary acidic protein 
(Dako, 1:1000); Myelin Basic Protein (MBP, Covance, 1:500) and RT-97 (Vector, 
1:20), CD3 (Dako, 1:100); CD20 (Dako, 1:200) and CD68 (Dako, 1:150).  Sections 
were also stained with routine haematoxylin and eosin (HE) stains to evaluate any 
structural or cellular abnormalities in the cases being examined. 
 
11.4  Grading system used to assess severity of cerebral amyloid angiopathy  
Score 0 was given to vessels devoid of amyloid deposition, while score 1 reflected trace 
to scattered distribution of amyloid in leptomeningeal or cortical blood vessels. A score 
of 2 indicated that at least some vessels demonstrated circumferential amyloid 
deposition. A score of 3 corresponded to widespread, circumferential staining of many 
leptomeningeal and superficial cortical vessels. A score of 4 indicated severe amyloid 
deposition accompanied by projection of amyloid into the adjacent parenchyma or the 
presence of amyloid deposition in capillaries (Olichney et al., 1996). The severity of 
CAA was graded in frontal, temporal, parietal and occipital cortex and cerebellum.  
 
11.5  Semi-quantitative assessment of myelin loss, gliosis and microglial 
expression. 
The deep white matter in the occipital and parietal lobes were semi-quantitatively 
assessed for white matter pallor, gliosis and microglial expression, through examination 
by eye down the microscope. This was based on a four-tier grading system where ‘0’ 
represented no change in the white matter, no gliosis or microglial activation; ‘+’ 
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represented mild pallor of the white matter, mild gliosis and the minimal presence of 
activated microglia (Figure 4.3,K); ‘++’ represented a moderate degree of white matter 
pallor, gliosis and microglial activation (Figure 4.3, L); ‘+++’ represents severe pallor 
of the white matter, severe gliosis and severe microglial activation; ‘++++’ represents 
very severe microglial activation where the majority of the microglial cells are 
highlighted using immunohistochemical methods (Figure 4.3, M).  
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13 Glossary 
 
AAO: Age at onset 
Aβ: amyloid-beta 
ABCA7: ATP-binding cassette, sub-family A, member 7 gene 
AD: Alzheimer’s disease 
ADAS-Cog: Alzheimer’s disease assessment scale, cognitive subscale 
ApoE: Apolipoprotein E 
APP: Amyloid precursor protein  
API: Alzheimer’s Prevention Initiative 
ARIA: Amyloid-related imaging abnormalities 
ARWMC: Age-related white matter change 
AxD: Axial diffusivity 
BACE-1: β-site amyloid precursor protein cleaving enzyme 
BIN1: Bridging integrator 1 
CAA: Cerebral amyloid angiopathy 
CAA-ri: CAA-related inflammation 
CBD: Corticobasal degeneration 
CERAD: Consortium to Establish a Registry for Alzheimer’s disease 
CJD: Creutzfold-Jakob disease 
CLU: Clusterin  
CNTNAP5: Contactin-associated protein-like 5 
CR1: Complement receptor type 1 
CSF: Cerebrospinal fluid 
CT: Computed tomography 
DARTEL: Diffeomorphic anatomical registration through exponentiated lie algebra 
DIAN: Dominantly inherited Alzheimer network 
DLB: Dementia with Lewy bodies 
DRC: Dementia Research Centre 
DTI: Diffusion tensor imaging 
DTI-TK: Diffusion tensor imaging toolkit 
DWI: Diffusion-weighted imaging 
EPHA1: EPH receptor A1  
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FA: Fractional anisotropy 
FAD: Familial Alzheimer’s disease 
FAM46A: Family with sequence similarity 46, member A1 
FDG-PET: Fluorodeoxyglucose positron emission tomography 
FLAIR: Fluid-attenuated inversion recovery 
FLIRT: FMRIB’s (Oxford centre for functional magnetic resonance imaging of the 
brain) linear image registration tool 
fMRI: Functional magnetic resonance imaging 
FTD: Frontotemporal dementia 
FWE: Family-wise error 
GDA: Graded difficulty arithmetic test 
GFAP: Glial fibrillary acidic protein 
GNT: Graded naming test 
GRE: Gradient echo  
HLA-DRB5-HLA-DRB1: Major histocompatibility complex, class II, DR beta 5 and DR 
beta 1 
ICC: Intra-class correlation co-efficient 
IQ: Intelligence quotient 
LBP: Lewy body pathology 
LP: Lumbar puncture 
LPA: Logopenic progressive aphasia 
MAPS: Multi-atlas propogation and segmentation 
MAPT: Microtubule-associated protein tau 
MBP: Myelin basic protein 
MC: Mutation carrier 
MCI: Mild cognitive impairment 
MD: Mean diffusivity 
MMSE: Mini-mental state examination 
MPRAGE: Magnetization-prepared rapid acquisition with gradient echo 
MRI: Magnetic resonance imaging 
MS4A6A: Membrane-spanning 4-domains, subfamily A, member 6A 
PCA: Posterior cortical atrophy 
PCR: Polymerase chain reaction 
PET: Positron emission tomography 
 231 
PIB: Pittsburgh compound B 
PICALM: Phosphatidylinositol binding clathrin assembly protein 
PMC: Presymptomatic mutation carrier 
PPA: Primary progressive aphasia 
PRNP: Prion protein  
PSEN1: Presenilin 1  
PSEN2: Presenilin 2  
PTK2B: Protein tyrosine kinase 2 beta 
RD: Radial diffusivity 
RMT: Recognition memory test 
ROI: Region of interest 
SD: Standard deviation 
SEMA3C: Semaphorin 3C 
SMC: Symptomatic mutation carrier 
SORL1: Sortilin-related receptor with A-type repeats 
SPECT: Single photon emission computed tomography 
SWI: Susceptibility-weighted imaging 
TBSS: Tract-based spatial statistics 
TFCE: Threshold-free cluster enhancement 
TIV: Total intracranial volume 
TREM2: Triggering receptor expressed on myeloid cells 2 
VBM: Voxel-based morphometry 
WMH: White matter hyperintensity 
 
 
 
 
 
 
 
 
 
 
 
